

annual report

TABLE OF CONTENTS



The annual report has been reviewed by the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This annual report has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this annual report, including the correctness of any of the statements or opinions made or reports contained in this annual report.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ ppcf.com.sg

CORPORATE PROFILE

Quantum Healthcare Limited ("**We**", or the "**Company**", "**Quantum Healthcare**" and together with its subsidiaries the "**Group**") is a Singapore-based company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") (Stock Code: V8Y.SI) since 29 July 2022.

Prior to 29 July 2022, the Group was previously known as QT Vascular Ltd ("**QTV**"), which underwent a scheme of arrangement to transfer its listing status to Quantum Healthcare on a 1:1 share arrangement, and QTV became a wholly-owned subsidiary of Quantum Healthcare. The transfer of listing was completed on 28 July 2022, and the Company began trading on the Catalist Board on 29 July 2022.

Prior to the restructuring, the Group was primarily engaged in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The Company collaborates with industry specialists and physicians who are key opinion leaders to develop and offer physicians and patients new and differentiated devices to improve outcomes in complex peripheral and coronary interventions. The Group still retains its original vascular business under QTV. Subsequent to the restructuring, the Group has also diversified its core business to include:

- (a) the Healthcare Business, which includes, inter alia, the following activities:i. provision of dental services; and
 - ii. operations management and consultancy services to certain government entities and/or corporate clients,

(collectively, the "Healthcare Business");

- (b) the Medical Equipment Business, which includes, inter alia, the following activities:
 - i. research, develop and design of medical equipment and other related products including but not limited to geriatric medical rehabilitation equipment and medical equipment for use in hospitals as well as for emergency and rescue ("**Medical Equipment**"); and
 - ii. to engage in the trading, manufacturing, distributing and/or marketing of these Medical Equipment,

(collectively, the "Medical Equipment Business"); and

(c) the Medical and Wellness Business, which includes the provision of general and specialized medical care including but not limited to the fields of aesthetics and wellness services ("Medical and Wellness Business").

ORGANIZATION CHART



LETTER FROM CEO

"Our unwavering commitment to excellence, coupled with our relentless pursuit of innovation, will continue to drive our success in the coming years."

Dear Shareholders,

I am honoured to present Quantum Healthcare Limited's Annual Report for the financial year ended 31 December 2023 ("FY2023"). This year has been marked by significant achievements and strategic initiatives that have propelled our company towards new heights of success and growth.

At the beginning of FY2023, we experienced robust growth following the acquisition of three (3) clinics out of six (6) clinics from The Dental Hub ("**TDH**") Group. This strategic move has not only expanded our market presence but has also strengthened our foothold in the healthcare sector. Building upon this momentum, we are proud to announce the opening of two (2) new dental clinics under the TDH umbrella: The Dental Hub (Jurong West) Pte Ltd and The Dental Hub (Canberra) Pte Ltd. These additions to our network signify our commitment to providing accessible and high-quality dental care to communities across the region.

The integration of TDH Group into our portfolio has yielded remarkable results, with strong revenue growth and increased patient satisfaction. Our focus on delivering exceptional dental services coupled with innovative treatment approaches has positioned us as a prominent presence in the dental healthcare landscape. Furthermore, our investment in advanced technology and continuous staff training ensures that we stay at the forefront of dental innovation, providing our patients with the best possible care.

As we look ahead to FY2024, our strategic vision remains centred on the expansion and enhancement of our dental business. We are dedicated to exploring new avenues for growth and implementing initiatives to further elevate our services and offerings. Through targeted marketing campaigns, strategic partnerships with industry leaders, and the introduction of cutting-edge treatments, we aim to attract more patients and solidify our position as a premier dental healthcare provider.

Our unwavering commitment to excellence, coupled with our relentless pursuit of innovation, will continue to drive our success in the coming years. I extend my heartfelt appreciation to our Board of Directors for their invaluable guidance and support throughout this journey. I also commend our dedicated management team and staff for their hard work and dedication to realizing our vision.

In closing, I would like to express my gratitude to you, our shareholders, for your unwavering confidence and support. Together, we will continue to deliver value and excellence in dental healthcare, shaping a healthier future for generations to come.

Thomas Tan Gim Chua

Chief Executive Officer and Executive Director

BOARD OF DIRECTORS

It should be noted that all Directors who were appointed to QTV prior to the restructuring have been subsequently re-appointed to Quantum Healthcare following the restructuring. Therefore, for the avoidance of doubt, QTV and Quantum Healthcare should be viewed as one group. This clarification is provided to avoid any ambiguity or confusion regarding the continuity of the Directors' roles and responsibilities throughout the financial year.



Ng Fook Ai Victor Independent Chairman

Mr Ng Fook Ai Victor was appointed to our Board as an Independent Non-Executive Director and Chairman on 31 January 2022. Victor is currently the Chairman of the Board of Directors and the Chairman of the Remuneration Committee as well as a member of the Audit Committee and Nominating Committee.

Victor has more than 30 years of experience as a director on various companies, including directorship held in companies listed in Singapore and Hong Kong. Victor is currently an independent non-executive director of SGX Mainboard listed The Place Holdings Limited, independent non-executive chairman of SGX Catalist listed HealthBanks Holdings Ltd, independent non-executive director of HKEX-Main Board listed Sunshine 100 China Holdings Ltd and independent non-executive chairman of IRockstead GIP Fund Ltd which is an approved fund under the Global Investor Program that invest in Singapore-based companies.

Victor holds BSc (Econs) (Hons), MSc (Econs) major in Econometrics, from Birkbeck College, University of London. He was awarded The University of London Convocation Book Prize (First) and the Lord Hailsham Scholarship, among other awards. In 1992, Victor was awarded the Public Service Medal (PBM) (Community Services) by the President of the Republic of Singapore.



Thomas Tan Gim Chua

Chief Executive Officer and Executive Director

Mr Thomas Tan Gim Chua was appointed to our Board as Chief Executive Officer and Executive Director and a member of the Nominating Committee on 13 January 2022.

Thomas's working experience includes appointment as engineer from 1997 to 2000 in Nokia (S) Pte Ltd which is in the business of telecommunications, managing director of Ridgeline Technology Pte Ltd from 2000 to 2016 which is in the business of information technology info-communications and director and chief executive officer of Lifeline Corporation Pte Ltd from 2019 to 2021, a company with a presence in Singapore, Malaysia, Philippines and Australia specialising in the manufacture, sale and distribution of certain medical rehabilitation devices such as wheelchairs and beds to hospitals.

Thomas graduated from the Nanyang Technological University in 1997 with a Bachelor of Engineering and is a full member of the Singapore Institute of Directors. Thomas also has 16 years of experience as a managing director of Ridgeline Technology Pte Ltd and 5 years of experience as an executive director/chief executive officer of Lifeline Corporation Pte Ltd.

Sho Kian Hin Independent Director

Mr Sho Kian Hin was appointed to our Board as an Independent Non-Executive Director on 25 September 2015. He is the Chairman of the Audit Committee as well as a member of the Remuneration Committee. He is currently also an Independent Director and Chairman of the Audit Committee of OUE Healthcare Limited and Choo Chiang Holdings Ltd., both listed on the Catalist Board of the SGX-ST.

Kian Hin has over 20 years of experience in financial reporting and regulatory compliance and was involved in various financial related activities such as equity and pre-IPO fund raising, mergers and acquisitions, restructuring and group tax optimization.

Kian Hin started off his professional training with Victor & Company in 1990. From 1995, Kian Hin was with Ernst & Young as an Assurance and Advisory Business Service Manager and left in 2002.

In 2007, Kian Hin was appointed as Executive Director and Chief Financial Officer of China Farm Equipment Limited ("China Farm Equipment"), a company formerly listed on the Mainboard of the SGX-ST. He was responsible for, amongst other things, the planning and management of China Farm Equipment's financial and taxation matters. He acted as the key liaison person with the stock exchange, supervised compliance with corporate governance, and handled investor relations, regional roadshows as well as funding options for China Farm Equipment. After China Farm Equipment was privatised in 2013, Kian Hin remained involved in the corporate exercise to list China Farm Equipment's assets in China until 2017.

Kian Hin is a fellow member of the Association of Chartered Certified Accountants and a member of the Singapore Institute of Directors.

Ng Boon Eng Independent Director

Mr Ng Boon Eng was appointed to our Board as an Independent Non-Executive Director on 30 July 2021. Boon Eng is currently the Chairman of the Nominating Committee as well as a member of the Audit Committee and Remuneration Committee.

Boon Eng has been the Chief Executive Officer and a director of CEL Investment Corporate Finance Pte. Ltd. since 2017, an entity that holds capital market services license issued by the Monetary Authority of Singapore. He formerly held the position of Director and Head of Corporate Finance in RHB Securities Pte. Ltd. (formerly known as DMG & Partners Securities Pte. Ltd.), and Executive Director and Head of Corporate Finance in Mitsubishi UFJ Securities (Singapore) Limited. Boon Eng has close to 30 years of experience in advising on corporate finance, covering IPOs, RTOs, general offers, privatization and delisting and mergers and acquisitions.

Boon Eng graduated from Nanyang Technological University with a Degree of Bachelor of Engineering (Electrical) with Honours and is also a Chartered Valuer and Appraiser.





KEY MANAGEMENT



Dr Gian Siong Lin Jimmy Chief Operating Officer (Dental)

Dr Gian Siong Lin Jimmy was appointed as the Group's Chief Operating Officer (Dental) on 13 January 2022. As the Group's Chief Operating Officer (Dental), Jimmy oversees the newly expanded Healthcare Business of the Group.

Jimmy graduated from the Bachelor of Dental Surgery, National University of Singapore with Dean's List Award in his Final Professional Examinations. He has been in private practice for more than 20 years and his interests is in Orthodontic and Implant Dentistry.

Jimmy is a Certified Invisalign Practitioner, Certified Incognito Lingual Braces Practitioner and Certified CEREC Practitioner.

He is also a member of the following associations:

- American Orthodontic Society USA
- Chicago Dental Society Michigan, USA
- Academy of General Dentistry USA
- Society for The Advancement of Gnathology Singapore
- Guild of Dental Graduates Singapore
- Aesthetic Dentistry Society of Singapore
- Singapore Dental Association



Fu Ching Xiong Chief Financial Officer

Mr Fu Ching Xiong was appointed as the Group's Chief Financial Officer on 9 January 2023. As the Group's Chief Financial Officer, he oversees the accounting and finance function of the Group.

He is also responsible for the compliance and risk management functions of the Group and is responsible for internal audit, risk management and compliance with requirements under the Listing Manual Section B: Rules of Catalist and the Companies Act 1967 of Singapore and advising the Group on its risk management and compliance processes.

Ching Xiong, who has recently joined Quantum Healthcare, brings with him more than a decade of auditing and merger and acquisition ("**M&A**") experience gained from working at some of the top accounting firms in Singapore. Prior to joining Quantum Healthcare, he was a Senior Manager of Regional Investment at Una Brands, a leading ecommerce aggregator in the region. Before that, he was an Associate Director of Deloitte Singapore, where he mainly focused on M&A advisory work across diverse industries such as healthcare, education, engineering, startups, and consumer goods across Southeast Asia. Ching Xiong started his career at KPMG Singapore and Malaysia, where he was primarily involved in auditing.

Ching Xiong graduated from University of Queensland with a Bachelor of Commerce (Accounting and Finance) degree and is a Certified Practising Accountant of CPA Australia.

FINANCIAL & OPERATIONS REVIEW

REVIEW OF INCOME STATEMENT

The Group recorded revenue of S\$13.1 million and cost of sales of S\$7.3 million for the year ended 31 December 2023 ("**FY2023**"), which was mainly contributed by dental business under Asia Dental Group Pte Ltd ("**ADG**") Group.

In FY2023, the Group's loss before taxation decreased by S\$5.5 million mainly due to the following reasons:

- Gross profit increased by S\$1.4 million in FY2023, mainly attributed to contribution from revenue growth from ADG Group, particularly growth in newly acquired business i.e. Eastern Dental Centre Group and acquisition of The Dental Hub Group ("**TDH**");
- Decrease of S\$0.7 million in research and development expenses as the milestone payment for InnoRa of S\$0.7 million during FY2022 was one-off in nature;
- Decrease in impairment loss on goodwill of S\$4.6 million from ADG goodwill impairment in FY2022 and loss from deemed disposal of subsidiary of S\$0.8 million attributed to loss arising from deconsolidation of TriReme Medical LLC in FY2022;
- Increase in other income of S\$0.1 million due to government grants; and
- Increase in administrative expenses by \$\$2.1 million in FY2023 mainly attributed to \$\$2.3 million legal fees for InnoRa legal case and increase in overall operation expenses resulting from acquisition of TDH clinics.

As a result of the above, the Group loss before taxation decreased from S\$8.9 million in FY2022 to S\$3.4 million for FY2023.

REVIEW OF FINANCIAL POSITION

Our non-current assets increased by S\$1.6 million mainly due to:

- (i) Goodwill on acquisition of S\$1.2 million from TDH acquisition and S\$0.2 million from TDHJW acquisition;
- (ii) Increase in plant and equipment of S\$0.2 million due to purchase of plant and equipment after the acquisition of The Dental Hub (Jurong West) Pte Ltd ("TDHJW"), assets acquisition from The Dental Hub (Canberra) Pte Ltd ("TDHC") and relevant depreciation for the year; and

Our current assets decreased by S\$3.1 million mainly due to:

- (i) Decrease in cash and cash equivalents of S\$4.3 million due to reasons presented in the cashflow analysis below; and
- (ii) Increase in trade and other receivables of S\$1.3 million mainly due to increase in working capital requirement from ADG Group.

Our non-current liabilities decreased by S\$3.0 million mainly due to:

FINANCIAL & OPERATIONS REVIEW

- (i) Decrease in loans and borrowings of approximately S\$1.5 million due to repayments made;
- (ii) Decrease in amounts due to non-controlling interests of approximately S\$1.2 million due to repayment made in January 2023 for first tranche payment of ADG acquisition; and
- (iii) Decrease in lease liabilities due to Group's rental leases of approximately \$\$0.3 million.

Our current liabilities increased by S\$3.1 million mainly due to:

- (i) Increase in trade and other payables of S\$2.2 million mainly attributed to increase in legal fees payable incurred for InnoRa Dispute;
- (ii) Increase in lease liabilities due to the Group's rental leases of approximately S\$0.3 million; and
- (iii) Increase in loan and borrowings of approximately S\$0.5 million due to transfer from non-current to current.

The Group has undertaken the following steps to address the Group's negative working capital of S\$7.2 million as at 31 December 2023 and deficit in shareholders' equity of S\$3.9 million as at 31 December 2023:

- (i) The Board has critically assessed the cash flow forecasts and working capital requirement of the Group for the next twelve (12) months and concluded that there will be sufficient cash flows and resources to allow the Group to continue its operations and meet its obligations for the foreseeable future;
- (ii) Management will continue to implement comprehensive cost-cutting measures and does not expect the Group to have any significant operational commitments that will require significant cash outflow in the next twelve (12) months other than those incurred in the ordinary course of business;
- (iii) Following the receipt of the Company shareholders' approval at an extraordinary general meeting held on 8 February 2024 for a proposed share placement, the share placement has been completed on 15 February 2024 and the Company received a gross share placement proceeds of S\$0.8 million which was used for partial repayment to Dr. Jimmy arising from the acquisition of ADG Group;
- (iv) In addition to iii. following the receipt of the Company shareholders' approval at an extraordinary general meeting held on 8 February 2024 for a proposed share settlement for liabilities owed by the Group to Dr. Jimmy, S\$0.3 million of liabilities owe to Dr. Jimmy was settled via share issuance to Dr. Jimmy, which will substantially reduce the cash requirement for the Group to repay aforementioned liabilities.
- (v) The Group has diversified into the healthcare business, primarily the provision of dental services, which are profitable and generating positive cash flows for the Group. The Group's acquisition of 100% of the businesses of four (4) clinics, via ADG's subsidiaries, The Dental Hub Pte. Ltd. and The Dental Hub (Jurong West) Pte. Ltd. during the financial year which has contributed positively to the Group's performance for the financial year ended 31 December 2023;
- (vi) Following the completion of the disposal of 11% of shares in ADG Group by the Company to Dr. Jimmy Gian on 14 March 2024, the consideration for this disposal will fully offset the Third Tranche Earn-Out Amount of S\$1.4 million. As a result, there shall be no further amounts owing by the Group to Dr. Jimmy in relation to the

acquisition of ADG Group;

- (vii) The Company believes that it will be able to raise funds from various parties as and when required, e.g. completion of the recent placement of Company on 15 February 2024; and
- (viii) Management continues to explore any potential for strategic initiatives with a view to generate new business opportunities and/or fund-raising exercises.

Based on the foregoing, the Board confirms that the Group will be able to meet its short-term debt obligations when they fall due based on the implementation of the aforementioned steps and continue to operate as a going concern and confirmed that all material disclosures have been provided for trading of the Company's shares to continue in an orderly manner.

REVIEW OF CASH FLOW

The Group recorded cash outflows from operating activities of approximately S\$0.7 million in FY2023 was mainly due to:

- (i) Operation loss before income tax after non-cash adjustments of S\$1.4 million;
- (ii) Decrease in changes in trade and other receivables recorded approximately S\$1.3 million;
- (iii) Tax payment of S\$0.1 million; and
- (iv) Offset by increase in changes in trade and other payables for approximately S\$2.1 million mainly attributed to the increase legal fees payables of S\$2.3 million.

Net cash used in investing activities for FY2023 of approximately S\$3.4 million was mainly due to:

- (i) Purchase of plant and equipment of approximately S\$0.3 million;
- (ii) Acquisition of business of TDH clinics and TDHJW clinic amounted to S\$1.7 million; and
- (iii) Repayment to non-controlling interest for first instalment payment of S\$1.4 million.

Net cash used in financing activities for FY2023 of approximately S\$0.2 million was mainly due to:

- (i) Proceeds from the share placement of S\$2.0 million;
- (ii) Repayment of loan borrowings of S\$1.3 million; and
- (iii) Repayment of lease liabilities of S\$1.0 million.

CORPORATE INFORMATION

BOARD OF DIRECTORS

Non-Executive:

Ng Fook Ai Victor Independent Director and Chairman of the Board of Directors

Ng Boon Eng Independent Director

Sho Kian Hin Independent Director

Executive:

Thomas Tan Gim Chua Chief Executive Officer and Executive Director

AUDIT COMMITEE Sho Kian Hin (Chairman) Ng Fook Ai Victor Ng Boon Eng

NOMINATING COMMITTEE Ng Boon Eng (Chairman) Thomas Tan Gim Chua Ng Fook Ai Victor

REMUNERATION COMMITTEE Ng Fook Ai Victor (Chairman) Sho Kian Hin Ng Boon Eng

COMPANY SECRETARY Lee Pih Peng

REGISTERED OFFICE

8 Temasek Boulevard, Level 42, Suntec Tower Three Singapore 038988

SHARE REGISTRAR Tricor Barbinder Share Registration Services (a division of Tricor Singapore Pte. Ltd.) 9 Raffles Place #26-01, Republic Plaza Tower I Singapore 048619

AUDITORS

Mazars LLP 135 Cecil Street #10-01 Singapore 069536 Audit Partner-in-charge Zhang Liang Since Financial Year ended 31 December 2023

SPONSOR

PrimePartners Corporate Finance Pte. Ltd. 16 Collyer Quay #10-00 Collyer Quay Centre Singapore 049318

PRINCIPAL BANK OCBC Bank 65 Chulia Street OCBC Centre Singapore 049513

BOARD STATEMENT

The Board of Directors ("Board") is pleased to present our Annual Sustainability Report ("Report") for year 2023. At Quantum Healthcare Limited ("Quantum Healthcare" or "Company", and together with its subsidiaries, the "Group"), we believe that sustainability is not just a responsibility but a fundamental principle that guides our business decisions and actions. As stewards of our planet and advocates for the well-being of our communities, we are committed to integrating Environmental, Social, and Governance ("ESG") considerations into every aspect of our operations.

In reflecting on the challenges faced in 2023, the Board acknowledges the resilience and dedication demonstrated by our team amidst a difficult operating environment. Despite the adversities encountered, we remain steadfast in our commitment to our vision and values. Looking ahead, we are optimistic that the strategic measures implemented during this challenging period will pave the way for a stronger future for our company. Leveraging the lessons learned and building upon our strengths, we are confident in our ability to navigate uncertainties and capitalize on opportunities for growth and innovation. With a clear focus on sustainability, agility, and customer-centricity, we believe that 2023 will serve as a foundation for our continued success and resilience in the years to come.

Sustainability Governance

The Board is reponsible for sustainability reporting and oversees and is supported by the Sustainability Committee ("SC") and the Sustainability Task Force ("STF") in its continuous efforts to integrate sustainability strategies into Quantum Healthcare's strategies formulation and oversee sustainability performance and reporting. The SC, comprising all board members, develops sustainability objectives and strategies based on the Board's directions, manages Quantum Healthcare's overall sustainability performance, and reports to the Board regularly. The STF, consisted of senior management representatives from different business functions, implements sustainability practices and action plans across Quantum Healthcare based on the sustainability objectives and strategies formulated.

We look forward to sharing our sustainability progress with you in this Report.

Board of Directors

Quantum Healthcare Limited

ABOUT THIS REPORT

REPORTING PERIOD AND SCOPE

This Report summarises Quantum Healthcare's sustainability policies, practices, and performance from 1 January 2023 to 31 December 2023 ("**FY2023**"), with a focus on its material ESG factors. The report covers the listed entity, Quantum Healthcare Limited and its subsidiaries, except for TriReme Medical LLC as it is an associated company.

REPORTING FRAMEWORK

This report has been prepared in accordance with 711A and 711B of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist with reference to the Global Reporting Initiative ("**GRI**") Standards. We have adopted the GRI reporting framework due to its comprehensive structure and detailed guidelines, which provide an internationally recognized standard for disclosing governance practices, environmental impacts, social performance, and economic indicators within organizations. The GRI content index, along with relevant references, is included at the end of the report.

This Report also incorporates recommendations from the Task Force on Climate-related Financial Disclosures ("**TCFD**") to give stakeholders on our climate-related disclosures. The TCFD framework enables the Group to evaluate how climate-related risks, such as physical and transition risks, may impact the Group and outlines strategies and actions for managing and mitigating these impacts, as well as potential opportunities.

In ensuring our commitment to sustainability, it's crucial to align executive remuneration with performance in this area. While this linkage may not currently exist, we recognize the importance of integrating sustainability metrics into our compensation structures in the future. This can involve methods such as performance-based incentives and embedding sustainability goals into overall performance evaluations. To guarantee that our compensation strategies are in line with our strategic objectives, we will carefully evaluate our existing frameworks. By identifying pertinent sustainability metrics for our industry and stakeholders, we aim to directly connect executive remuneration with our sustainability objectives. This not only motivates executives to prioritize sustainability initiatives but also demonstrates our dedication to long-term value creation and ethical business practices. Across the Report, for each of the initiative in the material ESG factors, we will indicate target timing of completion, i.e. within 1–2 years ("Short Term"), within 2–5 years ("Medium Term") or within 5–10 years ("Long Term"). All these initiatives are on ongoing basis and will be reviewed annually.

As part of our ongoing efforts to ensure that our sustainability reporting meets relevant industry standards, we've referenced and integrated, where applicable, our sustainability strategy with the 17 core Sustainable Development Goals ("**SDGs**"). These goals were introduced in the 2030 Agenda for Sustainable Development, which was adopted by all United Nations Member States in 2015 (the "**UN Sustainability Agenda**"). This agenda serves as a shared roadmap for achieving global peace and prosperity, emphasizing the importance of harmonizing human well-being with environmental health both presently and in the future.

SUSTAINABILITY REPORT



REVIEW

This Report has undergone the internal review process by Internal Auditors and has been reviewed by the Board.

The Group has not sought external assurance for FY2023 and may consider it for future periods.

FEEDBACK

All information is disclosed in good faith and to the best of our knowledge. No external assurance has been sought for this report. Please forward any enquiries or feedback to **ir@quantumhealthcare.com.sg**.

STAKEHOLDER ENGAGEMENT

We recognize the importance of engaging our stakeholders to improve our sustainability practices and enhance our social and environmental impact. As part of our commitment, we implemented a stakeholder engagement process as follows:

SUSTAINABILITY REPORT

Stakeholder	Method of Engagement	Frequency	Topics of Engagement
Patients	 Meetings - Physical or virtual Service quality feedback Telephone calls Email communications Reviews Surveys 	• Daily	 Quality, safety, and hygiene clinical services Privacy and data protection Health and safety regulations compliance
Employees, including dentists and nurses	 Regular staff meetings Training and development program Surveys 	• Daily	 Remuneration and benefits Safe, fair, and equal working environment Training and development
Suppliers	 Meetings - Physical or virtual Telephone calls Email communications 	• Daily	 Supplier quality assurance Pricing and payment terms
Shareholders and investors	 AGM / EGM meetings SGX announcement and circulars Annual Report 	 Yearly When Required Yearly 	Corporate goveranceFinancial performance
Government and Regulators	 Direct communication and meetings SGX announcement 	• When Required	 Compliance with laws and regulations
Financier	 Annual Report Telephone Calls Email communications 	YearlyWhen Required	Financial covenantsFinancial performance

MATERIALITY ASSESSMENT PROCESS

IDENTIFICATION

The materiality assessment is a process which begins by identifying and prioritizing sustainability issues that are of significant importance to a company's stakeholders and business operations. The aim of this assessment is to identify the key sustainability issues that are most relevant to the Quantum Healthcare, as well as its stakeholders, and to develop strategies to improve its sustainability performance.

ASSESSMENT

For this materiality assessment, Quantum Healthcare engaged a range of stakeholders, including patients, employees, suppliers, shareholders, regulators, and financier, to identify their concerns and expectations regarding the company's sustainability performance. The assessment also took into consideration the key sustainability issues that are relevant to the dental industry and the broader Singapore context.

PRIORITISATION

We have engaged stakeholders in prioritising material ESG factors by evaluating their impact on the Group and influence on stakeholders' decisions.

REVIEW

Applying the guidance from SGX Practice Note 7F Sustainability Reporting Guide, we have identified 9 material ESG factors that are material to our business. As there has not been any major change in our business model in FY2023. These material ESG factors and their prioritisation are reviewed and updated on annual basis to reflect changes in business operations, economic, environment, and sustainability trends.



The materiality matrix below displays the ranked priority according to stakeholders' assessments.

INTEGRATING TCFD GUIDANCE

Key Area	Our Response
Governance	Quantum Healthcare has established a Sustainable Committee, supported by the Sustainable Task Force and the Board, to oversee sustainability practices, review sustainability policies and address climate-related risks and opportunities.
Strategy	Quantum Healthcare has conducted an extensive evaluation of climate-related risks and opportunities to guide its business strategy. Acknowledging the potential effects of climate change on its operations, supply chains, and patient care, the company has formulated a strategy focused on pioneering sustainable healthcare practices. This approach involves investing in research and development for environmentally friendly medical equipment and procedures, advocating for energy-efficient technologies in healthcare facilities, and expanding services to address health issues exacerbated by climate change impacts.
	For risk assessment, the Sustainable Committee (SC) and Sustainable Task Force (STF) will proactively identify and address climate-related considerations within the business. This will involve evaluating key operational activities and identifying pertinent climate risks, conducting scenario analysis to comprehend potential impacts, and subsequently establishing climate targets. These efforts will enable the company to make informed decisions aimed at mitigating climate change impacts effectively. The company will progressively determine climate targets and provide detail scenario analysis wherever applicable in the future.
Risk Management	Quantum Healthcare has integrated climate risk assessments into its broader risk management framework. By evaluating key operational activities and identify relevant climate risks, and conducting scenario analysis to understand potential impacts, SC and STF identify and assess the key climate-related risks and opportunities as follows: 1) Regulatory risks due to healthcare waste management (Long Term) - Mitigation strategies are implemented to minimize these risks, including appointing Ministry of Health ("MOH") approved waste management company, diversifying suppliers to eco-friendly suppliers, enhancing disaster preparedness plans, and advocating for policies that promote climate resilience within the healthcare industry.
	2) Transitional risks to low carbon economy (Long Term) - In alignment with Singapore's commitment to reduce emissions to around 60 MTCO2e (metric tons of carbon dioxide equivalent) by 2030 and achieve net-zero emissions by 2050, Quantum Healthcare recognizes the importance of addressing transitional risks associated with the shift to a low-carbon economy. As global efforts intensify to mitigate climate change, regulatory changes, technological advancements, and market shifts are expected to impact businesses across various sectors, including healthcare. Quantum Healthcare is proactively assessing these transitional risks and implementing strategies to navigate the transition effectively. This includes evaluating the potential implications of evolving regulations on healthcare practices,

INTEGRATING TCFD GUIDANCE

Key Area	Our Response			
	energy-efficien suppliers and s By embracing thes reduce its carbon t and contribute to S	rtunities to invest in renewab It technologies, and fostering takeholders committed to su e initiatives, Quantum Healt footprint but also seize oppo ingapore's broader climate g uality healthcare services for	partnership ustainability. hcare aims ortunities for goals, while e	s with to not only innovation
Metrics and Targets	climate-related risk consumption, green and sets targets to service provided. To integrate TCFD in 2 GHG emission spe	re discloses relevant metrics and opportunities. The con nhouse gas (" GHG ") emission o reduce emissions intensity n our sustainability reporting ecifically on electricity below.	npany tracks ns across its per unit of , we disclose	s its energy operations healthcare our Scope
	GHG Emissions	Unit of Measurement	FY2023	FY2022
	GHG emissions (Scope 2)	Tonnes CO2e	65.3	60.9
	GHG emission intensity	Tonnes CO2e / revenue S\$′000	0.0050	0.0065
	We target to mainte	ain or reduce these emission	is by 5% for F	Y2024.
	Group because dir which are relatively / building for the Gr disclose Scope 3 Gr These metrics are reports, providing to	We target to maintain or reduce these emissions by 5% for FY2024. There are no material Scope 1 Emissions for services provided by the Group because direct emission refers to vehicle / building emissions which are relatively low for dental practice as there are no major vehicle / building for the Group. We will continue to monitor our emissions and disclose Scope 3 GHG emissions wherever applicable and practicable. These metrics are reported annually in the company's sustainability reports, providing transparency to stakeholders and demonstrating its commitment to addressing climate change while delivering quality		emissions ajor vehicle issions and racticable. Istainability nstrating its

ENVIRONMENTAL

WATER USE AND CONSERVATION PRACTICES

healthcare services.

Water is a fundamental resource, and its scarcity and quality are increasingly critical sustainability concerns. Within the dental industry, water plays a pivotal role in various activities such as cleaning, sterilization, and dental procedures. Thus, it's imperative for dental clinics to manage water usage efficiently and sustainably to minimize their environmental footprint and ensure future availability of this resource.

Our Group recognizes the significance of water conservation and has outlined planned initiatives to address this issue effectively:

- Conducting a comprehensive water audit (Aligned with GRI Standard 303, Short Term): Quantum Healthcare will conduct a thorough water audit to assess the company's water consumption and identify areas for potential conservation. This audit will pinpoint leaks, inefficient equipment, and other opportunities to save water.
- Implement water conservation policies (Aligned with SDG 6, Short Term): Quantum Healthcare is committed to implementing policies aimed at encouraging employee to conserve water. These policies will include practices such as turning off faucets when not in use and promptly reporting any leaks or water wastage.
- Educate employees and patients (Aligned with GRI Standard 404 and TCFD Recommendation on Metrics and Targets, Medium Term): Quantum Healthcare recognizes the importance of raising awareness about water conservation among both employees and patients. Through educational initiatives, we aim to inform and empower individuals to take proactive steps to reduce water usage in their daily activities.
- Monitor water usage (Aligned with GRI Standard 303 and TCFD Recommendation on Risk Management, Ongoing): Quantum Healthcare will establish a robust system for monitoring water consumption across its facilities. By tracking usage metrics and analyzing trends, we can identify areas of improvement and measure progress over time. Regular monitoring will allow us to assess the effectiveness of our conservation efforts and make necessary adjustments to optimize water usage further.

FY2023 Performance

In FY2023, the Group consumed a total of 1,019 m3 of water, marking a decrease of 5.6% compared to FY2022. Despite an increase in dental clinics due to acquisitions, Quantum Healthcare was able to significantly reduce water usage in FY2023.

Unit of Measurement	Target for FY2024	FY2023	FY2022
Cubic Meter, m ³	Maintain or reduce 5%	1,019 m ³	1,080m ³

As part of our commitment to sustainability, Quantum Healthcare is dedicated to continuously improving our water management practices. By implementing these initiatives and monitoring our progress, we aim to enhance water efficiency, minimize environmental impact, and demonstrate our unwavering dedication to sustainability.

ENERGY CONSUMPTION

We recognize that energy consumption is a significant contributor to greenhouse gas emissions and climate change, and we are committed to managing our energy usage in an efficient and sustainable manner. Our primary energy consumption occurs within our dental clinics and offices.

To reduce our energy consumption and improve efficiency, we are implementing several key steps:

• Conducting an Energy Audit (Aligned with GRI Standard 302, Short Term): We will conduct an energy audit to identify areas where we can conserve energy, such as

SUSTAINABILITY REPORT

pinpointing equipment or appliances that consume excessive energy.

- Implementing Smart Technology (Aligned with TCFD Recommendation on Governance, Medium Term): We will invest in smart technology and automation systems to optimize energy usage. This includes automated lighting, energy-efficient equipment, and appliances, as well as automated temperature control for air conditioning.
- Establishing Energy-Saving Policies (Aligned with SDG 7, Short Term): Quantum Healthcare will implement policies and procedures aimed at reducing energy consumption. This includes setting thermostats to appropriate temperatures, conducting regular maintenance for maximum efficiency, and ensuring equipment is turned off when not in use.
- Educating Employees and Patients (Aligned with GRI Standard 404 and TCFD Recommendation on Metrics and Targets, Medium Term): We will educate our employees and patients about the importance of energy conservation.
- Monitoring Electricity Usage (Aligned with GRI Standard 302 and TCFD Recommendation on Risk Management, Ongoing): Quantum Healthcare will establish a system for monitoring electricity usage across our facilities. By tracking usage metrics and analysing trends, we can identify areas for improvement and measure progress over time.

FY2023 performance

In FY2023, the Group consumed a total of 156,703 kWh of electricity, representing a 7% increase compared to FY2022. This increase is primarily attributed to the expansion of dental clinics resulting from acquisitions.

Unit of Measurement	Target for FY2024	FY2023	FY2022
Kilowatt-hour, kWh	Maintain or reduce by 5%	156,703	146,299
Electricity intensity, kWh / Revenue, S\$'000	Maintain or reduce by 5%	11.98	15.61

By considering these additional points and incorporating them into energy management strategies, Quantum Healthcare can maximize energy efficiency, reduce operational costs, and minimize environmental impact.

WASTE MANAGEMENT

At Quantum Healthcare, our typical waste includes biomedical waste, such as sharps and contaminated materials, along with non-biomedical waste like paper, plastic, and other materials used in daily operations. Improper waste management can have adverse effects on the environment, public health, and safety, contributing to landfills and pollution.

We are steadfast in our commitment to managing waste responsibly and sustainably, aiming to reduce waste generation. Here are the steps we're taking to achieve this goal and ensure safe and responsible waste management:

• Segregating Waste (Aligned with GRI Standard 306, Medium Term): We segregate

waste at the point of generation into categories such as biomedical waste, recyclable waste, and non-biodegradable waste. This practice makes it easier to manage and dispose of waste in an appropriate and sustainable manner.

- Recycling and Reusing (Aligned with SDG 12, Medium Term): Implementing recycling and reusing programs helps reduce landfill waste. This includes recycling paper, plastic, and other materials, as well as repurposing and reusing items wherever possible.
- Proper Disposal of Biomedical Waste (Ongoing): We ensure the proper disposal of biomedical waste, such as sharps and biohazardous materials, to uphold public health and safety standards. Quantum Healthcare engages licensed waste disposal services from MOH's approved list of medical waste contractors to collect and dispose of sharps and biohazardous waste.
- Educating Employees (Aligned with TCFD Recommendation on Governance, Ongoing): We educate our employees on proper waste management practices to ensure correct handling and disposal. This education emphasizes the importance of waste reduction and sustainability to all staff members.
- Monitoring and Evaluation (Aligned with GRI Standard 306 and TCFD Recommendation on Metrics and Targets, Ongoing): We monitor and evaluate our waste management practices to identify areas for improvement and uphold our sustainability goals. Through these efforts, we aim to lead by example in the industry and contribute to a more sustainable future for our patients, employees, and the community.

Additionally, Quantum Healthcare has consistently utilized MOH-approved waste management companies for both FY2022 and FY2023. Our target for FY2024 is to continue using the same approved waste management company, as they continue to be endoresed by MOH, thervby ensuring compliance and adherence to regulatory standards.

We will continue to monitor and evaluate our waste management practices to identify areas for improvement and uphold our sustainability goals, including obtaining waste management comparative data in the future. Through these efforts, we aim to lead by example in the industry and contribute to a more sustainable future for our patients, employees, and the community.

SOCIAL

OCCUPATIONAL HEALTH AND SAFETY

Occupational hazards in dental practices include exposure to infectious diseases, musculoskeletal disorders, and exposure to hazardous substances. We are committed to mitigating these hazards and creating a safe and healthy workplace for all.

By reporting on our occupational health and safety practices and taking steps to continuously improve workplace safety, we hope to reduce the risk of workplace accidents and illnesses, and contribute to a safer and healthier workplace for our employees and patients.

We recognize the importance of promoting a culture of safety in our workplace and ensure that our employees are properly trained and equipped to work safely, the following measures will be implemented progressively over next few years:

- Conducting risk assessments (Aligned with TCFD Recommendation on Risk Management, Short Term): Conducting regular risk assessments can help identify potential hazards and implement measures to prevent accidents or incidents from occurring.
- Providing training and education (Aligned with GRI Standard 404 and SDG 4, Medium Term): Providing employees with the necessary training and education on workplace hazards and safety measures can help to ensure that they are equipped with the necessary skillsets to work safely.
- Implementing safety protocols and procedures (Aligned with SDG 3, Short Term): Implementing safety protocols and procedures, such as infection control procedures, and the use of personal protective equipment (PPE), can help to minimize occupational hazards.
- Monitoring and reporting incidents (Aligned with GRI Standard 403 and TCFD Recommendation on Metrics and Targets, Ongoing): Regular monitoring and reporting of workplace incidents can help to identify trends and areas for improvement in our occupational health and safety practices.

During FY2023, we recorded Nil (FY2022: Nil) workplace fatalities, Nil (FY2022: Nil) work-related injuries, Nil (FY2022: Nil) occupational disease. We are committed to continuously improving our performance and ensuring a safe and healthy workplace for our employees, patients, and visitors.

	Target for FY2023	Performance in FY2023	Target for FY2023
Workplace fatalities	Nil	Target Met	Nil
Work-related injuries	Nil	One	Nil
Occupational disease	Nil	Target Met	Nil

We are committed to continuously improving our performance and ensuring a safe and healthy workplace for our employees, patients, and visitors.

DIVERSITY AND INCLUSION IN THE WORKFORCE AND LEADERSHIP

We believe that embracing diversity and creating an inclusive workplace is not only the right thing to do but also essential for our long-term success.

Diversity and inclusion in the workforce are crucial for creating a fair and equitable society. By ensuring that individuals from all backgrounds have equal access to opportunities, resources, and support, companies can help reduce social inequalities and promote social justice. This can also improve employee satisfaction, engagement, and retention, which can lead to a more stable and productive workforce.


We have taken the following approach to achieve our goals in promoting diversity and inclusion in our workforce:

• Recruitment and hiring practices (Aligned with GRI Standard 404, Ongoing): We have implemented recruitment and hiring practices that promote diversity and inclusivity. We actively seek out a diverse pool of candidates for all open positions and

ensure that our hiring process is fair, non-discriminative and unbiased.

- Employee Feedback and Engagement (Aligned with TCFD Recommendation on Metrics and Targets, Ongoing): We regularly seek feedback formally (via yearly appraisals) and informally (ongoing communication) from our employees to understand their experiences, perspectives, and suggestions for improving diversity and inclusion in the workplace. We also encourage open communication and dialogue through regular employee engagement and open-door policies.
- Flexible work arrangements (Aligned with SDG 3, Ongoing): We understand that our employees may face unique challenges when it comes to balancing work and personal responsibilities. As such, we offer flexible work arrangements, such as telecommuting and flexible schedules, to help our female employees achieve a healthy work-life balance.

As at 31 December 2023, our Group has a total of 99 employees (FY2022: 76) due to the overall increase in dental operation across Singapore.



Employees By Gender

BOARD OF DIRECTORS

The absence of female representation on the current Board of Directors prompts the Company to pursue a more inclusive and diverse decision-making approach. Actively seeking female participation aligns with the Company's dedication to sustainability and responsible business practices. Introducing gender diversity reflects the Company's commitment to embracing varied perspectives and experiences, essential for addressing future challenges and opportunities. As the Company gears up for its next sustainability report, it acknowledges the significance of fostering an inclusive and diverse board and is actively progressing toward this objective.

Since FY2022, the Board has implemented the following measures to uphold or enhance its balance and diversity:

• The Nominating Committee conducts an annual review to determine if the existing

attributes and core competencies of the Board complement one another, thereby bolstering the Board's effectiveness.

• Directors conduct an annual evaluation to assess the skill sets possessed by their peers, utilizing the Board Skill Matrix (reference to Corporate Goverance Section) as a reference point to identify areas where expertise may be lacking.

Based on these actions, the Board is reasonably content that it possesses the requisite blend of skills, experience, and diversity to meet the needs and objectives of the Group.

Nonetheless, in FY2024, the Group will prioritize optimizing the Board's composition in accordance with the Board Skill Matrix. Consequently, the Board affirms that its current practices align with Principle 2 of the Code of Corporate Goverance 2018 and 710A of the Catalist Rule 710A.

The Group aims to achieve gender diversity by ensuring at least 25% female representation on the Board by 2030.

At Quantum Healthcare, we recognize the importance of diversity and inclusion in driving our success. Our commitment lies in fostering a workplace environment where every individual is esteemed, respected, and aided. We acknowledge that the promotion of diversity and inclusion is an evolving endeavor, and we remain dedicated to advancing our objectives and implementing measures to cultivate an even more inclusive workspace for everyone.

TRAINING AND EDUCATION

Committed to fostering a sustainable growth trajectory, our workforce stands as a cornerstone of our success, deemed among our most invaluable assets. Embracing this ethos, the Group is steadfast in its commitment to employee development, epitomized through robust training and continuous development initiatives aimed at cultivating a competitive and sustainable workforce.

Dental Professionals (Ongoing)

Recognizing the importance of continued professional education, all dentists are mandated to obtain 70 Continuing Professional Education (CPE) hours within a two-year cycle to maintain their practicing license. Additionally, newly appointed dentists undergo a two-year supervision period by senior peers, during which they must accrue 33 hours of supervised practice before obtaining their license.

Our dentists have met all the training requirements target for FY2023 as we do not have any dentists that are unable to renew their practicing certificates due to non-compliance (FY2022: Nil).

New employees on-the-job training (Shor Term)

For new hires, closely guided handholding by senior mentors ensures the acquisition of requisite skills and knowledge essential for job efficacy. Each employee undergoes a

mandatory probation period, allowing for evaluation across various dimensions including abilities, work ethic, and efficiency. Further bolstering their integration, new employees shadow experienced counterparts, acquainting themselves with operational intricacies and job scopes under the direct guidance and support of senior mentors.

Regular training and career development for existing non-dental employees (Ongoing)

For existing non-dental employees, they will also be provided with training to improve their skills, knowledge and abilities. The main training programmes to be considered by existing employees includes customer services training, team building workshops, health and safety training, software and technology, financial reporting, etc which can be done via internal training or training by external experts.

Internship program (Short Term)

Our internship program offers students hands-on experience alongside dental professionals, providing a platform to learn about our practices while contributing to meaningful sustainability initiatives. Meanwhile, tailored training models cater to the development of dental professionals, ensuring service quality remains paramount. Internal training sessions throughout the year serve to nurture our employees' expertise, supplemented by platforms encouraging knowledge exchange and professional development discussions.

Performance Measures	Target for FY2024	FY2023	FY2022
Training hours by non-dental employees	20	4	0
Unlawful employee discrimination	0	0	0
Work related injury	0	1	0

At Quantum Healthcare, we are dedicated to fostering a culture of continuous learning and professional development among our employees. To further this commitment, we have set a target of providing a minimum of 20 training hours annually for our non-dental employees.

In both FY2023 and FY2022, Quantum Healthcare has not received any complaints regarding unlawful employee discrimination.

However, it is worth noting that there was a case of work-related injury due to chemical burning. In response, relevant staff member has been educated on safe chemical handling practices to prevent such incident from occurring again. Our aim for FY2024 is to have zero occurrence of similar incident.

GOVERNANCE

CUSTOMER PRIVACY

We are firmly committed to safeguarding the privacy and security of our customers' personal information. Recognizing the paramount importance of customer privacy, we prioritize stringent measures to ensure compliance with all relevant laws and regulations

while protecting our customers' data.

In our dental practices, we acknowledge various risks associated with customer privacy, such as the potential for data breaches, unauthorized access, and improper use or disclosure of personal information. These risks pose significant threats, including reputational damage, legal liabilities, and financial losses. Consequently, we treat these risks with the utmost seriousness and have implemented robust measures to mitigate them effectively.

To address these concerns, we have enacted the following initiatives:

- Privacy Policy (Aligned with GRI Standard 418, Short Term): Our dental group has developed a comprehensive privacy policy that outlines our commitment to protecting customer privacy and the steps we take to ensure compliance with all applicable laws and regulations.
- Enhanced IT Security Measures (Aligned with GRI Standard 418 and TCFD Recommendation on Governance, Short Term): We have implemented advanced IT security protocols, including firewalls, encryption technologies, and multi-factor authentication mechanisms, to safeguard customer data against unauthorized access and cyber threats. Additionally, our patient data management is fortified by third-party vendors who uphold stringent security standards in line with current sustainability reporting practices.
- Regular Data Privacy Assessments (Aligned with GRI Standard 418 and TCFD Recommendation on Risk Assessment, Ongoing): Routine data privacy impact assessments are conducted to proactively identify and mitigate potential risks and vulnerabilities in our data management practices, aligning with contemporary sustainability reporting frameworks.
- Appointment of Data Protection Officers (Aligned with TCFD Recommendation on Governance, Short Term): Dedicated Data Protection Officers (DPOs) oversee our data privacy initiatives, ensuring compliance with evolving regulatory requirements and contemporary sustainability reporting guidelines.
- Transparent Data Protection Policies (Aligned with SDG 16, Short Term): We have developed transparent data protection policies articulated within our Data Protection Notice (DPN), underscoring our unwavering commitment to protecting customer privacy and adhering to contemporary sustainability reporting standards.
- Stringent Vendor Vetting Process (Aligned with GRI Standard 418 and TCFD Recommendation on Governance): Our third-party vendors undergo rigorous vetting processes to ensure alignment with our data privacy and security standards, as well as compliance with contemporary sustainability reporting mandates.

Performance Measures	Target for FY2024	FY2023	FY2022
Breach of customer data privacy	0	0	0

In both FY2023 and FY2022, Quantum Healthcare has not received any complaints regarding breaches of customer data privacy.

At Quantum Healthcare, we prioritize data privacy and are committed to adhering to the Personal Data Protection Act (PDPA). We acknowledge the risks associated with data privacy and have implemented measures to mitigate them effectively. We remain dedicated to upholding the trust of our customers by safeguarding their personal information and complying with all relevant laws and regulations.

ANTI-CORRUPTION

Operating fairly and ethically is imperative in maintaining the trust of our stakeholders. At Quantum Healthcare, we uphold rigorous standards of business ethics and independence across all facets of our operations.

We are steadfast in our commitment to maintaining independence in our interactions with healthcare professionals across various business domains, including research and development, as well as marketing and sales. Our policies on the provision of gifts, entertainment, or any other form of value to healthcare professionals are clearly defined. Moreover, all engagements with healthcare professionals are meticulously recorded and verified in accordance with regulatory requirements. These measures serve to prevent any perceived or actual breaches of independence, thereby safeguarding the integrity of research outcomes and the delivery of healthcare services.

As part of our comprehensive business ethics monitoring and assurance framework, Quantum Healthcare has implemented a whistle-blowing policy. This policy establishes transparent channels for employees to anonymously report any suspected ethical issues. In both FY2023 and FY2022, we received no whistle-blowing reports, reflecting our unwavering dedication to fostering a culture of integrity and accountability. Furthermore, the contact details of the Independent Directors of the Group have been prominently disclosed to all employees, underscoring our commitment to transparency and accountability.

Performance Measures	Target for FY2024	FY2023	FY2022
Number of confirmed incidents of corruption	0	0	0
Significant findings of internal and external audits conducted in relation to business ethics and independence	0	0	0

REGULATORY COMPLIANCE

At Quantum Healthcare, we firmly believe that our reputation hinges on our commitment to responsibility and accountability. We consider regulatory compliance as the bedrock for our ongoing operations and are unwaveringly dedicated to upholding all pertinent laws and regulations. This encompasses regulations concerning customer health and safety, independence and anti-corruption, marketing and labeling, taxation, product pricing, as well as a range of audit and reporting requirements. We are proud to report that in both FY2022 and FY2023, Quantum Healthcare incurred no fines or penalties for non-compliance during regulatory audits. In addition to regulatory compliance, we continuously endeavor to fortify our internal controls.

Our organization actively identifies and manages enterprise risks through a robust risk management system and a comprehensive suite of Standard Operating Procedures (SOPs). These SOPs cover essential aspects of risk management, including the development of risk management plans, risk assessment, risk minimization and control, risk-based decision making, and ongoing risk monitoring, review, and reporting.

To remain abreast of evolving laws and regulations, our team maintains regular communication with regulators and industry associations to stay informed about updates. Whenever regulatory changes occur, we promptly adapt our policies and procedures, ensuring strict documentation control, and promptly communicate these changes to our employees.

Should any instances of non-conformance with relevant laws and regulations arise, Quantum Healthcare is committed to promptly reporting such occurrences to the appropriate government agencies, in adherence to corresponding reporting obligations across various jurisdictions. Furthermore, we conduct thorough internal investigations to identify the root causes of non-conformance and develop robust risk controls to mitigate future occurrences. Through these measures, we reaffirm our dedication to responsible business practices and sustaining the trust of our stakeholders.

Performance Measures	Target for FY2024	FY2023	FY2022
Number of non-compliant incidents with laws and regulations in the social and economic area that results in significant fines and non-monetary sanctions	0	0*	0

* A dentist has been temporarily suspended for 11 months since October 2023 due to an unfortunate outcome related to an implant procedure. This incident occurred at the dentist's previous dental company and is unrelated to the current workplace in the Company or the Group.

GRI content index

Statement of use	Quantum Healthcare Limited has reported the information of 1 January 2023 to 31 December 2023 with reference to the	
GRI 1 used	GRI 1: Foundation 2021	
GRI STANDARD	DISCLOSURE	LOCATION
GRI 2: General Disclosures 2021	2-1 Organizational details	Corporate Profile
	2-2 Entities included in the organization's	Organisation Chart
	sustainability reporting 2-3 Reporting period, frequency and contact	SR Report - About This Report
	point	No Doctotomont of information for prior year
	2-4 Restatements of information 2-5 External assurance	No Restatement of information for prior year SR Report - About This Report
	2-6 Activities, value chain and other business	SR Report - About This Report
	relationships	
	2-7 Employees	SR Report - Diversity and inclusion in the workforce and leadership
	2-8 Workers who are not employees	No workers who are not employees
	2-9 Governance structure and composition	Corporate Governance, SR Report - Board Statement
	2-10 Nomination and selection of the highest	Corporate Governance, SR Report - Board
	governance body 2-11 Chair of the highest governance body	Statement Corporate Governance, SR Report - Board
	2.12 Polo of the highest governance body in	Statement
	2-12 Role of the highest governance body in overseeing the management of impacts	SR Report - Board Statement
	2-13 Delegation of responsibility for managing impacts	SR Report - Board Statement
	2-14 Role of the highest governance body in sustainability reporting	SR Report - Board Statement
	2-15 Conflicts of interest	Corporate Governance, SR Report - Board Statement
	2-16 Communication of critical concerns	SR Report - About This Report
	2-17 Collective knowledge of the highest	Corporate Governance, SR Report - Board
	governance body	Statement
	2-18 Evaluation of the performance of the highest governance body	Corporate Governance
	2-19 Remuneration policies	Corporate Governance
	2-20 Process to determine remuneration	Corporate Governance
	2-21 Annual total compensation ratio	Corporate Governance
	2-22 Statement on sustainable development strategy	Corporate Governance, SR Report - Regulator Compliance
	2-23 Policy commitments	Corporate Governance, SR Report - Regulator Compliance
	2-24 Embedding policy commitments	Corporate Governance, SR Report - Regulator Compliance
	2-25 Processes to remediate negative impacts	Corporate Governance, SR Report - Regulator Compliance
	2-26 Mechanisms for seeking advice and raising	Corporate Governance, SR Report - Regulator
	concerns	Compliance
	2-27 Compliance with laws and regulations	Corporate Governance, SR Report - Regulator Compliance
	2-28 Membership associations	Corporate Governance
	2-29 Approach to stakeholder engagement	SR Report - Stakeholder Engagement
	2- <u>30 Collective bargaining agreements</u>	No collective bargaining agreements
GRI 3: Material Topics 2021	3-1 Process to determine material topics	SR Report - Materiality Assessment Process
	3-2 List of material topics 3-3 Management of material topics	SR Report - Materiality Assessment Process SR Report - Materiality Assessment Process
GRI 205: Anti-corruption 2016	205-1 Operations assessed for risks related to	SR Report - Anti Corruption
Siti 203. Anti-contuption 2010	<u>co</u> rruption	
	205-2 Communication and training about anti- corruption policies and procedures	SR Report - Anti Corruption
	205-3 Confirmed incidents of corruption and actions taken	SR Report - Anti Corruption
GRI 302: Energy 2016	302-1 Energy consumption within the organization	SR Report - Energy Consumption
	302-2 Energy consumption outside of the	Not applicable as Group does not have energy
	organization	consumption outside of the organisation.
	302-3 Energy intensity	SR Report - Energy Consumption
	302-4 Reduction of energy consumption	SR Report - Energy Consumption
	302-5 Reductions in energy requirements of	Not applicable as Group does not sell products

GRI content index

	antum Healthcare Limited has reported the information and anuary 2023 to 31 December 2023 with reference to the	
GRI 1 used GR	I 1: Foundation 2021	
GRI STANDARD	DISCLOSURE	LOCATION
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	SR Report - Water use and conservation practices
	303-2 Management of water discharge-related	Not applicable as the Group does no
	impacts	discharge water that contains Total
		Dissolved Solids or Total Suspended Solids that
		exceed legal limits of the country.
	303-3 Water withdrawal	Not applicable as the Group does not operate in country under water stress.
	303-4 Water discharge	Not applicable as daily water discharged into
	ő	public sewerage system and open drains,
		canals, and rivers is negligible.
	303-5 Water consumption	SR Report - Water use and conservation
		practices
GRI 306: Waste 2020	306-1 Waste generation and significant waste-	SR Report - Waste Management
	related impacts	
	306-2 Management of significant waste-related	SR Report - Waste Management
	impacts	
	306-3 Waste generated	SR Report - Waste Management
	306-4 Waste diverted from disposal	Not applicable as the Group does not divert an
		waste from / to disposal
	306-5 Waste directed to disposal	Not applicable as the Group does not divert any
		waste from / to disposal
GRI 403: Occupational Health and Safety 2018	ty 403-1 Occupational health and safety management system	SR Report - Occupational health and safety
	403-2 Hazard identification, risk assessment,	SR Report - Occupational health and safety
	and incident investigation	
	403-3 Occupational health services	SR Report - Occupational health and safety
	403-4 Worker participation, consultation, and	SR Report - Occupational health and safety
	communication on occupational health and safety	
	403-5 Worker training on occupational health and safety	SR Report - Occupational health and safety
	403-6 Promotion of worker health	SR Report - Occupational health and safety
	403-7 Prevention and mitigation of occupational	Not applicable as the Group does not have any
	health and safety impacts directly linked by	occupational health and safety issue linked by
	business relationships	business relationships.
	403-8 Workers covered by an occupational health and safety management system	Not applicable as the Group's principal activitie are not legally required to implement such system.
	403-9 Work-related injuries	SR Report - Occupational health and safety
	403-10 Work-related ill health	SR Report - Occupational health and safety
GRI 404: Training and Education 2016	404-1 Average hours of training per year per	SR Report - Training and Education
	employee	
	404-2 Programs for upgrading employee skills	SR Report - Training and Education
	and transition assistance programs	
	404-3 Percentage of employees receiving	SR Report - Training and Education
	regular performance and career development reviews	
GRI 405: Diversity and Equal Opportun		SR Report - Diversity and inclusion in the
016	employees	workforce and leadership
	405-2 Ratio of basic salary and remuneration of	Confidentiality constraints due to intense
	women to men	competition for talent in the industry.
GRI 418: Customer Privacy 2016	418-1 Substantiated complaints concerning	SR Report - Customer Privacy
	breaches of customer privacy and losses of	
	and lood of casternor privacy and lood of	

FINANCIAL CONTENTS



CORPORATE GOVERNANCE

DISCLOSURE TABLE FOR ANNUAL REPORT IN COMPLIANCE TO THE CODE OF CORPORATE GOVERNANCE 2018 AND CATALIST RULES

The Board of Directors (the "**Board**") of Quantum Healthcare Limited (the "**Company**" and together with its subsidiaries, the "**Group**") are committed to maintaining high standards of corporate governance and places importance on its corporate governance processes and systems so as to ensure greater transparency, accountability and maximisation of long-term shareholder value.

This report outlines the Company's corporate governance practices that were in place during the financial year ended 31 December 2023 ("**FY2023**"), with specific reference made to the principles and provisions of the Code of Corporate Governance 2018 (the "**Code**"), the accompanying Practice Guidance in 14 December 2023 (the "**PG**") as well as the disclosure guide developed by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") in January 2015 (the "**Guide**").

Provision	Code and/or Provision Description	Company's Compliance or Explanation						
General	(a) Has the Company complied with all the principles and provisions of the Code?	The Company has complied with the principles and provisions as set out in the Code and the Guide, where applicable. Not applicable.						
	If not, please state the specific deviations and alternative corporate governance practices adopted by the Company in lieu of the recommendations in the Code.							
	(b) In what respect do these alternative corporate governance practices achieve the objectives of the principles and conform to the guidelines of the Code?	Not applicable. The Company did not adopt any alternative corporate governance practices in FY2023.						
BOARD MA	TTERS							
The Board's	Conduct of Affairs							
1.1	What is the role of the Board?	As at the date of this report, the Board has 4 members and comprises the following:						
4.2		Table 1.1 – Board and Board committees composition						
6.2 10.2		Composition of the Board Composition of the Board Committees						
Catalist		• C – Chairma				n		
Rule				• M - Member				
406(3)(e)		Name of Director	Designation	AC ⁽¹⁾	NC ⁽²⁾	RC ⁽³⁾		
Catalist Rule		Thomas Tan Gim Chua	Chief Executive Officer ("CEO") and Executive Director	-	М	-		
1204(10B)		Ng Fook Ai Victor	Independent Chairman	М	М	С		
		Ng Boon Eng	Independent Director	М	С	М		
		Sho Kian Hin	Independent Director	С	-	М		
		 Notes: (1) The Audit Committee ("AC") comprises three (3) members, all of whom a independent. All members of the AC are non-executive Directors. (2) The Nominating Committee ("NC") comprises three (3) members, the major of whom, including the Chairman, are independent. Majority of the member of the NC are non-executive Directors. 				e majority		

CORPORATE GOVERNANCE

Provision	Code and/or Provision Description	Company's Compliance or Explanation			
		(3) The Remuneration Committee ("RC") comprises three (3) members, all of whom are independent. All members of the RC are non-executive Directors.			
		The terms of reference of the AC, NC and RC are set out in Provisions 10.1, 4.1 at 6.1 respectively.			
		The Board is entrusted to lead and oversee the Group, with the fundamental principle to act in the best interests of the Group and hold management accountable for performance. In addition to its statutory duties, the Board's principal functions are, <i>inter alia</i> :			
		overseeing the Group, including establishing and maintaining effective internal controls, risk management its control and accountability systems to safeguard shareholders' interest and the Group's assets;			
		 set out overall long-term strategic plans and objectives for the Group and ensure that the necessary resources are in place for the Group to meet its objectives; 			
		 monitoring and reviewing senior management's performance and implementation of strategy; 			
		 satisfying itself that senior management has developed and implemented a sound system of risk management and internal controls in relation to financial reporting risks and has reviewed the effectiveness of the operation of that system; 			
		 assessing the effectiveness of senior management's implementation of systems for managing material business risks, including the making of additional enquiries and to request assurances regarding the management of material business risks, as appropriate; 			
		ensuring compliance with all laws and regulations as may be relevant to the business;			
		 formulating and approving financial objectives of the Group and monitoring its performance such as reviewing and approving of financial results announcements and financial statements; and 			
		• implementing and maintaining corporate governance practices in the Group to protect the interests of shareholders.			
		The Company has in place practices to address potential conflicts of interest. All Directors are required to notify the Company promptly of all conflicts of interest as soon as it is practicable after the relevant facts become known to him as well as refreshing the required declaration annually. Director is required to recuse himself from all deliberations/voting in relation to the matters which he has a conflict of interest in, unless the Board is of the opinion that the participation of the conflicted Director is in the best interest to the Company. Nonetheless, he will abstain from voting in relation to the conflict-related matters.			
1.2 Catalist Rule 406(3)(a) Practice	 (a) Are new Directors given formal training? If not, please explain why. 	Newly appointed Directors will receive comprehensive and tailored induction upon joining the Board, including their duties as directors and how to discharge those duties. An orientation program including site visits to the Group's operations will be held where required to ensure that the Directors are familiar with and understand the Group's business, organisation structure, corporate strategies and policies, and governance practices. The Company will also provide training for newly appointed Directors who have no prior experience as a director of a Singapore public listed			
Note 4D		company as prescribed by the SGX-ST under Rule 406(3)(a) and Practice Note 4D of the SGX-ST Listing Manual Section B: Rules of Catalist (the " Catalist Rules "). Such training must be completed within one year of the newly appointed Directors' initial appointment. The training of Directors will be arranged and funded by the Company.			
	(b) What are the types of information and training provided to (i) new Directors and (ii) existing Directors to keep them up-to-date?	important that all Directors receive regular training so as to be able to serve			

CORPORATE GOVERNANCE

Provision	Code and/or Provision Description	Company's Compliance or	Explanation				
		To ensure Directors can fulfil their obligations and to continually improve the performance of the Board, all Directors are encouraged to undergo continual professional development during the term of their appointment. Professional development may relate to a particular subject area, committee membership, or ke developments in the Company's environment, market or operations which may be provided by accredited training providers such as the Singapore Institute of Directors. Directors are encouraged to consult the Chairman if they consider that they personally, or the Board as a whole, would benefit from specific education of training regarding matters that fall within the responsibility of the Board or relate to the Company's business. Such trainings costs are borne by the Company.					
		 the external auditors ("EA") had briefed the AC on changes or amendments to accounting standards; 					
		 the Sponsors and Company Secretary had briefed the Board of changes, such as changes to the Companies Act and/or the SG Manual Section B: Rules of Catalist; and 					
		by the CEO f the Group.	the CEO and Chief Financial Officer e Group.				
			the Catalist R	ules, all of the	he Directors have completed		
1.3	What are the types of material transactions which require approval from the Board?	Matters and transactions that require the Board's approval are clearly communicated to the Management in writing and it includes, amongst others, the following:					
		 major capital expenditure, capital management and acquisitions and divestitures; 					
		Chapter 9 and Chapter 10 transactions in the Catalist Rules ;					
		 the Company's control and accountability systems; share issuance, dividend release or sharees in capital; 					
		 share issuance, dividend release or changes in capital; the Company's policies on risk oversight and management, internal 					
		compliance and control, Code of Conduct, and legal compliance;					
		 the Company's financial statements, financial results announcements budgets; and 					
		or which the Board consider materiality in	all matters which cross the relevant thresholds stipulated in the Catalist Rules or which the Board considers material for announcement. The Board will consider materiality in the context that reflects the stage of development of the Company and also takes into consideration the guidelines provided in the Catalist Rules.				
1.4	Has the Board delegated certain responsibilities to committees? If yes, please provide details.	The Board has delegated certain responsibilities to the AC, the NC and the RC (collectively, the " Board Committees "). The compositions of the Board Committees have been set out in Section 1.1 of this report.					
1.5	Have the Board and Board	The Board meets at least			as and when	circumstances	
	Committees met in the last financial year?	require. Directors with multiple Board representations ensure that sufficient time and attention are given to the affairs of each company. During FY2023, the number of the Board and Board Committee meetings held and the attendance of each					
		Board member are shown below:					
		Table 1.5 – Attendance of Board and Board Committee Meetings in FY2023					
			Board	AC	NC	RC	
		Number of Meetings Held	5	2	1	1	
		Name of Director	Number of Meetings Attended			ed	
		Sho Kian Hin	5	2	1*	1	
		Ng Fook Ai Victor	5	2	1	1	
		Thomas Tan Gim Chua	5	2*	1	1*	
		Ng Boon Eng	5	2	1	1	

Provision	Code and/or Provision Description	Company's Compliance or Explanation					
		* By invitation					
		Note: (1) The Board had held additional three Board meetings in FY2023 to deliberate on matters in relation to the dilution of QT Vascular Ltd's, a wholly-owned subsidiary of the Company, shareholding interest in TriReme Medical LLC, from 50% plus one share to approximately 20.19%.					
		The Company's Constitution (the " Constitution ") allows for Board meetings to be held through teleconferencing and/or videoconferencing.					
1.6	What types of information does the Company provide to Non-Executive Directors to enable them to understand its business and financial environment as well as the risks faced by the Company? How frequently is the information provided?	 understandable assessment of the Company's performance, position, a prospects. This responsibility extends to the interim and full-year financial results announcements, other price-sensitive public reports, and reports to regulators required). Management provides the Board with key information that is complete, adequate 					
		Table 1.6 – Types of information provided by Manag	ement				
		Information	Frequency				
		1 Board papers (with background or explanator) information relating to the matters brough before the Board, where necessary)					
		2 Updates to the Group's operations and the markets in which the Group operates in	e Half-yearly				
		3 Reports on on-going or planned corporate actions	e Half-yearly				
		4 Internal auditors' ("IA") report(s)	Yearly				
		5 Regulatory updates and implications	As and when required				
		6 Significant project updates	As and when required				
		7 External Auditors' reports	Yearly				
		Management recognises the importance of circulating i to ensure that the Board has adequate time to review constructive and effective discussion during the sch Management endeavours to circulate information for one week prior to the meetings to allow sufficient time Key management personnel will also provide any addit that is requested by Directors or that is necessary to e balanced and informed assessment of the Group's prospects. Directors are also provided with the contact personnel to facilitate direct and independent access to	the materials to facilitate a eduled meetings. As such, he Board meetings at least for the Directors' review. onal material or information enable the Board to make a performance, position and details of key management				
1.7	Do the Directors have separate and independent access to Management, the Company Secretary and professional advisers?	All Directors have separate and independent access Company Secretary at all times.					
		The role of the Company Secretary, the appointment matter for the Board as a whole, is as follows:					
		 Ensuring that board procedures are followed Constitution, applicable rules and regulations, in Securities and Futures Act 2001 of Singapore, t Singapore and the Catalist Rules, are complied w 	cluding requirements of the he Companies Act 1967 of				
		Ensuring good information flows within the Boar and between the senior management and the Dir					
		Advising the Board on all corporate governance r	natters,				

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		 Facilitating orientation and assisting with professional developments; Attending all board and committee meetings; Ensuring coordination and liaison between the Board, the Board Committees and key management personnel; and Assisting the Chairman, the Chairman of each Board Committee and key management personnel in the development of agendas for the various Board and Board Committee meetings. Individually or collectively, in order to execute their duties, Directors are able to obtain independent professional advice at the Company's expense as and when required. The appointment of such independent professional advisors is subject to approval of the Board.
Board Comp	osition and Guidance	
2.1 2.2 2.3	Does the Company comply with the provisions on the proportion of Independent Directors and/ or Non- Executive Directors on the Board? If not, please state the reasons for the deviation and the remedial action taken by the Company.	As at the date of this Annual Report, the Board comprises one Executive Director and three Independent Non-Executive Directors. In view that the Chairman of the Company is an Independent Non-Executive Director and the Independent Directors make up more than one-third of the Board, there is a strong and independent element on the Board which provide independence of thought when making decisions which are in the best interest of the Company. The Company has complied with the relevant provisions as a majority of the Board members are Independent Non-Executive Directors. As the Chairman of the Company, Mr Ng Fook Ai Victor, is an Independent Non- Executive Director, no Lead Independent Director was appointed in the Company. Mr Ng Fook Ai Victor makes himself available to shareholders if they have any concerns relating to matters that contact through the CEO or CFO has failed to resolve, or where such contact is inappropriate, as well as at the Company's general meetings.
2.1 4.4	 Has the independence of the Independent Directors been reviewed in the last financial year? (a) Is there any Director who is deemed to be independent by the Board, notwithstanding the existence of a relationship as stated in the Code that would otherwise deem him not to be independent? If so, please identify the Director and specify the nature of such relationship. (b) What are the Board's reasons for considering him independent? Please provide a detailed explanation. 	Independent Directors make up the majority of the Board members. In determining the independence of the Independent Directors, the Board takes into account the existence of relationships or circumstances, including those identified by the Code, that are relevant in its determination as to whether a Director is independent. The Independent Directors have each declared their independence in accordance with the Code, PG and Catalist Rules, and the NC having reviewed such declarations, have confirmed the independence of the Independent Directors in accordance with the Code, PG and Catalist Rules. There is no Director who is deemed independent by the Board, notwithstanding the existence of a relationship as stated in the Code that would otherwise deem him not to be independent. Directors are required to disclose such relationship to the Board as and when it arises.

Provision	Cod	le and/or Provision Description	Company's Compliance or Explanation				
Catalist Rule 406(3)(d)	serv nine app the reas	any Independent Director ed on the Board for more than e years since the date of his first ointment? If so, please identify Director and set out the Board's ons for considering him ependent.	Pursuant to Rule 406(3)(d)(iv) of the Catalist Rules, an Independent Director who has held his or her position for an aggregate period of more than nine (9) years (whether before or after listing) will cease to be independent thereafter. However, such director may continue to be considered independent until the conclusion of the nex annual general meeting of the Company. As at the date of this Annual Report, there is no Independent Director who has served beyond nine (9) years since the date of his first appointment by the Company. Mr Sho Kian Hin, an Independent Non-Executive Director was first appointed to the board of directors of QT Vascular Ltd, the Company's wholly owned subsidiary, on 25 September 2015, and will be serving his ninth year as a director within the Group. Mr Sho Kian Hin will retire upon or prior to the conclusior of the annual general meeting for financial year ended 2024. The Company wil appoint a new independent non-executive director in compliance with guidelines				
2.4	(a)	What is the Board's policy with regard to diversity in identifying new director appointees?	The Board understands and believes that a diverse Board enhances the Board's decision-making capability and is more effective in dealing with business and industry challenges or developments and organizational changes faced by the Company and its subsidiaries (the " Group "). A diverse Board would comprise Directors with a balanced and diversified set of skills, experiences and perspectives, to ensure that decisions made by the Board have been considered from all points of view, and to foster or continue to foster robust or constructive debate. To that end, the Company has adopted a Board Diversity Policy that sets out a framework for promoting diversity in respect of the composition of the				
	(b)	Please state whether the current composition of the Board provides diversity on	The current Board composition provides a diversity of skills, experience and knowledge to the Company as follows:				
		each of the following – skills, experience, gender and		- ·			
		experience, gender and knowledge of the Company,	Table 2.4 – Balance and Diversity of the	Number of	Proportion of Board		
		and elaborate with numerical data where appropriate.		Directors	(%)		
			Core Competencies				
			Accounting or finance	3	75		
			Business management	4	100		
			Legal or corporate governance	4	100		
			Relevant industry knowledge or experience	4	100		
			Strategic planning experience	4	100		
			Customer based experience or knowledge	3	75		
			Information Technology	3	75		
			Gender				
			• Male	4	100		
			• Female	-	-		
	 (c) What steps have the Board taken to achieve the balance and diversity necessary to maximise its effectiveness? In designing, determining or assessing (as the case may composition, Board diversity has been considered from a wid including but not limited to skills, experience, educational bac service, gender, age and any other factors that the Board ma and applicable from time to time. High emphasis is placed on e composition of skills and experience at the Board level in order of core competencies, knowledge, perspectives and insights Board to discharge its duties and responsibilities effective decision-making in view of the core businesses and strategy o the Group, and support succession planning and developmen Board is of the view that, while it is important to promote board terms of gender or age, where the opportunity arises, the norm 						

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		based on an effective blend of skills and experience, including meeting a matrix of skills, competencies and knowledge in areas such as accounting and finance, legal, information technology (IT), human resources (HR) and business and industry knowledge (collectively the " Board Skills Matrix ") to strengthen the decision-making capabilities of the Board should remain a priority. The Board would take into consideration the following measures:
		a) Skills and Experience diversity
		The Committee will evaluate from time to time the existing attributes and core competencies of the Board based, <i>inter alia</i> , on the Board Skills Matrix, so as to assess and understand the range of expertise which is lacking by the Board (if applicable) and/or the necessary skills and experiences required on the Board. By using the Board Skills Matrix that sets out the mix of skills, knowledge and experience that the Board currently has or is looking for from its members from time to time, this will help identify any gaps in the collective skills of the Board that should be addressed as part of the Company's professional development initiatives for its directors or as part of its Board succession planning.
		b) Gender diversity
		The Company is committed to maintaining an environment of respect for people regardless of their gender in all business dealings and achieving a workplace environment free of harassment and discrimination on the basis of gender or family status. The same principle is applied to the selection of potential candidates for appointment to the Board in order to attract and retain women participation on the Board.
		c) Age diversity The Company does not fix an age limit for its Directors given that there is no
		The Company does not fix an age limit for its Directors given that there is no longer a statutory age limit requirement for Directors and senior Directors are generally more experienced and able to contribute or share their wealth of knowledge and experience with the rest of the Board. The Board is fully committed to promoting age diversity, but at the same time, valuing the contribution of its members regardless of age, and seek to eliminate age stereotyping and discrimination based on age.
		The Board has taken the following steps in FY2023 to maintain or enhance its balance and diversity:
		Annual review by the NC to assess if the existing attributes and core competencies of the Board are complementary and enhance the efficacy of the Board; and
		Annual evaluation by the Directors of the skill sets the Directors possess, <i>inter alia</i> , based on the Board Skills Matrix, with a view to understand the range of expertise which is lacking by the Board.
		Based on the foregoing, and considering the Company has diversified into dental business since FY2022, the Board is reasonably satisfied that the Board as a whole generally has the relevant combination of skills, experience, and diversity to ensure smooth transition of new dental business, serve the needs and plans of the Company and the Group and will continue to focus its efforts in FY2023 in optimising the Board composition based on the Board Skills Matrix.
		In addition, the Group target to achieve gender diversity by having at least 25% female participation on the Board by year 2030.
		The NC will consider the results of these exercises in its recommendation for the appointment of new directors and/or the re-appointment of incumbent directors.
		As mentioned above, Mr Sho Kian Hin, who is currently the Chairman of the Audit Committee and a member of the Remuneration Committee was first appointed to the board of directors of QT Vascular Ltd, the Company's wholly owned subsidiary, on 25 September 2015, and will be serving his ninth year as a director within the Group. The Company intends to identify suitable candidate(s) with the

Provision	Code and/or Provision Description	Company's Compliance or Explanation					
		relevant accounting and audit experience or diverse skills set to be appointed to take over the role and position of Mr Sho Kian Hin, <i>inter alia</i> , as Chairman of the Audit Committee to promote and enhance Board renewal and succession planning.					
2.5	Have the Non-Executive Directors and/or Independent Directors met in the absence of management in the last financial year?	The Non-Executive Directors and/or Independent Directors, led by the Independent Non-Executive Chairman, are scheduled to meet regularly, and as warranted, either via physical meetings or other means of communication such as email correspondence, to discuss concerns or matters such as the effectiveness of Management. Such discussions are conducted where appropriate in the absence of management.					
		The Non-Executive Directors and/or Independent Directors have met once in the absence of management in FY2023. The Chairman of such meetings provide feedback to the Board and/or Chairman as appropriate.					
<u>Chairman a</u>	nd Chief Executive Officer						
3.1 3.2 3.3	Are the duties between Chairman and CEO segregated?	The roles of the Chairman and CEO are separate to ensure a clear division of their responsibilities, increased accountability and greater capacity of the Board for independent decision making. The Chairman is not related to the CEO.					
		The responsibilities of the Chairman are as follows:					
		(a) to lead the Board to ensure its effectiveness on all aspects of its role;					
		(b) to promote a culture of openness and debate at the Board;					
		 (c) to facilitate the effective contribution of non-executive directors in particular; and 					
		(d) to promote high standards of corporate governance.					
		The responsibilities of the CEO are as follows:					
		(a) to progress and advance the strategic direction provided by the Board;					
		 (b) the operational running of the Company, pursuant to the Board delegating to the CEO certain of the Board's powers, authorities and discretions; 					
		 (c) to set the agenda of Board meetings and ensure that adequate time is available for discussion of all agenda items, in particular strategic issues; 					
		(d) to ensure that the directors receive complete, adequate and timely information;					
		(e) to ensure effective communication with shareholders; and					
		(f) to encourage constructive relations within the Board and between the Board and Management.					
		The Board is satisfied that there is sufficient transparency and accountability in view of the distinction of responsibilities. Mr Ng Fook Ai Victor is an Independent Director and is also the Chairman of the Board and he is also available to shareholders at the Company's general meetings and can be contacted at <u>victor@nextrevolutionnow.com</u> . Hence, the Board is of the view that there is no need to appoint a Lead Independent Director as there is a sufficiently strong independent element on the Board which enables the exercise of judgement with regards to the corporate affairs of the Group.					
Board Mem	bership						
4.1	What are the duties of the NC?	The NC is guided by key terms of reference as follows:					
		 (a) the review of board succession plans for directors, in particular, the Chairman, the CEO and key management personnel; 					
		(b) the development of a process and criteria for evaluation of the performance of the Board, its board committees and directors;					
		(c) the review of training and professional development programs for the Board;					
		 (d) to decide whether or not a director of the Company is able to and has been adequately carrying out his duties as a director; 					
		(e) board appointments and re-nominations of existing directors for re-election in accordance with the Company's Constitution (including alternate directors, if applicable) after having considered important issues, as part of the process for					

Provision	Code and/or Provision Description	Comp	any's Compliance or E	xplanation
		a c F v v a (f) s t t (g) t t fi f f (h) r c c E k s s	nd progressive renew ommitment, contribut participation, candour) yell as ensuring all di ppointment at regular etting the policy and d he Company's progres o review updates or ch rom time to time; and eviewing the composit of Directors and Boar Directors who as a gro nowledge, experience	ent and re-appointment of directors, as to composition val of the Board and each director's competencies, ion and performance (e.g. attendance, preparedness, including, if applicable, as an independent director as rectors submit themselves for re-nomination and re- intervals and at least once every three years; objectives for achieving board diversity and reviewing s towards achieving these objectives; anges to the board diversity policy, where appropriate, cion of the Board of Directors to ensure that the Board d committees are of an appropriate size, comprise pup provide an appropriate balance and mix of skills, and other aspects of diversity such as gender and age, think and foster constructive debate, and function ently
4.0				
4.3 Catalist	Please describe the board nomination process for the	Tab	le 4.3(a) – Process for t	he Selection and Appointment of New Directors
Rule 720(4)	Company in the last financial year for (i) selecting and appointing new directors and (ii) re-electing incumbent directors.	1.	Determination of selection criteria	 The NC, in consultation with the Board, would identify the current needs of the Board in terms of expertise and skills that are required in the context of the strengths and weaknesses of the existing Board to complement and strengthen the Board. In reviewing Board composition, the NC will consider the benefits of all aspects of diversity including, but not limited to, those described the Board Diversity Policy, in order to maintain an appropriate range, balance and diversity of skills, experience, and background on the Board. In identifying suitable candidates for appointment to the Board, the NC will consider
		2.	Search for suitable candidates	 candidates on merit against objective criteria and with due regard for the benefits of diversity on the Board. The NC would consider candidates proposed by the Directors, key management personnel or substantial shareholders, and may engage
				professional search firms where necessary.
		3.	Assessment of shortlisted candidates	The NC would meet and interview the shortlisted candidates to assess their suitability.
		4.	Appointment of director	The NC would recommend the selected candidate to the Board for consideration and approval.
		Tab	le 4.3(b) – Process for I	Re-electing Incumbent Directors
		Asse	essment of director	 The NC would assess the contributions and performance of the director in accordance with the performance criteria set by the Board; and The NC would also review the range of expertise, skills and attributes of current Board members and consider the current needs of the Board.
		Re-a dire	ppointment of ctor	Subject to the NC's satisfactory assessment of their overall contributions and performance, the NC would recommend the proposed re-

Provision	Cod	de and/or Provision Description	Company's Compliance or	Explanation			
				appointment of the consideration and a	director to the Board for its pproval.		
			Pursuant to Article 110 of the Constitution, at least one-third of the Directors for the time being (or if their number is not a multiple of three (3), the number nearest to but not less than one-third), selected in accordance with Article 111, shall retire from office by rotation (excluding Directors appointed as causal vacancies who are required to retire at the AGM pursuant to Article 114 of the Constitution). Pursuant to Article 111 of the Constitution, Directors who wish to retire and not to offer himself for re-election and Directors who have been longest in office since their last re-election or appointment or have been in office for the three (3) years since their last election shall be selected to retire. Between Directors who were re-elected on the same day, those to retire shall (unless they otherwise agree among themselves) be determined by lot. A retiring Director shall be eligible for re-election. Rule 720(4) of the Catalist Rules also requires all Directors to submit themselves for renomination and re-appointment at least once every three (3) years. Any further Directors so to retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last election or appointment at least once every three (3) years. Any further Directors were re-appointment at least once every three (3) years. Any further Directors so to retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last election.				
			accepted the NC's recome upcoming AGM for the re-	mendation to seek the app	proval of Shareholders at the irectors:		
			Name	Designation	Roles		
			Thomas Tan Gim Chua	Chief Executive Officer and Executive Director	NC member		
			Ng Fook Ai Victor	Independent Chairman	RC Chairman and AC, NC member		
			Ng Fook Ai Victor is consid the Catalist Rules.	dered independent for th	e purpose of Rule 704(7) of		
			0		n Gim Chua as per Appendix 162 of the Annual Report.		
4.5	(a)	What is the maximum number of listed company board representations that the Company has prescribed for its directors? What are the reasons for this number?	 as 8. As of date of this report, none of the directors have directorship in more than listed companies. 				
	(b)	If a maximum has not been determined, what are the reasons?	Not applicable.				

Provision	Code and/or Provision Description	Company's Con	npliance or Explanation			
	(c) What are the specific considerations in deciding on the capacity of directors?	 Expected and/or competing time commitments of Directors, includin whether such commitment is a full-time or part-time employment capacity; Geographical location of Director; Size and composition of the Board; Nature and scope of the Group's operations and size; and Capacity, complexity and expectations of the other listed directorships an principle commitments held. The measures and evaluation tools in place to assess the performance and conside competing time commitments of the Directors include the following:- Declarations by individual Directors of their other listed company boar directorships and principal commitments; Annual confirmations by each Director on his/her ability to devote sufficient time and attention to the Company's affairs, having regard to his/her other commitments; and Assessment of the individual Director's performance based on the criteria se out in Section 5 of this report. 				
	(d) Have the Directors adequately discharged their duties?					
PG 4	Are there alternate Directors?		does not have any alternate direc ed as and when the Board deems	tors currently. Alternate Directors necessary.		
Board Perfo	ormance					
5.1 5.2	What are the performance criteria set to evaluate the effectiveness of the Board as a whole and its board committees, and for assessing the contribution by each Director to the effectiveness of the Board?	approved by the Board, to be relied upon to evaluate the effectiveness of the Board as a whole and its Board Committees, and for assessing the contribution by each				
l		Table 5 – Perfe	ormance Criteria for Evaluating Bo	oard Effectiveness		
1		Performance	Board and Board	Individual Directors		
		Criteria	Committees 1. Size and composition 2. Access to information 3. Board processes 4. Inputs to strategic planning 5. Board accountability	 Commitment of time Knowledge and abilities Teamwork Overall effectiveness Engagement with Management 		
			 CEO/Top Management interaction Standards of Conduct Board Committee' performance in relation to discharging their responsibilities set out in their respective terms of reference 	6. Independence and objectivity		

Provision	Coc	le and/or Provision Description	Company's Compliance or Explanation
			The evaluations are designed to assess the Board's effectiveness to enable the NC Chairman and Board to identify the areas of improvement or enhancement which can be made to the Board. No external facilitator was used in the evaluation process.
			The NC would review the criteria on a periodic basis to ensure that the criteria is able to provide an accurate and effective performance assessment taking into consideration industry standards and the economic climate with the objective to enhance long term shareholders value, thereafter propose amendments if any, to the Board for approval.
			The NC has reviewed and adopted the same performance criteria for evaluation of the Board after the completion of the restructuring scheme between the Company and its wholly owned subsidiary, QT Vascular Ltd carried out pursuant to a scheme of arrangement under Section 210 of the Companies Act, in accordance with the terms of the scheme document dated 1 June 2022 (" Scheme ") pursuant to which there was a transfer of the listing status from QT Vascular Ltd to Quantum Healthcare Limited with effect from 29 May 2022, the Board composition of the Company has remained the same since the transfer of the listing from QT Vascular Ltd on 29 July 2022 to Quantum Healthcare Limited.
	(a)	What was the process upon which the Board reached the conclusion on its performance for the financial year?	The review of the performance of the Board and the Board Committees is conducted by the NC annually via a performance evaluation questionnaire to be completed by each Director and each Board Committee member. The review of the performance of each Director is also conducted at least annually and when the individual Director is due for re-election.
			For FY2023:
			 All Directors individually completed a board evaluation questionnaire on the effectiveness of the Board and Board Committees, and the individual Directors based on criteria disclosed in Table 5 above.
			2. The questionnaire results are collated for the NC's discussion and the NC concluded the performance results during the NC meeting; and
			 All NC members have abstained from the voting or review process of any matters in connection with the assessment of his performance.
			No external facilitator was used in the evaluation process.
	(b)	Has the Board met its performance objectives?	Yes, the Board Committees and the Directors have met their performance objectives for FY2023.
REMUNERA	TION	MATTERS	
Procedures f	or De	veloping Remuneration Policies	
6.1	Wha	at is the role of the RC?	The RC is guided by key terms of reference which include, amongst others, the
6.3			 following: (a) Review and recommend to the Board a general framework of remuneration for the Board and key management personnel, as well as specific remuneration packages for each Director and key management personnel of the Company;
			(b) Review annually the remuneration of the key management personnel and the Executive Director(s) including the terms of renewal for their Service Agreements;
			(c) Review the Company's obligations arising in the event of termination of the Executive Director(s) and key management personnel's contracts of service

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		and to ensure that such contracts of service contain fair and reasonable termination clauses which are not overly generous; and
		(d) Oversee the allotment and issue of Shares pursuant to the Varied Options granted under the Option Scheme and the Varied Awards granted under the Share Plan. Please refer to page 119 of this Annual Report for further details of the Varied Options and Varied Awards
		Termination Clause
		There is currently no amount for termination, retirement and post-employment benefits granted to the Executive Director and the top key management personnel (who are not Executive Directors).
		Claw-back mechanism
		The Company does not use contractual provisions to allow the Company to reclaim incentive components of remuneration from the Executive Director and key management personnel in exceptional circumstances of misstatement of financial results, or of misconduct resulting in financial loss to the Company. The Executive Director owes a fiduciary duty to the Company. The Company will avail itself to remedies against the Executive Director in the event of such breach of fiduciary duties.
		The Board is of the view that as the Group pays performance bonuses based on the actual performance of the Group and/or Company (and not on forward-looking results) as well as the actual results of its Executive Director and key management personnel, hence, "claw-back" provisions in the service agreements may not be relevant or appropriate.
6.4	Were remuneration consultants engaged in the last financial year?	In FY2023, the Company did not engage any remuneration consultants.
Level and M	ix of Remuneration	
7.1 7.3	What is the Company's remuneration policy?	The Company's remuneration policy, which covers all aspects of remuneration, including but not limited to directors' fees, salaries, allowances, benefits-in-kind, bonuses, options, share-based incentives and awards, is one that seeks to attract, retain and motivate talent to achieve the Company's business vision and create sustainable value for its stakeholders. The policy articulates to staff the link that total compensation has to the achievement of organisational and individual performance objectives and benchmarked against relevant and comparative compensation in the market.
	(a) Please describe how the remuneration received by Executive Directors and key management personnel has been determined by the performance criteria.	The remuneration received by the Executive Director and key management personnel are based on the terms of service contracts or employment letters entered into between the Company and the Executive Director and key management personnel respectively. Their remuneration is made up of fixed and variable compensation. The fixed compensation consists of an annual base salary, fixed allowance and annual wage supplement. The variable compensation is determined based on the level of achievement of corporate and individual performance objectives, at the sole discretion of the Board on the recommendation of the RC.
		There was no variable compensation paid to the Executive Director and key management personnel for FY2023.

Provision	Code and/or Provision Description	Company's Com	pliance or	Explanat	ion				
	(b) What were the performance conditions used to determine their entitlement under the short term and long term incontive schomos?	conditions used to determine competitive and to motivate the Executive Director to provide good their entitlement under the Group and for key management personnel to work in alignment							rdship of
	incentive schemes:	Table 7 – Incer	ntive Perfor	mance C	Condition	าร			
		Performance				centives			
		Conditions		(such	as perfo	ormance bo	nus)		
		Qualitative			Leaders		,		
						developme	nt		
				3.	Commit	ment			
				4.	Teamwo	ork			
		Quantitative		The Company currently does not have in place any profit-sharing or performance incentive arrangements for the Executive Director or the key management personnel which is based on the Company or the Group meeting a prescribed financial performance or financial condition target or condition. The RC will monitor and evaluate whether to provide for such quantitative performance conditions depending, <i>inter alia</i> , on the business and plans of the Company and the Group.					the key on the scribed n target evaluate ntitative alia, on
7.2	(c) Were all of these performance conditions met? If not, what were the reasons? Yes, the RC has reviewed and is satisfied that the performance condition met for FY2023. Please describe how the remuneration received by Non-Executive Directors has been determined by the performance criteria. The Non-Executive Directors do not have any service agreements Company. Except for directors' fees, which have to be approved by shat AGMs, the Non-Executive Directors do not receive any other remuneration from the Company. The fees for the financial year in review are determined in the current fina proposed by the Management, submitted to the RC for review and recommended to the Board for approval. The RC has reviewed and assessed that the remuneration of the Nor						eements ed by sha ny other rrent finar iew and t the Non-	with the reholders forms of ncial year, hereafter Executive	
		Directors for F responsibilities o				nsidering t	he effort	;, time sp	pent and
	on Remuneration					.			
8.1	(a) Has the Company disclosed each Director's and the CEO's	The breakdown f				Directors fo	or FY2023	s is as follo	WS:
	remuneration as well as a	Table 8.1 – Dire	1		1	Director	Donofi	Chara	Total
	breakdown (in percentage) into base/fixed salary, variable or performance-related income/bonuses, benefits in	Name	Remune ration Bands ⁽¹⁾	Salary (%)	Bonus (%)	Directors Fees (%)	Benefi ts-in- kind (%)	Share awards (%)	Total (%)
	kind, stock options granted, share-based incentives and	Thomas Tan Gim Chua	В	100	-	-	-	-	100
	awards, and other long-term incentives? If not, what are the reasons for not disclosing so?	Ng Fook Ai Victor	A	-	-	100	-	-	100
	reasons for not disclosing so?	Ng Boon Eng	A	-	-	100	-	-	100
		Sho Kian Hin	А	-	-	100	-	-	100

Provision	Cod	de and/or Provision Description	Company's Compliance or Explanation							
			Band "A" refers to remuneration of up to \$\$250,000 per annum; and							
			Band "B" refers to remuneration from S\$250,001 to S\$500,000 per annum.							
			There were no termination, retirement and post-employment benefits that may be granted to Directors, the CEO and the top key management personnel (who are not Directors or the CEO).							
	(b)	Has the Company disclosed each key management personnel's remuneration, in bands of \$\$250,000 or more in	The breakdo		muneration	n of the Cor	ment personne npany's key ma is as follows:	Ū		
		detail, as well as a breakdown (in percentage) into base/fixed								
		salary, variable or performance-related		- Remunerati	1	T			1	
		income/bonuses, benefits in kind, stock options granted,	Name	Remuner ation Bands ⁽¹⁾	Salary (%)	Bonus (%)	Benefits-in- kind (%)	Share awards (%)	Total (%)	
		share-based incentives and awards, and other long-term incentives? If not, what are the reasons for not disclosing so?	Dr Gian Siong Lin Jimmy	В	100	-	-	-	100	
		reasons for not disclosing so:	Fu Ching Xiong ⁽²⁾	А	100	-	-	-	100	
			Band "A' Band "B" (2) Fu Ching After review disadvantag personnel to disclosure w environment required. There were	refers to ren Xiong was a wing the ir es in relation to the nearest ould be preju t and the na no terminatio	nuneration ppointed o dustry pr to the discl thousand udicial to it ture of th	from S\$250 n 9 th Januar actice and losure of ren dollars, the s business in e industry	250,000 per an 0,001 to S\$500, ry 2023. analysing th nuneration of ea e Company is o nterest given th for which spec st-employment (who are not D	000 per ani e advanta ach key mai of the view ie highly co ialised skil benefits tha	ages and nagement that such ompetitive I sets are at may be	
	(c)	Please disclose the aggregate remuneration paid to the top five key management personnel (who are not Directors or the CEO).	Director and management renumeratio Report as the the Compart industry and personnel (effor non-disc of the remut provide shart as the level of	d CEO) in F at personnel n of the key be Board is of ny's' business the fact that excluding the losure state a uneration pre- reholders with	FY2023. The in FY2023 is a first second seco	he total ag 3 was S\$50 hent person on that such given the h gement tear and CEO). A Board is of erein in this on on the G h. According	personnel (exc gregate remu 05,000. The sp nel is not disc in disclosure wo highly competit in consists of or offer taking into the view that the s report is reas roup's remuner gly, the Board is e.	neration of becific disc losed in th uld be pre- ive conditionally two key account th he current sonably sur- ation polici-	f the key closure of judicial to judicial to ons in the executive he reasons disclosure fficient to es, as well	
8.2	sub Cor	there any employee who is stantial shareholder of the npany or is an immediate family mber of a Director or the CEO or	is a substan member of	tial sharehold	ler or emp substantial	loyee of the	reholder, there e Group who is r or the CEO	an immedi	ate family	

Provision	Code and/or Provision Description	Company's Compliance or Explanation	
	is immediate family of substantial shareholder of the Company, and whose remuneration exceeds S\$100,000 during the last financial year? If so, please identify the employee and specify the relationship with the relevant Director or the CEO.		
8.3	Please provide details of the employee share scheme(s).	 The Company does not have any employee share scheme(s). Under the Scheme mentioned under Provision 5.1 and 5.2 above: a) the Company had assumed all liabilities and obligations of QT Vascular Ltd, its wholly-owned subsidiary, in connection with the outstanding options ("Varied Options") granted by QT Vascular Ltd to the holders of the options under the 2014 QTV Employee Share Option Scheme ("Option Scheme"). b) the Company had assumed all liabilities and obligations of QT Vascular Ltd, its wholly-owned subsidiary in connection with the outstanding awards ("Varied Awards") granted by QT Vascular Ltd to the holders of the awards under the QT Vascular Restricted Share Plan 2015 (the "Share Plan"). pursuant to which the Company shall be liable to allot and issue new ordinary shares in the capital of the Company pursuant to the exercise of the Varied Options and/or the vesting of the Varied Awards. information relating to the Varied Options and Varied Awards is set out on pages 117 to 121 of this Annual Report. 	
	ABILITY AND AUDIT		
	ement and Internal Controls		
9.1 9.2 Catalist Rule 1204(10)	(a) In relation to the major risks faced by the Company, including financial, operational, compliance, information technology and sustainability, please state the bases for the Board's view on the adequacy and effectiveness of the Company's internal controls and risk management systems.	The Board is responsible for the overall risk governance, risk management and internal control framework of the Group and is fully aware of the need to put in place a system of internal controls within the Group to safeguard shareholders' interests and the Group's assets, and to manage risks. The CEO meets with key management personnel on a regular basis to discuss operational, business and strategic matters. During these meetings, key projects and operational risks are identified and discussed, along with proposed mitigating measures to address these risks to ensure residual risks are mitigated to an acceptable level. Follow-ups are then performed in subsequent meetings to ensure mitigating actions are executed. Any significant issues identified from these meetings are brought to the attention of the Board. The Group has in place a structured and systematic approach to risk management and aims to mitigate the exposures through appropriate risk management strategies and internal controls. Risk management in the Group is a continuous, iterative and	
		 integrated process which has been incorporated into various planning, approval, execution, monitoring, review and reporting systems. The Group adopts a top-down as well as bottom-up approach on risk management to ensure strategic, business, operational, financial, reporting, compliance and information technology risk exposures are identified and appropriately managed. The Board and the AC is of the view that the Company's internal controls (including financial, operational, compliance and information technology controls) and risk management systems were adequate and effective for FY2023. The bases for the Board's view are as follows: 	

Provision	Code and/or Provision Description	Company's Compliance or Explanation		
		 Assurance has been received from the CEO and CFO (refer to Section (b) below); 		
		 An internal audit has been done by the internal auditors and significant matters highlighted to the AC and key management personnel were appropriately addressed; 		
		 Key management personnel regularly evaluates, monitors and reports to the AC on material risks; 		
		4. Discussions were held between the AC and auditors in the absence of the key management personnel to review and address any potential concerns;		
		 An enterprise risk management framework was established to identify, manage and mitigate significant risks; and 		
		 Risk appetite statements with tolerance limits have been approved by the Board to contain risks within acceptable levels. 		
		The Company is gradually placing emphasis on sustainability and would implement appropriate policies and programmes when the opportunities arise.		
	(b) In respect of the past 12 months, has the Board received assurance from the CEO and the CFO as well as the IA that: (i) the financial records have been properly maintained and the financial statements give true and fair	The Board has received assurance from the CEO and CFO (a) that the financial records have been properly maintained and the financial statements for the financial year ended 31 December 2023 give a true and fair view of the Group's operations and finances; and (b) that the Group's risk management and internal control systems are adequate and effective to address the financial, operational, compliance and information technology risks in the context of the current scope of the Group's business operations.		
	view of the Company's operations and finances; and (ii) the Company's risk management and internal control systems are effective? If not, how does the Board assure itself of points (i) and (ii) above?	Based on the assurance from the CEO and CFO referred to in the preceding paragraph, the framework of risk management and internal controls established and maintained by the Group, the review performed by the Management and the AC, the work performed by the internal auditors and the review undertaken by the external auditors as part of their statutory audit, the Board, with the concurrence of the AC is satisfied with the adequacy and effectiveness of the Group's internal		
Audit Comm	ittee			
10.1	What is the composition of and role of the AC?	All members of the AC are Independent, Non-Executive Directors who do not have any management and business relationships with the Company or any substantial shareholder of the Company. None of the AC members were previous partners or directors of the Company's external audit firm within the last twelve (12) months and none of the AC members hold any financial interest in the external audit firm.		
		The AC is guided by the following key terms of reference:		
		 (a) reviewing the significant financial reporting issues and judgements to ensure the integrity of the financial statements of the Company and any formal announcements relating to the Group's financial performance; 		
		(b) considering the appointment, re-appointment or removal of the external auditors, the level of their remuneration and matters relating to resignation or removal of the external auditors, and reviewing with the external auditors the audit plans, their evaluation of the system of internal accounting controls and accounting system, their audit reports, their management letter and the Company's management's response before submission of the results of such review to the Board for approval;		

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		 (c) considering the appointment, re-appointment or removal of the internal auditors, the level of their remuneration and matters relating to resignation or removal of the internal auditors, and reviewing with the internal auditors the internal audit plans and their evaluation of the adequacy of the Company's system of internal accounting controls and accounting system before submission of the results of such review to the Board for approval prior to the incorporation of such results in the Company's Annual Report (where necessary);
		 (d) reviewing the system of internal accounting controls and procedures established by management and discussing problems and concerns, if any, arising from the interim and final audits, and any matters which the auditors may wish to discuss (in the absence of management where necessary);
		 (e) overseeing the development of the Company's risk framework to manage the current risk exposures and future risk strategy of the Company;
		(f) reviewing the annual and half yearly financial statements and results announcements, where applicable, before submission to the Board for approval, focusing in particular, on changes in accounting policies and practices, major areas of judgement, significant adjustments resulting from the audit, the going concern statement, compliance with accounting standards as well as compliance with any stock exchange and statutory/ regulatory requirements;
		 (g) reviewing the effectiveness and adequacy of the Company's administrative, operating, internal accounting, financial control procedures and risk management system;
		 (h) reviewing the scope and results of the external and internal audit, and the independence and objectivity of the external and internal auditors;
		 reviewing the assurance from the CEO and CFO on the financial records and financial statements; and
		(j) reviewing whistleblowing reports by which the staff may, in confidence, raise concerns about possible improprieties in matters of financial reporting and to ensure that arrangements are in place for the independent investigations of such matter and for appropriate follow-up.
	Does the Company have a whistle- blowing policy?	Yes. The Company's staff and any other persons may, in confidence, raise concerns about possible improprieties in matters of financial reporting or other matters by submitting a whistle blowing report to whistleblowing@quantumhealthcare.com.sg which will be redirected to individual emails for each of the AC members.
		The AC, upon receipt of complaints or allegations from any employee, determines if an investigation is necessary. If an investigation should be carried out, it will direct an independent investigation to be conducted on the complaint received. The independent investigation has a well-defined process which ensures independent investigation of issues/concerns raised and appropriate follow-up action and provides assurance that employees and whistle blowers will be protected from detrimental, unfair treatment and/or reprisal within the limits of the law or victimisation for whistle blowing in good faith. Anonymous reporting will also be attended to, and anonymity honoured.
		The AC is responsible for oversight and monitoring of the whistle blowing policy and procedures and review them from time to time to ensure that they remain relevant.
		The AC reports to the Board on such matters at the Board meetings. Should the AC receive reports relating to serious offences and/or criminal activities within the Group, the AC and the Board have the option to seek external advice where necessary. Where appropriate or required, a report will be made to the relevant government authorities for further investigation or action.
		In FY2023, there were no whistle-blowing reports received by the whistle-blowing committee.

Provision	Code and/or Provision Description	Company's Compliance or Explanation			
Catalist Rules 1204 (6)(a) and	Has the AC reviewed the independence of the EA?	The AC has reviewed the non-audit services provided by the EA and is satisfied that the nature and extent of such services would not prejudice the independence of the EA, and has recommended the re-appointment of the EA at the forthcoming AGM.			
1204(6)(b)	(a) Please provide a breakdown of the fees paid in total to the EA	Table 10.1 – Fees Paid/F	Payable to the EA for FY20	23	
	for audit and non-audit services for the financial year.		S\$'000	% of total	
	services for the infaricial year.	Audit fees	175	100	
		Non-audit fees	-	-	
		Total	175	100	
	(b) If the EA have supplied a substantial volume of non- audit services to the Company, please state the bases for the AC's view on the independence of the EA.	external auditors and has appointed auditors, Maza	recommended to the Boa rs LLP, be nominated for eneral Meeting of the Com	ndence and objectivity of the ard of Directors that the newly re-appointment as auditors at apany. The EA has not provided	
10.2	Qualification of the AC members	accounting and financial n	nanagement knowledge ar n Eng and Mr Ng Fook Ai	b has extensive and practical and experience, well qualified to Victor of the AC are also well	
		Further details on the key information and profile of the AC membe academic and professional qualifications, are presented under the Dire section of this Annual Report.			
		The members of the AC collectively have many years of strong accounting and related financial management expertise and experience and are appropriately qualified to discharge their responsibilities.			
10.3	Exclusion from membership of AC	auditing firm or audit cor	poration within the last tw	ector of the Company's existing wo years and none of the AC udit firm.	
10.4 Catalist Rules 719(3) and 1204(10C)	Please provide details of the Company's internal audit function, if any.	members hold any financial interest in the external audit firm. The Company's internal audit function is outsourced to BDO LLP that reports directly to the AC Chairman and administratively to the CEO and CFO. The AC is responsible for the hiring, removal, evaluation and compensation of the accounting or auditing firm or corporation which the internal audit function of the Company is outsourced to. The AC is satisfied that internal auditor is able to discharge its duties effectively as the internal auditor:			
			n that the internal auditor ent of the Company;	reports directly to the AC and	
		personnel, including in the Company, giv being able to meet t	direct access to the AC, an en, <i>inter alia</i> , its involveme the AC without the presen- which allows the internal	ments, records, properties and ad has the appropriate standing ent in certain AC meetings and ce of the Management at least auditors to be effective in their	
 is adequately qualified, given that the partner and audit of the Company are members of the Institu adheres to the Standards for the Professional Pra- down in the International Professional Practice Institute of Internal Auditors; and 		itute of Internal Auditors and it ractice of Internal Auditing laid			
 is adequately resourced as there is a team of between assigned to the Company's internal audit, led by Will than 15 years of diverse audit experience. 					

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		Pursuant to the requirement under Rule 711B(3) of the Catalist Rules for the Group's sustainability reporting to be subject to internal review, the Company has expanded the Internal Audit function to include the review and coverage of material environmental, social and governance (" ESG ") areas in the annual internal audit plan. The Board will continue to monitor and assess if external assurance is required for the subsequent sustainability reports.
10.5	Has the AC met with the External and Internal Auditors in the absence of key management personnel?	Yes, the AC has met with the IA and the EA once in the absence of key management personnel in FY2023.
SHAREHOLI	DER RIGHTS AND RESPONSIBILITIES	
Shareholder	Rights and Conduct of General Meetin	gs
11.1	Shareholders' Participation at General Meetings	Shareholders are encouraged to attend the general meetings to ensure a greater level of shareholders' participation and for them to be kept up to date with the strategies and goals of the Group. All shareholders of the Company will receive printed copies of the notice of AGM, the notice pertaining to any extraordinary general meetings of the Company, the accompanying proxy form in relation to such meetings and the request form for shareholders to request for physical copies of the Annual Report or the circular (as the case may be). As part of the Group's commitment to conserving the environment, the Company will NOT send printed copies of the Annual Report or circular to shareholders. All notice of AGM, the notice pertaining to any extraordinary general meetings of the Company, the accompanying proxy form and request form, the Annual Report and circular in relation to an extraordinary general meeting of the SGX-ST at its URL https://www.sgx.com/securities/company-announcements and may be accessed at the Company's website at its URL https://www.quantumhealthcare.com.sg/.
	Appointment of Proxies	To facilitate participation by the shareholders, the Constitution allows the shareholders to attend and vote at general meetings of the Company or to appoint not more than two proxies, other than a relevant intermediary (as defined in section 181(6) of the Companies Act) to attend and vote on their behalf. A relevant intermediary is entitled to appoint more than two (2) proxies to attend, speak and vote at the general meetings.
11.2	Bundling of Resolutions	Separate resolutions on each distinct issue are requisite unless they are closely related and are more appropriately tabled together. Reasons, and implications of why resolutions are bundled will be set out in the circulars sent out.
11.3	Directors' Attendance	At all general meetings, all Directors (including the respective chairman of the Board Committee) are required to present and to answer queries from shareholders. Shareholders are given the opportunity at the general meetings of the Company to air their views and query the Directors and the Management on matters relating to the Group and its operations. The EA is also required to be present to address shareholders' queries about the conduct of audit and the preparation and content of the independent auditor's report.
		All the Directors and the EA attended the AGM for the financial year ended 31 December 2022 held on 27 April 2023.
		The Company views the AGM as a principal forum of dialogue and interaction with all shareholders. The Company will consider the use of other forums set out in the Code as and when such needs arise.
11.4	Absentia Voting	Voting in absentia such as voting via mails, electronic mails or facsimile at the general meetings may only be possible following careful study to ensure that integrity of the information and authentication of the identity of shareholders through the web is not compromised.
11.5	Publication of Minutes	The Company prepares minutes of general meetings which include substantial and relevant comments and queries from shareholders relating to the agenda of the general meetings together with responses from the Board and Management.

Provision	Code and/or Provision Description	Company's Compliance or Explanation
		For the general meetings held during FY2023, all minutes of such meetings were announced on the Company's corporate website and SGXNET. The minutes to the Company's upcoming AGM will be published on SGXNET and the Company's corporate website within one month after the AGM.
11.6	Does the Company have a dividend policy?	The Company does not have a fixed dividend policy. Nonetheless, key management personnel will review, <i>inter alia</i> , the Group's performance in the relevant financial period, projected capital needs and working capital requirements and make appropriate recommendations to the Board on dividend declaration.
	Is the Company paying dividends for the financial year? If not, please explain why.	The Board has not declared or recommended any dividends for FY2023 as the Company was not profitable and intends to retain all available funds for working capital requirements.
Engagemer	t with Shareholders	
12.1 12.2 12.3	Please disclose if the Company has an investor policy in place.	In line with continuous disclosure obligations, the Company is committed to provide regular and proactive communication with its shareholders but considers advice from its corporate lawyers and professionals on appropriate disclosure requirements before announcing material information to shareholders.
		All announcements are released via SGXNET including the quarterly/half yearly and full year financial results, distribution of notices, press releases and other major developments. Price sensitive information to shareholders is publicly released on an immediate basis where required under the Catalist Rules. Physical copies of the Annual Report will not be sent to the shareholders of the Company. Instead, the Annual Report will be made available on the website of the SGX-ST at its URL https://www.sgx.com/securities/company-announcements and the Company's website at its URL https://www.quantumhealthcare.com.sg/.
		 To facilitate effective two-way communication between the Company and its shareholders, including <i>inter alia</i>, the solicitation of feedbacks from and addressing the concerns of shareholders, the Company has the following mechanisms: dedicated investor relations contact at <u>in.sg@quantumhealthcare.com.sg</u> for shareholders to ask questions and receive responses in a timely manner; a webpage dedicated for Investor Relations at <u>https://www.quantumhealthcare.com.sg/investor-relations</u>, where the Company's past announcements and Annual Reports as well as the email address for the dedicated investor relations contact (<u>ir.sg@quantumhealthcare.com.sg</u>) can be found media publications; and investor/analyst briefings.
		The Company's investor relations website at <u>https://www.quantumhealthcare.com.sg/investor-relations</u> is a key resource of information for the investment community as it contains comprehensive information on the Company, including past announcements, Annual Reports, past financial results, shares and dividend information.
	(a) Does the Company regularly communicate with shareholders and attend to their questions? How often does the Company meet with institutional and retail investors?	The Company strives to communicate regularly and beneficially with its shareholders, by providing interim updates that are in addition to the mandatory financial statements which shareholders may find useful, including, <i>inter alia</i> , a discussion of the significant factors that affected the company's interim performance, relevant market trends, and the foreseeable risks and opportunities that may have a material impact on the company's prospects. Such information provides shareholders a better understanding of the Company's performance in the context of the current business environment. The Company also meets shareholders, investors and media who wish to seek a better understanding of the Group's operations as and when necessary and appropriate.
	(b) Is this done by a dedicated investor relations team (or equivalent)? If not, who performs this role?	The Company does not have a dedicated internal investor relations team. The Company's CEO and CFO are responsible for managing investor relations.

Provision	Code and/or Provision Description	Company's Compliance or Explanation
	(c) How does the Company keep shareholders informed of corporate developments, apart from SGXNET announcements and the Annual Report?	Apart from the SGXNET announcements and its Annual Report, the Company updates shareholders on its corporate developments through its corporate website at <u>www.quantumhealthcare.com.sg</u> and its investor relations webpage at <u>https://www.quantumhealthcare.com.sg/investor-relations</u> . The Company also has a dedicated investor relations contact at <u>ir.sg@quantumhealthcare.com.sg</u> , through which shareholders are able to ask questions and receive responses in a timely manner. This contact point is operated by the Company's CEO and CFO, who, as part of the Management, will be best suited to address questions from shareholders given that they are well acquainted with the matters of the Group which the shareholders would be concerned with. They may be assisted by the Company Secretary and/or professional advisers as and when necessary.
MANAGIN	G STAKEHOLDERS RELATIONSHIP	
Engagemer	nt with Stakeholders	
13.1 13.2 13.3		The Company undertakes an annual review to identify its material stakeholders through various medium and channels and seek to understand their needs and expectations, and to address their concerns so as to improve product standards, as well as to align the business interest with those of the stakeholders and ultimately to generate sustainable value in the long-run. It assesses the material ESG factors that affects the Group.
		Please refer to the Company's latest sustainability report FY2023 set out on pages 12 to 30 of this Annual Report for the assessment process and how such relationships with stakeholders are managed.
COMPLIAN	ICE WITH APPLICABLE CATALIST RULE	8
<u>Catalist</u> <u>Rule</u>	Rule Description	Company's Compliance or Explanation
712, 715	Appointment of Auditors	The Company confirms its compliance to the Catalist Rules 712 and 715.
		Mazars LLP is the auditor for all Singapore subsidiaries in the Group except for insignificant subsidiaries Kairogenix Pte Ltd, Quantum Healthcare Holdings Sdn. Bhd. and Quantum Specialist Sdn. Bhd. which were audited by TY Teoh International. Associate company TriReme Medical LLC is not required to be audited in the country of incorporation (USA).
		Notwithstanding the above, the Board and Audit Committee are satisfied that the appointment of auditors would not compromise the standard and effectiveness of the audit of the Company.
1204(8)	Material Contracts	Save for the service agreement entered into with the CEO and controlling shareholder, there were no material contracts entered into by the Group involving the interest of the CEO, any Director, or controlling shareholder, which are either still subsisting at the end of FY2023 or if not then subsisting, entered into since the end of the previous financial year.
1204(10)	Confirmation of adequacy of internal controls	The Board and the AC are of the opinion that the internal controls are adequate to address the financial, operational and compliance and information technology risks which the Group considers relevant and material to its current business scope and environment for FY2023 based on the following:
		 internal controls and the risk management system established by the Company;
		work performed by the internal and external auditors;
		 assurances from the CEO and CFO; and reviews done by the various Board Committees and key management personnel.

Provision	Code and/or Provision Description	Company's Compliance or Explanation
1204(17)	Interested Persons Transaction ("IPT")	The Group has procedures governing all IPTs to ensure that they are properly documented and reported on a timely manner to the AC and that they are carried out on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders.
		In FY2023, there were no other interested person transactions which were S\$100,000 and above entered into during the current financial period reported on.
1204(19)	Dealing in Securities	The Company has adopted an internal policy which prohibits the Directors and officers from dealing in the securities of the Company while in possession of price-sensitive information.
		The Company, its Directors and officers are also discouraged from dealing in the Company's securities on short term considerations and are prohibited from dealing in the Company's securities during the period beginning two weeks before the announcement of the Company's quarterly financial statements and one month before the announcement of the Company's full-year financial statements respectively, and ending on the date of the announcement of the relevant results.
1204(21)	Non-sponsor fees	There were S\$32,000 non-sponsor fees paid to the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd for FY2023.
1204(22)	Use of Proceeds	Share Placements
		On 28 March 2023, the Company announced the completion of the placement of 571,428,600 new ordinary shares of the Company at the issue price of S\$0.0035 per share, which took place on 29 March 2023. The estimated net proceeds is approximately S\$1.9 million ("March 2023 Placement Net Proceeds")
		On 8 February 2024, the Company announced the completion of the placement of 400,000,000 new ordinary shares and settlement share issuance of 150,000,000 new ordinary shares at the issue price of \$\$0.002 per share. The estimated net cash proceeds is approximately \$\$740,000 ("February 2024 Placement Net Proceeds") which will be used for partial payment of the remaining balance of \$\$1,083,333.33 of second tranche earn-out amount payable to Dr. Jimmy.
		As at the date of this announcement, the March 2023 Placement Net Proceeds and the February 2024 Placement Net Proceeds have been fully utilised.
		The above utilisation is in accordance with the intended use of proceeds as stated in the Company's circular dated 11 March 2023 and 24 January 2024. Details of the use of proceeds for working capital can be found in the Company's annual report announced on 13 April 2023 and the Company's circular dated 24 January 2024.
Practice Note 7F	Update on Sustainability Report	The Group recognises the importance of sustainability that creates long-term value to our stakeholders by embracing opportunities and managing risks derived from social developments and governance. The Group is committed towards implementing sustainable practices in order to achieve the right balance between the needs of the wider community and the requirements of stakeholders and business growth.
		The Company's sustainability report has been prepared in accordance with the Global Reporting Initiative Standards and in line with the requirements of the Catalist Rules on sustainability reporting. The report will highlight the key factors such as product quality, business ethics and regulatory compliance. The Company's Sustainability Report is set out on pages 12 to 30 of this Annual Report.

DIRECTORS' STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

The directors present their statement to the members together with the audited consolidated financial statements of Quantum Healthcare Limited (the "Company") and its subsidiaries (collectively, the "Group") for the financial year ended 31 December 2023 and the statement of financial position of the Company as at 31 December 2023.

1. Opinion of the directors

In the opinion of the directors,

- (a) the financial statements of the Group and the statement of financial position of the Company are drawn up so as to give a true and fair view of the financial position of the Group and of the Company as at 31 December 2023, and of the financial performance, changes in equity and cash flows of the Group for the financial year ended on that date; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Group and the Company will be able to pay the debts as and when they fall due. The financial statements have been prepared on a going concern basis, after taking into consideration the factors as disclosed in Note 2.1(b) to the financial statements.

2. Directors

The directors of the Company in office at the date of this statement are:

Ng Fook Ai Victor Thomas Tan Gim Chua Sho Kian Hin Ng Boon Eng

3. Arrangements to enable directors to acquire shares and debentures

Neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose objects were, or one of whose objects was, to enable the directors of the Company to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate, except as disclosed in paragraphs 4 and 5 below.

4. Directors' interests in shares or debentures

The directors of the Company holding office at the end of the financial year had no interests in the shares and debentures of the Company and its related corporations as recorded in the Register of Directors' Shareholdings kept by the Company under Section 164 of the Singapore Companies Act 1967 (the "Act"), except as disclosed below:

	Direct interest		Deemed interest	
Name of directors and company in which interest are held	As at 1 January <u>2023</u>	As at 31 December <u>2023</u>	As at 1 January <u>2023</u>	As at 31 December <u>2023</u>
The Company (Ordinary shares)				
Ng Fook Ai Victor	2,000,000	2,000,000	-	-
Thomas Tan Gim Chua Sho Kian Hin	1,671,296,804 60	871,296,804** 60	27,424,658*	827,424,658** -

DIRECTORS' STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

4. Directors' interests in shares or debentures (Continued)

- Thomas Tan Gim Chua is deemed to be interested in 27,424,658 shares ("the shares") held in Emerald Apex Pte. Ltd. and MDIE Pte. Ltd. pursuant to Section 7 of the Act, as he has entered into a sale and purchase agreement with Emerald Apex Pte. Ltd. and MDIE Pte. Ltd. to purchase the shares. The shares have yet to be transferred pending payment and processing of the transfer.
- ** There was a reduction in Thomas Tan Gim Chua's direct interest and conversely an increase in deemed interest of 800,000,000 shares during the year, following his transfer of 800,000,000 ordinary shares to his spouse on 30 June 2023.

There are no changes to the above shareholdings as at 21 January 2024.

5. Share options

Share option programme

In September 2005 ("2005 Stock Plan"), November 2010 ("2010 Stock Plan") and September 2013 ("2013 Stock Plan"), QT Vascular Ltd. ("QTV") had established share option plans that entitle certain employees, directors and consultants to purchase ordinary shares in QTV. Further, in April 2014, QTV adopted the 2014 QTV Employee Share Option Scheme ("2014 Stock Plan") which had become effective upon the listing of QTV on the Catalist of the SGX-ST in April 2014.

As part of the corporate restructuring as disclosed in Note 2.1(a) to the financial statements, all liabilities and obligations in connection with the outstanding share options ("Options") granted under QTV's 2005, 2010, 2013 and 2014 Stock Plans (collectively, the "Option Schemes") are assumed by the Company ("Options Variation"). The Options Variation do not involve any changes made to the terms of the share options granted or the rules of the Option Schemes except the outstanding Options will be exercisable into shares of the Company.

The above schemes are administered by the remuneration committee of the Company authorised and appointed by the board of directors and are available to all employees and non-executive directors of the Group.

At the reporting date, the Option Schemes have 11 Option holders with 4,219,000 outstanding Options. Details of the outstanding Options are set out below.

Options granted	Date granted	Exercise period	Exercise price per <u>option (S\$)</u>	Options outstanding at <u>31</u> <u>December 2023</u>	Number of Option holders
2014 Stock Option	14 August 2015	Ten years from date of grant	0.095	4,219,000	11

The Company does not intent to issue additional Options under the Option Schemes.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

5. Share options (Continued)

Share option programme (Continued)

The detail movement of the Option during the financial year are as follow:

	Group <u>No. of options</u>	
	<u>2023</u> ′000	<u>2022</u> ′000
Outstanding at 1 January Expired during the year	12,186 (7,967)	22,504 (10,318)
Outstanding at 31 December	4,219	12,186
Exercisable at 31 December	4,219	12,186

The details of the options granted under the Schemes to participants, who receive 5% or more of the total number of options available under the schemes:

	during financial	granted since commencement of scheme to end of	commencement of scheme to end of	outstanding as at
	year under review	financial year under	financial year under	end of financial year
Name of participant	(including terms)	review	review	under review
Ardakani, Shiva	-	1,127,000	-	1,127,000
Binyamin, Gary	-	1,000,000	-	1,000,000
Huynh, Gina	-	300,000	-	300,000
Ong, Gim Moey	-	972,000	-	972,000
Piva, Guillermo	-	400,000	-	400,000

As at 31 December 2023, no directors or controlling shareholders of the Company or their associate who held office at the end of the financial year have outstanding options under the Option Schemes.

Restricted share awards

The QT Vascular Restricted Share Plan 2015 ("Award Scheme") was adopted to allow QTV to grant share awards ("Awards") to employees and directors of the Company or its subsidiaries, including controlling shareholders and their associates.

As part of the corporate restructuring as disclosed in Note 2.1(a) to the financial statements, all liabilities and obligations in connection with the outstanding Awards granted under the Award Scheme are assumed by the Company ("Awards Variation"). The Awards Variation do not involve any changes made to the terms of the Awards granted or the rules of the Award Scheme except the outstanding Awards shall be referenced to shares of the Company.

DIRECTORS' STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

5. Share options (Continued)

Restricted share awards (Continued)

The above awards are administered by the remuneration committee of the Company authorised and appointed by the board of directors and are available to all employees and non-executive directors of the Group.

Since the commencement of the Scheme, no award has been granted to the directors, controlling shareholders of the Company or their associates and no participants under the Award Scheme have been granted 5% or more of the total number of award available under the Award Scheme.

As at 31 December 2023, the Award Scheme has 5 share awards holders with an aggregate of 1,091,544 outstanding Awards. The Company does not intend to grant additional Awards under the Award Scheme.

The detail movement of the Awards during the financial year are as follow:

	Group <u>No. of Aw</u>		
	<u>2023</u> ′000	<u>2022</u> ′000	
Outstanding at 1 January Forfeited during the year	1,242 (150)	1,242	
Outstanding at 31 December	1,092	1,242	

As at 31 December 2023, other than Sho Kian Hin who has 331,631 outstanding Awards, no directors who held office at the end of the financial year have outstanding Awards under the Award Scheme.

Other than disclosed above, there were no options granted by the Company or its subsidiaries during the financial year.

There were no shares issued during the financial year by virtue of the exercise of options to take up unissued shares of the Company or its subsidiaries.

There were no unissued shares under option in the Company or its subsidiaries as at the end of the financial year.

6. Audit committee

The audit committee of the Company comprises three members, all of whom are Independent Directors and at the date of this statement are:

Sho Kian Hin (Chairman) Ng Boon Eng Ng Fook Ai Victor

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

6. Audit committee (Continued)

The audit committee carried out its functions in accordance with Section 201B (5) of the Act, the SGX Listing Manual and the Code of Corporate Governance. In performing those functions, the audit committee:

- reviewing the significant financial reporting issues and judgements to ensure the integrity of the financial statements of the Company and any formal announcements relating to the Group's financial performance;
- considering the appointment, re-appointment or removal of the external auditors, the level of
 their remuneration and matters relating to resignation or removal of the external auditors, and
 reviewing with the external auditors the audit plans, their evaluation of the system of internal
 accounting controls and accounting system, their audit reports, their management letter and the
 Company's management's response before submission of the results of such review to the Board
 for approval;
- considering the appointment, re-appointment or removal of the internal auditors, the level of their remuneration and matters relating to resignation or removal of the internal auditors, and reviewing with the internal auditors the internal audit plans and their evaluation of the adequacy of the Company's system of internal accounting controls and accounting system before submission of the results of such review to the Board for approval prior to the incorporation of such results in the Company's Annual Report (where necessary);
- reviewing the system of internal accounting controls and procedures established by management and discussing problems and concerns, if any, arising from the interim and final audits, and any matters which the auditors may wish to discuss (in the absence of management where necessary);
- overseeing the development of the Company's risk framework to manage the current risk exposures and future risk strategy of the Company;
- reviewing the annual and half yearly financial statements and results announcements, where applicable, before submission to the Board for approval, focusing in particular, on changes in accounting policies and practices, major areas of judgement, significant adjustments resulting from the audit, the going concern statement, compliance with accounting standards as well as compliance with any stock exchange and statutory/ regulatory requirements;
- reviewing the effectiveness and adequacy of the Company's administrative, operating, internal accounting, financial control procedures and risk management system;
- reviewing the scope and results of the external and internal audit, and the independence and objectivity of the external and internal auditors;
- reviewing the assurance from the CEO and CFO on the financial records and financial statements; and
- reviewing whistleblowing reports by which the staff may, in confidence, raise concerns about possible improprieties in matters of financial reporting and to ensure that arrangements are in place for the independent investigations of such matter and for appropriate follow-up.

The audit committee has full access to and has the co-operation of the management and has been given the resources required for it to discharge its function properly. It also has full discretion to invite any director and executive officer to attend its meetings. The external auditors have unrestricted access to the audit committee.

DIRECTORS' STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

6. Audit committee (Continued)

Further details regarding the audit committee are disclosed in the Report on Corporate Governance included in the Company's Annual Report.

The audit committee has recommended the nomination of Mazars LLP for re-appointment as external auditors of the Group at the forthcoming Annual General Meeting of the Company.

In appointing the auditors for the Company and its subsidiaries, Rules 712, and 715 of the SGX Listing Manual have been complied with.

7. Independent auditors

The auditors, Mazars LLP, have expressed their willingness to accept re-appointment.

On behalf of the directors

Ng Fook Ai Victor Director Thomas Tan Gim Chua Director

Singapore 12 April 2024

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF QUANTUM HEALTHCARE LIMITED (INCORPORATED IN SINGAPORE)

Report on the Audit of Financial Statements

Disclaimer of Opinion

We were engaged to audit the financial statements of Quantum Healthcare Limited (the "Company") and its subsidiaries (collectively, the "Group"), which comprise the consolidated statement of financial position of the Group and the statement of financial position of the Company as at 31 December 2023, and the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements, including a summary of material accounting policies, as set out on pages 64 to 142.

We do not express an opinion on the consolidated financial statements of the Group and the statement of financial position of the Company. Because of the significance of the matters described in the "Basis for Disclaimer of Opinion" section of our report, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.

Basis for Disclaimer of Opinion

The financial statements of the Group and the Company for the financial year ended 31 December 2022 were audited by another firm of auditors who expressed a disclaimer of opinion on the matter described in the "Other Matters" section below as well as the matter below which remains unresolved during the course of our audit of the financial statements for the financial year ended 31 December 2023.

Going concern assumption

For the financial year ended 31 December 2023, the Group incurred a net loss and a total comprehensive loss of \$\$3,381,000 and \$\$3,385,000, respectively, and has net cash flows used in operating activities of \$\$628,000. As at 31 December 2023, the Group's and Company's current liabilities exceeded its current assets by \$\$7,189,000 and \$\$7,147,000 respectively, and the Group and Company have a deficit in shareholders' equity of \$\$3,028,000 and \$\$5,038,000, respectively, as at that date. These conditions indicate the existence of a material uncertainty which may cast a significant doubt on the ability of the Group and the Company to continue as going concern.

Notwithstanding the above, the directors are of the view that it is appropriate for the financial statements to be prepared on a going concern basis after considering the assumptions as disclosed in Note 2.1(b) to the financial statements.

The use of the going concern assumption by the directors in the preparation of the financial statements is dependent on various assumptions that are premised on future events, of which the viability relating to certain assumptions is materially uncertain in the absence of supporting evidence. Consequently, we are unable to conclude on the appropriateness of the directors' use of the going concern assumption in preparation of these financial statements.

Should the going concern assumption be inappropriate, adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are recorded in the statement of financial position. In addition, the Group and the Company may have to provide for further liabilities that might arise, and to reclassify non-current assets and non-current liabilities, where applicable, as current assets and current liabilities respectively. No such adjustments have been made to these financial statements.

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF QUANTUM HEALTHCARE LIMITED (INCORPORATED IN SINGAPORE)

Report on the Audit of Financial Statements (Continued)

Responsibilities of Management and Directors for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and SFRS(I)s, and for devising and maintaining a system of internal accounting controls sufficient to provide reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our responsibility is to conduct an audit of the Group's financial statements in accordance with Singapore Standards on Auditing and to issue an auditor's report. However, because of the matters described in the Basis for Disclaimer of Opinion section of our report, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.

We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority (ACRA) Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code.

Other Matter

The financial statements of the Group and the Company for the financial year ended 31 December 2022 were audited by another firm of auditors who expressed a disclaimer of opinion on those statements on 12 April 2023 for the matter described in the Basis for Disclaimer of Opinion and also the matter described below:

Consolidation of Trireme Medical LLC ("TriReme")

There was a purported dilution of Group's interest in TriReme during the financial year ended 31 December 2022 and the Group has continued to consolidate TriReme as a subsidiary of the Group in the consolidated financial statements for the financial year ended 31 December 2022. The predecessor auditors were unable to obtain sufficient appropriate evidence concerning the veracity of the aforesaid dilution in the Group's interest in TriReme. Consequently, they were unable to ascertain whether the continuing consolidation of TriReme as a subsidiary in the consolidated financial statements of the Group for the financial year ended 31 December 2022 is appropriate.

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF QUANTUM HEALTHCARE LIMITED (INCORPORATED IN SINGAPORE)

Other Matter (Continued)

Further, they were unable to access the accounting records of TriReme, perform audit procedures, or alternative procedures, as auditors of the Company on the unaudited management accounts of TriReme for the purpose of providing an opinion on the consolidated financial statements of the Group for the financial year ended 31 December 2022. Consequently, they were unable to determine if the consolidated financial statements of the Group for the financial statements of the Group for the financial year ended 31 December 2022 were fairly stated. Any adjustments and/or additional disclosure that may be required to be made in relation to the unaudited management accounts of TriReme may have a significant impact on the consolidated financial statements of the Group.

Report on Other Legal and Regulatory Requirements

In view of the significant of the matter referred to in the "Basis for Disclaimer of Opinion" section of our report, we do not express an opinion on whether the accounting and other records required by the Act to be kept by the Company and by those subsidiary corporations incorporated in Singapore of which we are the auditors have been properly kept in accordance with the provisions of the Act.

The engagement partner on the audit resulting in this independent auditors' report is Zhang Liang.

MAZARS LLP Public Accountants and Chartered Accountants

Singapore 12 April 2024

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

	Group		
	<u>Note</u>	<u>2023</u>	<u>2022</u>
		S\$'000	S\$'000
			(Restated)
Revenue	4	13,081	9,368
Cost of sales		(7,321)	(5,019)
Gross profit		5,760	4,349
Administrative expenses		(8,730)	(6,608)
Research and development expenses		-	(743)
Other income	5	179	85
Impairment loss on goodwill		-	(4,625)
Loss from deemed disposal of a subsidiary		-	(787)
Finance costs	6	(490)	(450)
Loss before income tax	7	(3,281)	(8,779)
Income tax expense	8	(100)	(117)
Loss for the financial year		(3,381)	(8,896)
Other comprehensive income:			
Components of other comprehensive income that will be			
reclassified to profit or loss, net of taxation			
Exchange differences on translating foreign operations		(4)	-
Total comprehensive loss for the financial year		(3,385)	(8,896)
Loss attributable to:			
Owners of the Company		(3,621)	(9,066)
Non-controlling interests		240	170
Loss for the financial year		(3,381)	(8,896)
Total comprehensive loss for the financial year			
attributable to:			
Owners of the Company		(3,625)	(9,066)
Non-controlling interests		240	170
		(3,385)	(8,896)
Loss per share attributable to owners of the			
Company (cents per share)			
Basic and diluted	9	(0.05)	(0.13)

STATEMENTS OF FINANCIAL POSITION

AS AT 31 DECEMBER 2023

		Group			<u>Company</u>		
	<u>Note</u>	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)	<u>2021</u> S\$′000 (Restated)	<u>2023</u> S\$'000	<u>2022</u> S\$'000	
ASSETS			. ,				
Non-current assets							
Plant and equipment	10	1,050	827	-	12	-	
Goodwill	11	5,580	4,120	-	-	-	
Intangible assets	12	686	688	-	-	-	
Investments in subsidiaries	13	-	-	-	3,411	7,573	
Investments in associate	14	-	-	-	-	-	
Other investment	15 24(a)	-	-	-	-	-	
Right-of-use assets Other non-current assets	24(a) 16	1,968 27	2,029 3	493 49	-	-	
Total non-current assets	- 10	9,311	7,667	542	3,423	7,573	
Total non-current assets	-	9,311	7,007		5,425	7,073	
Current assets							
Inventories	17	37	32	-	-	-	
Trade and other receivables	18	2,939	1,681	30	13	7	
Cash and cash equivalents	19	744	5,065	344	21	1,062	
Total current assets	_	3,720	6,778	374	34	1,069	
Total assets	-	13,031	14,445	916	3,457	8,642	
EQUITY AND LIABILITIES							
EQUITY	20	226 162	224.220	225 100	226 162	224 220	
Share capital	20 21	236,163 9,638	234,230	235,188	236,163	234,230	
Reserves Accumulated losses	21	9,638 (249,666)	9,714 (246,045)	4,790 (242,526)	(228,714) (12,487)	(228,714) (6,861)	
Accumulated 1033e3	-	(249,000)	(240,043)	(242,320)	(12,407)	(0,001)	
Equity attributable to owner of							
the Company		(3,865)	(2,101)	(2,548)	(5,038)	(1,345)	
Non-controlling interests	-	837	597	(43)	-	-	
Total equity	-	(3,028)	(1,504)	(2,591)	(5,038)	(1,345)	
Non-current liabilities							
Deferred tax liabilities	22	128	61	-	-	-	
Other payables	23	31	-	-	-	-	
Lease liabilities	24(b)	919	1,251	309	-	-	
Loans and borrowings	25	2,758	4,238	-	-	-	
Amount due to a non-controlling							
interest	26	1,314	2,563		1,314	2,563	
Total non-current liabilities	-	5,150	8,113	309	1,314	2,563	
Current liabilities							
Trade and other payables	23	6,338	4,177	2,510	5,798	6,041	
Lease liabilities	24(b)	1,027	756	203	-	-	
Loans and borrowings	25	1,804	1,309	485	-	-	
Amount due to a non-controlling							
interest	26	1,383	1,383	-	1,383	1,383	
Provisions	27	263	155	-	-	-	
Provision for income tax	_	94	56	-	-	-	
Total current liabilities	-	10,909	7,836	3,198	7,181	7,424	
Total liabilities	-	16,059	15,949	3,507	8,495	9,987	
Total equity and liabilities	-	13,031	14,445	916	3,457	8,642	

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

Group	Share capital	Merger reserve	Reserve for own shares	Translation reserve	Share- based payment reserve	Accumulated (losses) / profits	Attributable to equity holders of the Company	Non- controlling interests	Total equity
	S\$′000	S\$′000	S\$′000	S\$′000	S\$′000	S\$′000	\$\$'000	S\$′000	S\$′000
Balance at 31 December 2021 Effect of change in	235,188	(1,866)	(104)	(4,831)	11,591	(242,526)	(2,548)	(43)	(2,591)
presentation currency	(9,647)	-	6	3,327	87	6,227	-	-	-
Balance at 1 January 2022	225,541	(1,866)	(98)	(1,504)	11,678	(236,299)	(2,548)	(43)	(2,591)
Loss for the year	-	-	-	-	-	(9,066)	(9,066)	170	(8,896)
Total comprehensive loss for the year	-	-	-	-	-	(9,066)	(9,066)	170	(8,896)
Shares issued pursuant to share placement	7,300	-	-	-		-	7,300	-	7,300
Shares issued pursuant to acquisition (Note 20)	1,389		-	-		-	1,389	-	1,389
Acquisition of partial interest in a subsidiary (Note 13(f))	-	-	-		-		-	427	427
Deemed disposal of a subsidiary (Note 13(g))	-	-	-	1,504	-	(680)	824	43	867
Balance at 31 December 2022 (Restated)	234,230	(1,866)	(98)	-	11,678	(246,045)	(2,101)	597	(1,504)
Loss for the year	-	-	-	-	-	(3,621)	(3,621)	240	(3,381)
Other comprehensive income: Exchange translation differences	-	-	-	(4)	-	-	(4)	-	(4)
Total other									
comprehensive loss, net of taxation		-	-	(4)	-	(3,621)	(3,625)	240	(3,385)
Shares issued pursuant to share placement (Note 20)	2,000	-	-	-	-	-	2,000	-	2,000
Share-based payment transactions	-	-	-		(72)	-	(72)		(72)
Share issuance expenses (Note 20)	(67)	-	-	-	-	-	(67)	-	(67)
Balance at 31 December 2023	236,163	(1,866)	(98)	(4)	11,606	(249,666)	(3,865)	837	(3,028)

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

	Note	<u>2023</u> S\$′000	<u>2022</u> S\$′000 (Restated)
Operating activities			(Restated)
Loss before income tax		(3,281)	(8,779)
Adjustments for:			
Depreciation of plant and equipment	10	191	101
Depreciation of right-of-use assets	24	864	771
Amortisation of intangible assets	12	287	229
Impairment loss on goodwill	11	-	4,625
Provision for reinstatement costs	27	67	155
Provision for unutilised leave	27	41	-
Loss allowance for trade receivables	18	27	-
Loss on deemed disposal of subsidiary		-	787
Interest expense	6	490	448
Share-based compensation forfeited	28	(72)	-
Unrealised foreign exchange gain		(4)	
Total operating cash flows before movements in working capital Changes in working capital		(1,390)	(1,663)
Inventories		(5)	(32)
Trade and other receivables		(1,285)	(999)
Other non-current assets		(24)	201
Trade and other payables		2,128	1,209
Cash used in operations		(576)	(1,284)
Tax paid		(52)	(16)
Net cash used in operating activities		(628)	(1,300)
Investing activities			
Purchase of plant and equipment	10	(298)	(926)
Acquisition of subsidiaries, net of cash acquired		-	(2,726)
Acquisition of business, net of cash acquired	13	(1,740)	(1,257)
Deemed disposal of subsidiary		-	(130)
Repayment made to non-controlling interest	26	(1,383)	-
Net cash used in investing activities		(3,421)	(5,039)
Financing activities			
Proceeds from issue of ordinary shares	20	2,000	7,300
Share issuance expenses		(67)	-
Proceeds from loans and borrowings		-	5,990
Repayment of loans and borrowings		(1,255)	(1,309)
Repayment of lease liabilities		(950)	(921)
Net cash (used in)/generated from financing activities		(272)	11,060
Net changes in cash and cash equivalents		(4,321)	4,721
Cash and cash equivalents at beginning of financial year		5,065	344
Cash and cash equivalents at end of financial year	19	744	5,065
The accompanying notes form an integral part of and should be read in con			

CONSOLIDATED STATEMENT OF

CASHFLOWS

liabilities

512

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

Reconciliation of liabilities arising from financing activities

					Non-c	ash moveme	nts	
		At	t F	inancing F	Purchase of	Addition	Interest	At
		1 Jan	1 January cash 2023 outflows		plant and from	from	•	31 December
					equipment	acquisition		2023
		S\$′0	00	S\$′000	S\$'000	S\$'000	S\$′000	S\$'000
Loans and b	orrowings		5,547	(1,255)	-	-	270	4,562
Lease liabilit	ies		2,007	(950)	597	206	86	1,946
	At	Proceeds	Financin	g Purchase		Ion-cash mo Interest	vements Deconsolidatio	n At 31
	At 1 January	Proceeds from loan	Financing cash	g Purchase of plant	Addition from	Interest expense	Deconsolidatio of a	n At 31 December
	2022	drawdown	outflows	•	acquisition		subsidiary	2022
				equipmer				
	S\$'000	S\$′000	S\$′000	S\$′000	S\$′000	S\$'000	S\$'000	S\$′000
Loans and								
borrowings Lease	485	5,990	(1,309	?) -	250	131		- 5,547

715

2,085

111

(495)

2,007

(921)

-

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1. General

Quantum Healthcare Limited (the "Company") (Registration 202218645W) is incorporated and domiciled in Singapore and listed on the Catalist Board of the Singapore Exchange Securities Trading Limited ("SGX-ST"). The registered office of the Company is at 8 Temasek Boulevard, #42 Suntec Tower Three, Singapore 038988 and principal place of business is at 745 Lorong 5 Toa Payoh #01-00 Singapore 319455.

The principal activities of the Company are those of investment holding. The principal activities of the subsidiaries are set out in Note 13.

The financial statements of the Group and the statement of financial position of the Company for the financial year ended 31 December 2023 were authorised for issue by the Board of Directors at the date of the Directors' Statement.

2. Summary of material accounting policies

2.1 Basis of preparation

The financial statements of the Group and the statement of financial position of the Company have been drawn up in accordance with the provisions of the Singapore Companies Act 1967 (the "Act") and Singapore Financial Reporting Standards (International) ("SFRS(I)s") including related Interpretations of SFRS(I) ("SFRS(I) INTs") and are prepared on the historical cost basis, except as disclosed in the accounting policies below.

The individual financial statements of each Group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The financial statements of the Group and the statement of financial position of the Company are presented in Singapore Dollar ("S\$") which is also the functional currency of the Company, and all values presented are rounded to the nearest thousand (S\$'000), unless otherwise indicated.

a) <u>Corporate restructuring</u>

In prior financial year, The Group has completed a corporate restructuring exercise through which the Company acquired all the issued and paid-up ordinary shares of QT Vascular Ltd. (referred to herein as "QTV") through the issuance of ordinary shares in exchange for QTV's ordinary shares. Consequently, the Company became the ultimate holding company of QTV and its subsidiaries (collectively, referred to herein as the "QTV Group"). The Group resulting from the corporate restructuring is regarded as a continuing entity throughout the financial year ended 31 December 2022 and 2021 as the shareholders and management of the Group remain the same as those of QTV Group.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.1 Basis of preparation (Continued)

b) Going concern assumption

For the financial year ended 31 December 2023, the Group incurred a net loss and a total comprehensive loss of approximately \$\$3,381,000 and \$\$3,385,000, respectively, and has net cash flows used in operating activities of \$\$628,000. As at 31 December 2023, the Group's current liabilities exceeded its current assets by approximately \$\$7,189,000 and the Company's current liabilities exceeded its current assets by \$\$7,147,000, and the Group and Company have a deficit in shareholders' equity of \$\$3,028,000 and \$\$5,038,000 respectively, as at that date.

The above conditions may cast a significant doubt on the ability of the Group and the Company to continue in operational existence for the foreseeable future and to discharge their liabilities in the normal course of business.

To support the financial statements having been prepared on a going concern basis and to ensure the adequacy of funds required to meet its obligations, working capital and capital commitment needs, management prepared a 16-months consolidated cash flow forecast from 1 January 2024 ("Cash Flow Forecast"). In preparing the Cash Flow Forecast, the management has taken the following into consideration:

- (i) The Company has completed a share placement of 400,000,000 shares at \$\$0.002 per share by way a private placement on 15 February 2024. The total cash placement shares consideration received is \$\$800,000 which will be used for partial repayment to the vendor of ADG Group arising from the acquisition of ADG Group.
- (ii) The Company also completed the issuance of settlement shares to the vendor of ADG group to settle part of the Second Tranche Earn-Out amount on 15 February 2024. The total settlement shares issued are 150,000,000 at \$\$0.002 per share, total settlement shares consideration is \$\$300,000, which will substantially reduce the cash requirement for the Group to repay its liabilities.
- (iii) The Group is expected to obtain additional loan from the financial institution with a repayment term of 5 years.
- (iv) The Group is not expected to pay out the legal fee payables recognised as current liabilities in the other payables account.
- (v) Positive cash inflow from the healthcare businesses. Since FY2022, the Group diversified into the healthcare business, primarily the provision of dental services, which are profitable and generating positive cash flows for the Group. The Group's acquisition of 100% of the businesses of four clinics, via Asia Dental Group Pte. Ltd.'s subsidiaries, The Dental Hub Pte. Ltd. and The Dental Hub (Jurong West) Pte. Ltd. during the financial year has contributed positively to the Group's performance for the financial year ended 31 December 2023.

Based on the cash flow projection, the Group and the Company will have sufficient working capital to continue in operation for the foreseeable future.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.1 Basis of preparation (Continued)

Additionally, management will continue to implement comprehensive cost-cutting measures and does not expect the Group to have any significant operational commitments that will require significant cash outflow in the foreseeable future other than those incurred in the ordinary course of business and also continues to explore any potential for strategic initiatives with a view to generate new business opportunities and/or fund-raising exercises.

Based on the above, the Directors of the Company are of the view that the Group and the Company will have sufficient cash resources to satisfy its working capital requirements, and the Group and the Company to continue in operational existence for the foreseeable future and to discharge their liabilities in the normal course of business, as and when they fall due. The directors are of the opinion that the preparation of the financial statements on a going concern basis remains appropriate.

New and revised SFRS(I)s and SFRS(I) INTs

In the current year, the Group has adopted all the new and revised SFRS(I)s and SFRS(I) INTs that are relevant to its operations and effective for annual periods beginning on or after 1 January 2023. The adoption of these new or revised SFRS(I)s and SFRS(I) INTs did not result in changes to the Group's and Company's accounting policies, and has no material effect on the current or prior year's financial statements and is not expected to have a material effect on future periods.

The Group adopted the amendments to *SFRS(I)* 1-1 and *SFRS(I)* Practice Statement 2: Disclosure of Accounting Policies in the current financial year. The amendments require the disclosure of "material" instead of "significant" accounting policy information and provides guidance to assist the entity in providing useful, entity-specific accounting policy information for the users' understanding of the financial statements. Accordingly, management had reviewed the accounting policies and updated the information disclosed in Note 2 Summary of material accounting policies in line with the amendments.

SFRS(I)s and SFRS(I) INTs issued but not yet effective

At the date of authorisation of these financial statements, the following SFRS(I)s and SFRS(I) INTs that are relevant to the Group were issued but not yet effective:

		Effective date (annual periods beginning
SFRS(I)	Title	on or after)
SFRS(I) 1-1	Amendments to SFRS(I) 1-1: Classification of Liabilities as Current or Non-current	1 January 2024
SFRS(I) 16	Amendments to SFRS(I) 16: Lease Liability in a Sale and Leaseback	1 January 2024
Various	Amendments to SFRS(I) 1-1: Non-current Liabilities with Covenants	1 January 2024
SFRS(I) 1-7, SFRS(I) 7	Amendments to SFRS(I) 1-7 and SFRS(I) 7: Supplier Finance Arrangements	1 January 2024
SFRS(I) 1-21, SFRS(I) 1	Amendments to SFRS(I) 1-21: Lack of Exchangeability	1 January 2025
SFRS(I) 10, SFRS(I) 1-28	Amendments to SFRS(I) 10 and SFRS(I) 1-28: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.1 Basis of preparation (Continued)

Consequential amendments were also made to various standards as a result of these new/revised standards.

The Group does not intend to early adopt any of the above new/revised standards, interpretations and amendments to the existing standards. Management anticipates that the adoption of the aforementioned revised/new standards will not have a material impact on the financial statements of the Group and the Company in the period of their initial adoption.

2.2 Basis of consolidation

The financial statements of the Group comprise the financial statements of the Company and its subsidiaries. Subsidiaries are entities (including structured entities) (i) over which the Group has power and the Group is (ii) able to use such power to (iii) affect its exposure, or rights, to variable returns from then through its involvement with them.

The Group reassesses whether it controls the subsidiaries if facts and circumstances indicate that there are changes to the one or more of the three elements of control.

When the Group has less than a majority of the voting rights of an investee, it still has power over the investee when the voting rights are sufficient, after considering all relevant facts and circumstances, to give it the practical ability to direct the relevant activities of the investee unilaterally. The Group considers, among others, the extent of its voting rights relative to the size and dispersion of holdings of the other vote holders, currently exercisable substantive potential voting rights held by all parties, rights arising from contractual arrangements and voting patterns at previous shareholders' meetings.

Subsidiaries are consolidated from the date on which control is transferred to the Group up to the effective date on which control ceases, as appropriate.

Intra-group assets and liabilities, equity, income, expenses and cashflows relating to intragroup transactions are eliminated on consolidation.

The financial statements of the subsidiaries used in the preparation of the financial statements are prepared for the same reporting date as that of the Company. Where necessary, accounting policies of subsidiaries have been changed to ensure consistency with the policies adopted by the Group.

Non-controlling interests are identified separately from the Group's equity therein. On an acquisition-by-acquisition basis, non-controlling interests may be initially measured either at fair value or at their proportionate share of the fair value of the acquiree's identifiable net assets. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent changes in equity. Losses in the subsidiary are attributed to non-controlling interests even if this results in the non-controlling interests having a deficit balance.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.2 Basis of consolidation (Continued)

Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any differences between the amount by which the non-controlling interests are adjusted to reflect the changes in the relative interests subsidiary and the fair value of the consideration paid or received is recognised directly in equity and attributed to the owners of the Company.

When the Group loses control over a subsidiary, the profit or loss on disposal is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. Amounts previously recognised in other comprehensive income in relation to the subsidiary are accounted for (i.e. reclassified to profit or loss or transferred directly to accumulated profits) in the same manner as would be required if the relevant assets or liabilities were disposed of. The fair value of any investments retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under *SFRS(I) 9 Financial Instruments* (*"SFRS(I) 9"*) or, when applicable, the cost on initial recognition of an investment in an associate or jointly controlled entity.

Investments in subsidiaries are carried at cost less any impairment loss that has been recognised in profit or loss in the Company's separate financial statements.

2.3 Business combinations

The acquisition of subsidiaries is accounted for using the acquisition method when the acquired set of activities and assets constitute a business. When determining the acquired set of activities and assets constitute a business, the Group assesses whether the acquired set of activities and assets includes, at a minimum, an input and substantive process, which together contribute to the creation of outputs.

The Group has the option to apply a "concentration test" as a simplified assessment to determine whether an acquired set of activities and assets is a business. The Group makes the election separately for each transaction or other event. The concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

The fair value of the acquisition consideration is measured at the aggregate of the fair values, at the date of exchange, of assets given, liabilities incurred or assumed, and equity instruments issued by the Group in exchange for control of the acquiree. For each business combination, the Group determines whether to measure the non-controlling interests in the acquiree at fair value or at proportionate share in the recognized amounts of the acquiree's identifiable net assets. Acquisition-related costs are recognized in profit or loss as incurred.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.3 Business combinations (Continued)

The acquiree's identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition under *SFRS(I)* 3 Business Combinations are recognized at their fair values at the acquisition date, except for non-current assets (or disposal groups) that are classified as held-for-sale in accordance with *SFRS(I)* 5 Non-Current Assets Held for Sale and Discontinued Operations, which are recognized and measured at the lower of cost and fair value less costs to sell.

The Group recognizes any contingent consideration to be transferred to the acquiree at the fair value on the acquisition date. Contingent consideration classified as equity is not remeasured and its subsequent settlement shall be accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of SFRS(I) 9 Financial Instruments is measured at fair value with the changes in fair value recognized in the statement of profit or loss in accordance with SFRS(I) 9. Other contingent consideration that is not within the scope of SFRS(I) 9 is measured at fair value at each reporting date with changes in fair value recognized in profit or loss.

Where a business combination is achieved in stages, the Group's previously held interests in the acquired entity are remeasured to fair value at the acquisition date (i.e. the date the Group attains control) and the resulting gain or loss, if any, is recognized in profit or loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to profit or loss, where such treatment would be appropriate if that interest were disposed of.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see below), or additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognized as of that date.

The measurement period is the period from the date of acquisition to the date the Group obtains complete information about facts and circumstances that existed as of the acquisition date and is subject to a maximum of one year.

Goodwill arising on acquisition is recognized as an asset at the acquisition date and is initially measured at cost, being the excess of the sum of the consideration transferred, the amount of any non-controlling interest in the acquiree and the fair value of the acquirer previously held equity interest (if any) in the entity over net acquisition-date fair value amounts of the identifiable assets acquired and the liabilities assumed.

If, after reassessment, the Group's interest in the net fair value of the acquiree's identifiable net assets exceeds the sum of the consideration transferred, the amount of any non-controlling interest in the acquiree and the fair value of the acquirer's previously held equity interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.3 Business combinations (Continued)

For the purpose of impairment testing, goodwill is allocated to each of the Group's cashgenerating units expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit (including the goodwill), the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognised for goodwill is not reversed in a subsequent period.

The attributable amount of goodwill is included in the determination of gain or loss on disposal of the subsidiary or jointly controlled entity.

2.4 Revenue recognition

The Group is principally in the business of provision of dental and consultancy services. Revenue from contracts with its customers is recognised when or as the Group satisfies a performance obligation by transferring a promised goods or service generated in the ordinary course of the Group's activities to its customer, at a transaction price that reflects the consideration the Group expects to be entitled in exchange for the goods or service and that is allocated to that performance obligation. The goods or service is transferred when or as the customer obtains control of the goods or service.

Dental service income

The Group provides dental service to customers.

Dental service income is recognised at a point in time and arising from rendering of dental services to individual patients that typically completes within the same day from the point of commencement of the process.

Consultancy service income

Consultancy service fee income is recognised over time, arising from rendering of consultancy services to related parties.

2.5 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Borrowing costs on general borrowings are capitalised by applying a capitalisation rate to construction or development expenditures that are financed by general borrowings. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.5 Borrowing costs Continued)

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

2.6 Retirement benefit costs

Payments to defined contribution retirement benefit plans are charged as an expense as they fall due. Payments made to state-managed retirement benefit schemes, such as the Singapore Central Provident Fund, are dealt with as payments to defined contribution plans where the Group's obligations under the plans are equivalent to those arising in a defined contribution retirement benefit plan.

2.7 Employee leave entitlements

Employee entitlements to annual leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave as a result of services rendered by employees up to the end of the financial year.

2.8 Share-based payment transactions

The grant date fair value of equity-settled share-based payment awards granted to employees are recognised as an employee expense with a corresponding increase in equity, over the period that the employees unconditionally become entitled to awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes.

2.9 Income tax

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of profit or loss and other comprehensive income because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are not taxable or tax deductible. The Group's liability for current tax is calculated using tax rates (and tax laws) that have been enacted or substantively enacted in countries where the Company and subsidiaries operate by the end of the financial year.

Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.9 Income tax (Continued)

Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised.

Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit and does not give rise to equal taxable and deductible temporary differences.

Deferred tax liabilities are recognised on taxable temporary differences arising on investments in subsidiaries and interests in joint ventures, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.

A deferred income tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised based on the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the financial period and based on the tax consequence that will follow from the manner in which the Group expects, at the end of the financial year, to recover or settle the carrying amounts of its assets and liabilities.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Current and deferred tax are recognised as an expense or income in profit or loss, except when they relate to items credited or debited directly to equity, in which case the tax is also recognised directly in equity, or where they arise from the initial accounting for a business combination. In the case of a business combination, the tax effect is taken into account in calculating goodwill or determining the excess of the acquirer's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities over cost.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.9 Income tax (Continued)

Revenue, expenses and assets are recognized net of the amount of sales tax except:

- when the sales tax that is incurred on purchases is not recoverable from the tax authorities, in which case the sales tax is recognised as part of cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables that are stated with the amount of sales tax included.

2.10 Dividends

Equity dividends are recognised as a liability when they become legally payable. Interim dividends are recorded in the financial period in which they are declared payable. Final dividends are recorded in the financial period in which dividends are approved by shareholders. A corresponding amount is recognised in equity.

2.11 Foreign currency transactions and translation

Foreign currency transactions are translated into the individual entities' respective functional currencies at the exchange rates prevailing on the date of the transaction. At the end of each financial year, monetary items denominated in foreign currencies are retranslated at the rates prevailing as of the end of the financial year. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on retranslation of monetary items are included in profit or loss for the year. Exchange differences arising on the retranslation of non-monetary items carried at fair value are included in profit or loss for the year except for differences arising on the retranslation of non-monetary items in respect of which gains and losses are recognised directly in equity. For such non-monetary items, any exchange component of that gain or loss is also recognised directly in equity through other comprehensive income.

Exchange differences relating to assets under construction for future productive use, are included in the cost of those assets where they are regarded as an adjustment to interest costs on foreign currency borrowings.

For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group's foreign operations (including comparatives) are expressed in Singapore Dollars using exchange rates prevailing at the end of the financial year. Income and expense items (including comparatives) are translated at the average exchange rates for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are classified as equity and transferred to the Group's translation reserve. Such translation differences are recognised in profit or loss in the period in which the foreign operation is disposed of.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.11 Foreign currency transactions and translation (Continued)

On consolidation, exchange differences arising from the translation of the net investment in foreign entities (including monetary items that, in substance, form part of the net investment in foreign entities), and of borrowings and other currency instruments designated as hedges of such investments, are taken to the foreign currency translation reserve.

Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate.

2.12 Plant and equipment

Plant and equipment are stated at cost less accumulated depreciation and any accumulated impairment losses. The cost of plant and equipment includes its purchase price and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of plant and equipment if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the plant and equipment.

Subsequent expenditure relating to plant and equipment is added to the carrying amount of the asset only when it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenance expenses are recognised in profit or loss when incurred.

Depreciation is charged so as to write off the cost of assets over their estimated useful lives, using the straight-line method, on the following bases:

Dental machinery	10 years
Dental equipment and instrument	5 years
Renovation	3 years
Furniture, fixtures and office equipment	3 years
Computers, network and software	3 years
Machinery and equipment	3 years
Motor vehicles	5 years

The carrying values of plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The estimated useful lives, residual values and depreciation methods are reviewed, and adjusted as appropriate, at the end of each financial year.

The gain or loss, being the difference between the sales proceeds and the carrying amount of the asset, arising on disposal or retirement of an item of plant and equipment is recognised in profit or loss.

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.13 Intangible assets

Intangible assets acquired separately are measured initially at cost. The cost of intangible assets acquired in a business combination is initially measured at their fair values as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses.

The useful lives of intangible assets are assessed to be either finite or indefinite.

(a) Intangible assets with finite useful lives

Intangible assets with finite lives are amortised on a straight-line basis over the estimated economic useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortisation period or method, as appropriate, and are treated as changes in accounting estimates.

Research and development

Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in profit or loss as incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and capitalised borrowing costs. Other development expenditure is recognised in profit or loss as incurred.

Capitalised development expenditure is carried at cost less accumulated amortisation and accumulated impairment losses.

Customer relationships

Customer relationships acquired in a business combination are measured at its fair value as at the date of acquisition. Following initial recognition, customer relationships are amortised over the estimated useful life of 5 years.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.13 Intangible assets (Continued)

(a) Intangible assets with finite useful lives (Continued)

Other intangible assets

Other intangible assets that are acquired by the Group and have finite useful lives are carried at cost less accumulated amortisation and accumulated impairment losses. These intangible assets include intellectual property and developed technology which amortised to profit or loss over their estimated useful lives of 5 years and 15 years respectively.

(b) Intangible assets with indefinite useful lives

Intangible assets with indefinite useful lives are tested for impairment annually, or more frequently if the events and circumstances indicate that the carrying value may be impaired either individually or at the cash-generating unit level. Such intangible assets are not amortised.

Goodwill

Goodwill arising on the acquisition of a subsidiary represents the excess of the cost of acquisition over the Group's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the subsidiary recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less any accumulated impairment losses.

For the purpose of impairment testing, goodwill is allocated to each of the Group's cashgenerating units expected to benefit from the synergies of the combination. Cashgenerating units to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognised for goodwill is not reversible in subsequent periods.

On disposal of a subsidiary, the attributable amount of goodwill is included in the determination of the gain or loss on disposal.

2.14 Associate

An associate is an entity over which the Group has the power to participate in the financial and operating policy decisions of the investee but does not have control or joint control of those policies.

The Group accounts for its investment in associate using the equity method from the date on which it becomes an associate.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.14 Associate (Continued)

On acquisition of the investment, any excess of the cost of the investment over the Group's share of the net fair value of the investee's identifiable assets and liabilities represents goodwill and is included in the carrying amount of the investment. Any excess of the Group's share of the net fair value of the investee's identifiable assets and liabilities over the cost of the investment is included as income in the determination of the entity's share of the associate's profit or loss in the period in which the investment is acquired.

Under the equity method, the investment in associate is carried in the statement of financial position at cost plus post-acquisition changes in the Group's share of net assets of the associate. The profit or loss reflects the share of results of the operations of the associate. Distributions received from associate reduce the carrying amount of the investment. Where there has been a change recognised in other comprehensive income by the associate, the Group recognises its share of such changes in other comprehensive income. Unrealised gains and losses resulting from transactions between the Group and associate are eliminated to the extent of the interest in the associate.

Where the Group's share of losses in an associate equals or exceeds its interest in the associate, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate.

After application of the equity method, the Group determines whether it is necessary to recognise an additional impairment loss on the Group's investment in associate. The Group determines at the end of each reporting period whether there is any objective evidence the investment in the associate is impaired. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value and recognises the amount in the profit or loss.

The financial statements of the associate are prepared as the same reporting date as the Group. Where necessary, adjustments are made to bring the accounting policies in line with those of the Group.

2.15 Impairment of non-financial assets excluding goodwill

The Group reviews the carrying amounts of its non-financial assets as at each reporting date to assess for any indication of impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

The recoverable amount of an asset or cash-generating unit is the higher of its fair value less costs to sell and its value-in-use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.15 Impairment of non-financial assets excluding goodwill (Continued)

An impairment loss for the amount by which the asset's carrying amount exceeds the recoverable amount is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cashgenerating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

2.16 Financial instruments

The Group recognises a financial asset or a financial liability in its statement of financial position when the Group becomes party to the contractual provisions of the instrument.

Financial assets

Initial recognition and measurement

With the exception of trade receivables that do not contain a significant financing component or for which the Group applies a practical expedient, all financial assets are initially measured at fair value, plus transaction costs, except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value. Such trade receivables that do not contain a significant financing component or for which the Group applies a practical expedient are measured at transaction price as defined in *SFRS(I)* 15 Revenue from Contracts with Customers in Note 2.4.

The classification of the financial assets at initial recognition as subsequently measured at amortised cost, fair value through other comprehensive income ("FVTOCI") and fair value through profit or loss ("FVTPL") depends on the Group's business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

The Group's business model refers to how the Group manages its financial assets in order to generate cash flows which determines whether cash flows will result from collecting contractual cash flows, selling financial assets or both.

The Group determines whether the asset's contractual cash flows are solely payments of principal and interest ("SPPI") on the principal amount outstanding to determine the classification of the financial assets.

The Group recognises a financial asset or a financial liability in its statement of financial position when the Group becomes party to the contractual provisions of the instrument.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.16 Financial instruments (Continued)

Financial assets (Continued)

Financial assets at amortised cost

A financial asset is subsequently measured at amortised cost if the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Subsequent to initial recognition, the financial asset at amortised cost are measured using the effective interest method and is subject to impairment. Gains or losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial instrument and allocating the interest income or expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts or payments (including all fees on points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial instrument, or where appropriate, a shorter period, to the net carrying amount of the financial instrument. Income and expense are recognised on an effective interest basis for debt instruments other than those financial instruments at fair value through profit or loss.

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, and recognised in interest income.

Impairment of financial assets

The Group recognises a loss allowance for expected credit losses ("ECL") on financial assets measured at amortised cost. At each reporting date, the Group assesses whether the credit risk on a financial asset has increased significantly since initial recognition by assessing the change in the risk of a default occurring over the expected life of the financial instrument. Where the financial asset is determined to have low credit risk at the reporting date, the Group assumes that the credit risk on a financial asset has not increased significantly since initial recognition.

The Group uses reasonable and supportable forward-looking information that is available without undue cost or effort as well as past due information when determining whether credit risk has increased significantly since initial recognition.

Where the credit risk on that financial instrument has increased significantly since initial recognition, the Group measures the loss allowance for a financial instrument at an amount equal to the lifetime ECL. Where the credit risk on that financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECL.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.16 Financial instruments (Continued)

Financial assets (Continued)

Impairment of financial assets (Continued)

The Group applies the simplified approach to recognise the ECL for trade receivables and unbilled receivables, which is to measure the loss allowance at an amount equal to lifetime ECL. As a practical expedient, the Group uses an allowance matrix derived based on historical credit loss experience adjusted for current conditions and forecasts of future economic conditions for measuring ECL.

While they are not financial assets, contract assets arising from the Group's contracts with customers under SFRS(I) 15 are assessed for impairment in accordance with SFRS(I) 9, similar to that of trade receivables.

The amount of ECL or reversal thereof that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognised is recognised in profit or loss.

The Group directly reduces the gross carrying amount of a financial asset when the entity has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof.

For details on the Group's accounting policy for its impairment of financial assets, refer to Note 32.

Derecognition of financial assets

The Group derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Group neither transfers nor retains substantially all the risks and rewards of ownership of the financial asset and continues to control the transferred asset, the Group recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognise the financial asset and also recognises a capitalised borrowing for the proceeds receivables.

Financial liabilities and equity instruments

Classification as debt or equity

Financial liabilities and equity instruments issued by Group are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.16 Financial instruments (Continued)

Financial liabilities and equity instruments (Continued)

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities. Equity instruments are recorded at the proceeds received, net of direct issue costs.

Ordinary share capital

Ordinary share capital is classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognised as a deduction from equity.

Financial liabilities

Initial recognition and measurement

All financial liabilities are initially measured at fair value, minus transaction costs, except for those financial liabilities classified as at fair value through profit or loss, which are initially measured at fair value.

Financial liabilities are classified as either financial liabilities at fair value through profit or loss or other financial liabilities.

Financial liabilities are classified as at fair value through profit or loss if the financial liability is either held for trading or it is designated as such upon initial recognition. Financial liabilities classified as at fair value through profit or loss comprise derivatives that are not designated or do not qualify for hedge accounting.

Other financial liabilities

Trade and other payables

Trade and other payables are initially measured at fair value, net of transaction costs, and are subsequently measured at amortised cost, where applicable, using the effective interest method, with interest expense recognised on an effective yield basis in finance cost. A gain or loss is recognised in profit or loss when the liability is derecognised and through the amortisation process.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.16 Financial instruments (Continued)

Financial liabilities and equity instruments (Continued)

Other financial liabilities (Continued)

Borrowings

Interest-bearing bank loans are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest method. Any difference between the proceeds (net of transaction costs) and the settlement or redemption of borrowings is recognised over the term of the borrowings in accordance with the Group's accounting policy for borrowing costs (see Note 2.5 above). A gain or loss is recognised in profit or loss when the liability is derecognised and through the amortisation process.

Financial guarantee contracts

The Company has issued corporate guarantee to a bank for banking facilities granted by them to a subsidiary and these guarantees qualify as financial guarantee because the Company is required to reimburse the bank if this subsidiary breach any repayment terms.

Financial guarantee contract liabilities are measured initially at their fair values plus transaction costs and subsequently at the higher of the amount of the loss allowance and the amount initially recognised less cumulative amortisation in accordance with *SFRS(I)* 15 *Revenue from Contracts with Customers*.

Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or they expire.

Offsetting of financial instruments

A financial asset and a financial liability shall be offset, and the net amount presented in the statements of financial position when and only when, an entity:

- (a) currently has a legally enforceable right to set off the recognised amounts; and
- (b) intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2.17 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposits with financial institutions which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.18 Inventories

Inventories are stated at the lower of cost and net realisable value. Costs comprise direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the weighted average method. Net realisable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in profit or loss.

2.19 Leases

At inception of a contract, the Group assessed whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

As lessee

(a) Right-of-use assets

The Group recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. The estimated useful lives of right-of-use assets are determined between 1 to 3 years.

If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment set out in Note 2.15.

(b) Lease liabilities

At the commencement date of the lease, the Group recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating the lease, if the lease term reflects the Group exercising the option to terminate.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.19 Leases (Continued)

As lessee (Continued)

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

(c) Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low value assets are recognised as expense on a straight-line basis over the lease term.

2.20 Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle that obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows, which is discounted using a pre-tax discount rate.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Changes in the estimated timing or amount of the expenditure or discount rate are recognised in profit or loss as they arise.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

2. Summary of material accounting policies (Continued)

2.21 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the group of executive directors and the chief executive officer who make strategic decisions. Additional disclosures on each of these segments are shown in Note 30, including the factors used to identify the reportable segments and the measurement basis of segment information.

2.22 Government grants

Government grants are recognised when there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Where the grant relates to an expense, the grant is recognised as income in profit or loss on a systematic basis over the periods in which the related costs, for which the grants are intended to compensate, is expensed. Where the grant relates to an asset, the grant is recognised as deferred capital grant on the statement of financial position and is amortised to profit or loss over the expected useful life of the relevant asset by equal annual instalment.

2.23 Contingencies

A contingent liability is:

- a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group; or
- (ii) a present obligation that arises from past events but is not recognised because:
 - (a) it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
 - (b) the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group.

Contingencies are not recognised on the statements of financial position of the Group, except for contingent liabilities assumed in a business combination that are present obligations and which the fair value can be reliably determined.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

3. Critical accounting judgements and key sources of estimation uncertainty

The Group made judgements, estimates and assumptions about the carrying amounts of assets and liabilities that were not readily apparent from other sources in the application of the Group's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors that are considered to be reasonable under the circumstances. Actual results may differ from the estimates.

3.1 Critical judgements in applying the Group's accounting policies

Management is of the opinion that any instances of applications of judgements are not expected to have a significant effect on the amounts recognised in the financial statements.

3.2 Key sources of estimation uncertainty

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Impairment of goodwill

The Group tests goodwill for impairment at least on an annual basis. Determining whether goodwill is impaired requires an estimation of the value-in-use of the cash-generating units ("CGU") to which goodwill has been allocated. The value-in-use calculation requires the entity to estimate the future cash flows expected to arise from the CGU, including their best estimate of a suitable discount rate in order to calculate present value. The carrying amount of goodwill as at 31 December 2023 was \$\$5,580,000 (2022: \$\$4,120,000). No impairment loss were recognised during the financial year (2022:\$\$4,625,000) (Note 11).

Measurement of ECL of trade receivables

The Group uses an allowance matrix to measure ECL for trade receivables. The ECL rates are based on the Group's historical loss experience of the customers, for the last 3 years prior to the reporting date for various customer groups that are assessed by geographical locations, product types and internal ratings, adjusted for forward looking factors specific to the debtors and the economic environment which could affect the ability of the debtors to settle the trade receivables. In considering the impact of the economic environment on the ECL rates, the Group assesses, for example, the gross domestic production growth rates of Singapore and the growth rates of the major industries in which its customers operate. The Group adjusts, as necessary, the allowance matrix at each reporting date. Such estimation of the ECL rates may not be representative of the actual default in the future. The carrying amount of the Group's trade receivables as at 31 December 2023 was S\$1,846,000 (2022: S\$1,237,000). The expected loss allowance on the Group's trade receivables as at 31 December 2023 was S\$1,846,000 (2022: S\$1,237,000) (2022: S\$Nil) (Note 18).

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

3. Critical accounting judgements and key sources of estimation uncertainty (Continued)

3.2 Key sources of estimation uncertainty (Continued)

Impairment of investments in subsidiaries

At the end of each financial year, an assessment is made on whether there are indicators that the Group's and the Company's investments are impaired. Where necessary, the Group's and Company's assessments are based on the estimation of the value-in-use of the assets defined in *SFRS(I)* 1-36 Impairment of Assets by forecasting the expected future cash flows for a period of up to 5 years, using a suitable discount rate in order to calculate the present value of those cash flows. The carrying amount of the Company's investments in subsidiaries as at 31 December 2023 was \$\$3,411,000 (2022: \$\$7,573,000) (Note 13). An impairment loss of \$\$4,162,000 (2022: \$\$6,072,000) was recognised during the financial year (Note 13).

Business combination

During the financial year, the Group had completed the acquisition of four clinics via its subsidiaries, The Dental Hub Pte. Ltd. and The Dental Hub (Jurong West) Pte. Ltd., from external parties (or the "Vendors"). The acquisition was accounted for using the acquisition method involving a Purchase Price Allocation ("PPA") exercise.

Significant judgements and estimates are made in the PPA exercise on the identification of intangible assets, ascertaining the fair values of the acquired assets and liabilities as disclosed in Note 13 of the financial statements.

Impairment of intangible assets

The Group assess intangible assets for any indication of impairment at least on an annual basis. Determining whether intangible assets are impaired requires an estimation of the value-in-use. The value-in-use calculation requires the entity to estimate the future cash flows expected to arise from the intangible assets, including their best estimate of a suitable discount rate in order to calculate present value. The carrying amount of intangible assets as at 31 December 2023 was \$\$686,000 (2022: \$\$688,000). No impairment loss was recognised during the current and prior financial year (Note 12).

Measurement of ECL of other receivables

For other receivables, the Group and the Company considers the performance, financial capability as well as payment profile of these other receivables in order to determine the appropriate stage of expected credit loss for these receivables. Probability or risk of default is then being estimated by considering the future conditions. The carrying amounts of other receivables of the Group and the Company as at 31 December 2023 were \$\$1,093,000 (2022: \$\$444,000) and \$\$13,000 (2022: \$\$7,000), respectively. The Company has recognised an impairment loss of \$\$71,000 (2022: \$\$Nil),

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

4. Revenue

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
<u>At a point in time</u> Rendering of dental services	12,611	8,828
Over time Rendering of consultancy services	470	540
	13,081	9,368

The Group's revenue is derived wholly from Singapore and healthcare segment and is disaggregated by timing of revenue recognition.

5. Other income

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Government grants Others		80 5
	179	85

6. Finance costs

	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)
Interest expense on loan from a related company Interest expense on bank loans Interest expense on lease liabilities Imputed interest expense on Earn-Out Amount	90 180 86 134	72 59 111 207
Foreign exchange loss, net	490	450

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

7. Loss before income tax

The following charges were included in the determination of loss before income tax:

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Auditors' remuneration:		
	175	156
- Auditors of the Company		
- Other auditors	9	3
Professional fee	2,457	1,699
Depreciation of plant and equipment	191	101
Depreciation of right-of-use assets	864	771
Amortisation of intangible assets	287	229
Directors' fees – directors of the Company	145	160
Employee benefits – director of the Company		
- Short term benefits	300	290
- Post-employment benefits	13	13
Key management remuneration other than directors		
- Short term benefits	468	566
- Post-employment benefits	37	38
Employee benefits expenses (including directors remuneration)		
- Salaries and other related costs	2,996	1,953
- Defined contribution plan	332	275

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

8. Income tax expense

	<u>2023</u> S\$′000	<u>2022</u> S\$'000
Current tax expense		
Current financial year	94	56
Overprovision in prior financial year	(4)	
	90	56
Deferred tax expense (Note 22)		
Current financial year	33	61
Overprovision in prior financial year	(23)	
Income tax expense	100	117

The income tax varied from the amount of taxation determined by applying the Singapore statutory income tax rate of 17% (2022: 17%) to loss before tax as a result of the following differences:

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Loss before income tax	(3,281)	(8,779)
Tax expense at statutory rate of 17% (2022:17%) Tax effects of :	(558)	(1,492)
Effect of tax concessions and tax exemptions	(69)	(52)
Effects of non-deductible expenses	744	1,661
Overprovision for prior financial year	(27)	-
Deferred tax assets not recognised	10	
	100	117

The following deductible temporary difference has not been recognised:

	<u>2023</u> S\$'000	<u>2022</u> S\$′000	
Tax losses	57	-	

The tax losses are subject to agreement by tax authorities and compliance with tax regulations in Singapore in which the Company and subsidiaries operate. Deferred tax assets have not been recognised in respect of the capital allowance and tax losses due to uncertainty in the availability of future taxable profit against which the Group and the Company can utilise the tax losses.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

9. Loss per share

Basic and diluted loss per share are calculated by dividing the loss for the financial year attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial year. The following table reflects the profit and share data used in the computation of basic earnings per share:

	<u>2023</u> S\$′000	<u>2022</u> S\$'000 (Restated)
Loss for the financial year attributable to the owners of the Company	(3,625)	(9,066)
Weighted average number of ordinary shares outstanding	7,326,732	6,750,607
Basic and diluted loss per share (cents)	(0.05)	(0.13)

The basic and diluted loss per share is the same as there were no potentially dilutive instruments.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

10. Plant and equipment

<u>Group</u>	Dental machinery S\$'000	Dental equipment and instrument S\$'000	Renovation S\$'000	Furniture, fixtures and office equipment S\$'000	Computer , network and software S\$'000	Machinery and equipment S\$'000	Motor vehicles S\$'000	Total S\$′000
-	54 000	30 000	50 000	54 000	54 000	34 000	54 000	30 000
<u>Cost</u> At 1 January 2022 Additions due to	-	-	-	210	65 2	1,005	-	1,280 2
acquisition (Note 13) Additions	516	85	78	7	96	13	131	926
At 31 December 2022 Additions due to acquisition (Note 13)	516 -	85 101	78	217 3	163 12	1,018 -	131 -	2,208 116
Additions	90	169	5	10	24	-	-	298
At 31 December 2023	606	355	83	230	199	1,018	131	2,622
Accumulated depreciation At 1 January 2022	-	-	-	210	65	1,005	-	1,280
Depreciation	28	8	13	1	24	3	24	101
At 31 December 2022 Depreciation	28 55	8 35	13 26	211 6	89 38	1,008 5	24 26	1,381 191
At 31 December 2023	83	43	39	217	127	1,013	50	1,572
Carrying amount At 31 December 2023	523	312	44	13	72	5	81	1,050
At 31 December 2022	488	77	65	6	74	10	107	827

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

10. Plant and equipment (Continued)

<u>Company</u>	Computer, network and <u>software</u> S\$'000
Cost At 1 January 2022 and 31 December 2022 Addition	13
At 31 December 2023	13
Accumulated depreciation At 1 January 2022 and 31 December 2022 Depreciation	- 1
At 31 December 2023	1
Carrying amount At 31 December 2023	12
At 31 December 2022	

11. Goodwill

	Gro	up
	<u>2023</u> S\$'000	<u>2022</u> S\$'000
At 1 January Arising from acquisition of subsidiaries/business (Note 13) Impairment loss on goodwill	4,120 1,460	8,745 (4,625)
At beginning and end of financial year	5,580	4,120

Goodwill acquired is allocated to the cash-generating units ("CGU") that are expected to benefit from the CGU.

The carrying amount of goodwill had been allocated to the respective CGU under the healthcare business operating segments as follows:

	<u>2023</u> S\$′000	<u>2022</u> S\$'000
ADG Group ("ADG Group CGU")	2,863	2,863
EDS Group ("EDS Group CGU")	1,257	1,257
The Dental Hub Pte Ltd ("TDH Group CGU")	1,262	-
The Dental Hub (Jurong West) Pte Ltd ("TDHJW CGU")	198	
	5,580	4,120

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

11. Goodwill (Continued)

Impairment of goodwill

The Group tests CGU for impairment annually, or more frequently when there is an indication for impairment.

The recoverable amounts of the CGU are determined from value-in-use calculations. Cash flow projections used in the value-in-use calculations were based on financial budgets approved by Directors covering a five-year period. The key assumptions for these value-in-use calculations are those regarding the discount rates, growth rates, terminal value and expected changes to gross margins during the period. Management estimates discount rates using pre-tax rates that reflect current market assessments of the time value of money and the risks specifics to the CGUs. The growth rates are based on industry growth forecasts. Changes in gross margins are based on past practices and expectations of future changes in the market.

Key assumptions on which management has based its cash flow projections for the respective periods of the significant CGU are as follows:

	Rever <u>growth</u>		Tern <u>growt</u>			-tax <u>nt rate</u>
	<u>2023</u> %	<u>2022</u> %	<u>2023</u> %	<u>2022</u> %	<u>2023</u> %	<u>2022</u> %
	70	70	70	70	70	70
ADG Group	3.0	2.8	2.0	1.0	11.1	11.7
EDS Group	3.0	2.8	2.0	1.0	11.1	11.7
TDH Group	3.0	-	2.0	-	11.1	-
TDHJW CGU	6.5-596	-	2.0	-	11.9	-

Key assumptions used in the value-in-use calculations

- (i) Revenue growth rates The forecasted revenue growth rates are based on management's expectations for each CGU from historical trends and planned business strategies, as well as longterm average growth rates of the healthcare industry in the respective countries.
- (ii) *Terminal value growth rates* The terminal growth rates are determined based on management's estimate of the long-term industry growth rates.
- (iii) *Discount rates* The discount rates used are based on the weighted average cost of the CGU's capital (the "WACC"), adjusted for the specific circumstances of the CGU and based on management's experience, and re-grossed back to arrive at the pre-tax rates.

Sensitivity to changes in assumptions

Management has determined the most likely revenue growth rates scenario based on their best estimates on the expectations for each CGU. Management has taken into consideration the historical trend and long term average growth rates of the healthcare industry.

Management is of the view that no reasonable possible changes in any of the key assumptions would cause the CGU's carrying amount to materially exceed its recoverable amount.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

11. Goodwill (Continued)

Impairment of goodwill (Continued)

Impairment loss recognised

There was an impairment loss \$\$4,625,000 was recognised in the profit or loss of the Group for the financial year ended 31 December 2022 in relation to the goodwill allocated to ADG Group CGU, as the recoverable amount of ADG Group CGU was estimated to be less than its carrying amount.

No impairment loss was recognised during the current financial year.

12. Intangible assets

		Developed		
Group	Intellectual <u>property</u> S\$'000	technology <u>in</u> progress S\$'000	<u>Customer</u> <u>relationship</u> S\$'000	<u>Total</u> S\$′000
<u>Cost</u> At 1 January 2022 Additions due to acquisition (Note 13)	501 -	1,922	- 917	2,423 917
At 31 December 2022 Additions due to acquisition (Note 13)	501 -	1,922	917 285	3,340 285
At 31 December 2023	501	1,922	1,202	3,625
Accumulated depreciation At 1 January 2022 Depreciation	501 -	1,922	- 229	2,423 229
At 31 December 2022 Depreciation	501	1,922	229 287	2,652 287
At 31 December 2023	501	1,922	516	2,939
Carrying amount At 31 December 2023	_	_	686	686
At 31 December 2022	-	-	688	688

Customer relationships

Customer relationships are acquired as part of business combinations. They are recognised at their fair value at the date of acquisition and are subsequently amortised on straight-line based on the timing of projected cash flows of the customer relationship over their estimated useful lives. The useful lives of the customer relationships are estimated to be 5 years by the management. The customer relationships related to the ADG Group and TDH CGU.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries

	<u>Compa</u>	ny
	<u>2023</u>	<u>2022</u>
	S\$'000	S\$'000
Unquoted shares, at cost		
- QT Vascular Ltd	5,516	5,516
- Asia Dental Group Pte. Ltd.	8,129	8,129
- Kairogenix Pte. Ltd.	_#	_#
- Quantum Healthcare Holdings Sdn. Bhd.	_#	_#
	13,645	13,645
Less: Accumulated impairment loss		
At 1 January	(6,072)	-
Additions	(4,162)	(6,072)
At 31 December	(10,234)	(6,072)
	3,411	7,573
[#] Less than S\$1,000		

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Details of subsidiaries directly held by the Company and held by subsidiaries of the Company as at respective financial year ended are as follows:

Name of subsidiary	Principal activities	Country of incorporation and principal place of business		equity held
	<u>- moparaetmice</u>	<u>pido or basiliou</u>	<u>2023</u> %	<u>2022</u> %
Held directly by the Company				
QT Vascular Ltd. ⁽¹⁾ ("QTV")	Investment holding company	Singapore	100	100
Asia Dental Group Pte. Ltd. ⁽¹⁾ ("ADG")	Management consultancy services for healthcare organisations and	Singapore	60	60
Kairogenix Pte. Ltd. ⁽³⁾ (" Kairogenix")	dental services Management consultancy services for healthcare organisations	Singapore	70	70
Quantum Healthcare Holdings Sdn. Bhd ⁽²⁾⁽³⁾ ("QHHSB")	Investment holding	Malaysia	60	-
Held through QTV				
Quattro Vascular Pte. Ltd. ⁽¹⁾ TriReme Medical (Singapore) Pte. Ltd. ⁽¹⁾	Medical clinic Orthopaedic clinic	Singapore Singapore	100 100	100 100
Held through ADG				
St. Andrew's Dental Pte. Ltd. ⁽¹⁾ Asia Healthcare Dental Pte. Ltd. ⁽¹⁾ Corporate Dental Pte. Ltd. ⁽¹⁾ Seafarers Dental Pte. Ltd. ⁽¹⁾ Eastern Dental Centre Pte. Ltd. ⁽¹⁾ The Dental Hub Pte. Ltd. ⁽¹⁾ ("TDH") ⁽¹⁾ The Dental Hub (Jurong West) Pte. Ltd. ⁽¹⁾⁽²⁾ ("TDJW") The Dental Hub (Canberra) Pte. Ltd. ⁽¹⁾⁽²⁾ ("TDHC")	Dental services Dental services Dental services Dental services Dental services Dental services Dental services	Singapore Singapore Singapore Singapore Singapore Singapore Singapore	60 60 60 60 60 60 60	60 60 60 60 60 -
Held by QHHSB				
Quantum Specialist Sdn. Bhd. ⁽²⁾⁽³⁾	Dental services	Malaysia	60	-
⁽¹⁾ Audited by Mazars LLD for year 20	122 and Moora Stank	one LLD for yoar 202	5	

⁽¹⁾ Audited by Mazars LLP for year 2023 and Moore Stephens LLP for year 2022

⁽²⁾ Incorporated during the financial year

⁽³⁾ Insignificant subsidiary of the Group audited by TY Teoh International

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

The Group has the following subsidiaries which have non-controlling interests ("NCI") that are material to the Group:

<u>Subsidiaries</u>	Proporti ownership in by N	terest held	Profit/ allocated to the finan	NCI during	Accumu NCI at the rep	
	<u>2023</u> %	<u>2022</u> %	<u>2023</u> S\$'000	<u>2022</u> S\$'000	<u>2023</u> S\$'000	<u>2022</u> S\$'000
ADG and its subsidiaries	40	40	247	180	854	607

Summarised financial information (before intercompany eliminations):

	ADG and its	ADG and its subsidiaries	
	<u>2023</u> S\$′000	<u>2022</u> S\$'000	
Assets:			
Non-current	5,862	4,897	
Current	3,695	5,490	
Liabilities:			
Non-current	(3,602)	(4,562)	
Current	(4,737)	(4,307)	
Net assets	1,218	1,518	
Revenue	13,081	9,368	
Profit after taxation	617	450	
Total comprehensive income	617	450	
Net cash flow generated from operation	802	1,301	

There are no significant restrictions on the Group's ability to access or use the assets and settle the liabilities of the Group.

Incorporation of subsidiaries and acquisition of business or assets

a) Acquisition of business – The Dental Hub Pte. Ltd.

On February 2023, ADG completed the acquisition of 100% of the businesses of three clinics ("TDH Group"), via ADG's subsidiary, The Dental Hub Pte. Ltd., for a cash consideration of \$\$1,650,000 from a third party. TDH Group is principally engaged in the provision of dental healthcare related services.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

a) Acquisition of business - The Dental Hub Pte. Ltd (Continued)

	Fair value recognised on date of acquisition S\$'000
Assets Plant and equipment	61
Intangible assets Cash and cash equivalents	285 90
	436
Liability Deferred tax liability	48
	48
Net assets	484
Goodwill arising from acquisition Total consideration	1,262 1,650
	<u>2023</u> S\$'000
Aggregate cash flow arising from acquisition of business Consideration paid for the acquisition of TDH Group Less: Cash and cash equivalents of TDH Group acquired	1,650 (90)
Net cash outflow arising from acquisition	1,560

Included in the loss for the year is net profit of approximately S\$102,000 attributable to the additional business generated by TDH Group. Revenue for the year included approximately S\$2,324,000 in respect of revenue generated by TDH Group. Had this business combination been effected at 1 January 2023, the impact to the revenue of the Group and the loss for the year is considered not material.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

b) Incorporation of subsidiary and acquisition of business – The Dental Hub (Jurong West) Pte. Ltd.

In September 2023, the Group incorporated a wholly owned subsidiary, The Dental Hub (Jurong West) Pte. Ltd. in Singapore, through ADG. Subsequently in the same month, the Group, via TDHJW, completed the acquisition of the business of 100% of Wow Dental Surgery for a total cash consideration of approximately \$\$250,000 from a third party, with \$\$180,000 upfront payment and \$\$70,000 to be paid in two different tranches.

	Fair value recognised on date of acquisition S\$'000
Assets	
Plant and equipment	55
Right-of-use assets	206
	261
Liabilities	
Lease liabilities	206
Deferred tax liability	9
	215
Net assets	46
Goodwill arising from acquisition	198
Total consideration	250
Fair value adjustment for consideration	(6)
	<u>2023</u> S\$′000
Aggregate cash flow arising from acquisition of business	
Consideration paid for the acquisition of TDHJW	250
Second and third tranche to be paid	(70)
Net cash outflow arising from acquisition	180

Included in the loss for the year is net loss of approximately S\$72,000 attributable to the transitioning of newly acquired business. Revenue for the year included approximately S\$60,000 in respect of revenue generated by TDHJW. Had this business combination been effected at 1 January 2023, the impact to the revenue of the Group and the loss for the year is considered not to be material.

c) Incorporation of subsidiary – The Dental Hub (Canberra) Pte. Ltd.

In October 2023, the Group incorporated a wholly owned subsidiary, The Dental Hub (Canberra) Pte. Ltd. ("TDHC"), in Singapore through ADG, where ADG subscribed and was allotted 1,000 ordinary shares for a total consideration of S\$1,000 fully paid in cash.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

d) Incorporation of subsidiary – Quantum Healthcare Holdings Sdn. Bhd.

In February 2023, the Company incorporated a subsidiary, Quantum Healthcare Holdings Sdn. Bhd. ("QHHSB"), in Malaysia where the Company subscribed and was allotted 60 ordinary shares for a total consideration of S\$18 fully paid in cash.

e) Incorporation of subsidiary – Quantum Specialist Sdn. Bhd.

In February 2023, the Company incorporated a subsidiary, Quantum Specialist Sdn. Bhd. ("QSSB"), in Malaysia through its 60% owned subsidiary, QHHSB, where QHHSB subscribed and was allotted 100 ordinary shares for a total consideration of S\$30 fully paid in cash.

f) Acquisition of subsidiary – Asia Dental Group Pte. Ltd.

In January 2022, QTV, a 60% owned subsidiary of the Group completed the acquisition of 60% of the entire issued and paid-up share capital of Asia Dental Group Pte. Ltd. ("ADG"). ADG has the following wholly owned subsidiaries, namely St. Andrew's Dental Pte. Ltd., Asia Healthcare Dental Pte. Ltd., Corporate Dental Pte. Ltd. and Seafarers Dental Pte. Ltd. (collectively, the "ADG Group"). The acquisition of ADG Group was for an aggregate consideration of up to S\$7.65 million to be satisfied in both cash and shares as follows:

- S\$3.0 million in cash to be paid on completion of the acquisition;
- S\$0.5 million to be satisfied by the allotment and issuance of ordinary shares in the Company ("Consideration Shares") upon completion of the corporate restructuring as disclosed in Note 2.1(a); and
- An earn-out amount of up to S\$4.15 million ("Earn-Out Amount") to be made subject to and in accordance with the below:
 - (i) S\$1.383 million in cash on the first anniversary of the completion date of the acquisition;
 - (ii) S\$1.383 million in cash on the second anniversary of the completion date of the acquisition; and
 - (iii) up to \$\$1.383 million in cash ("Contingent Consideration") if the aggregate audited EBITDA of the ADG Group for the three full completed financial years immediately following completion of the acquisition, namely the financial years ended/ending 31 December 2022, 31 December 2023 and 31 December 2024 ("Aggregate EBITDA"), provided that such Aggregate EBITDA is equal to or exceeds \$\$3.6 million ("Aggregate EBITDA Threshold"). Where the aggregate EBITDA is less than \$\$3,600,000 (such difference being the "Shortfall Amount"), the Third Tranche Earn-Out Amount shall be reduced by the Shortfall Amount, and the Final Earn-Out Payment Amount (being the Third Tranche Earn-Out Amount reduced by such Shortfall Amount) shall be payable instead.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

f) Acquisition of subsidiary – Asia Dental Group Pte. Ltd. (Continued)

	Fair value recognised on date of acquisition S\$'000
Assets	
Plant and equipment	2
Intangible assets	917
Right-of-used assets	2,085
Trade and other receivables	918
Cash and banks balances	274
	4,196
	Fair value recognised on date of acquisition S\$'000
Liabilities	
Trade and other payables	758
Lease liabilities	2,105
Loans and borrowings	250
Provision for income tax	15
	3,128
Net assets	1,068
Non-controlling interest	(427)
Net assets acquired	641
Goodwill arising from acquisition	7,488
Cash consideration paid	3,000
Consideration shares issued	1,389*
Earn-Out Amount	3,740

* Fair value of Consideration Shares based on the market value of the shares at the date of issuance.

	<u>2022</u> S\$'000
Aggregate cash flow arising from acquisition of business Consideration paid for the acquisition of ADG Group Les: Cash and cash equivalents of ADG Group acquired	3,000 (274)
Net cash outflow arising from acquisition	2,726

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

g) Disposal of subsidiary - TriReme Medical, LLC

The QTV's shareholdings interest in TriReme has purportedly diluted from 50% plus one share to approximately 23.75% after the completion of first capital call from TriReme on 5 January 2022. The shareholdings interest has further diluted to approximately 20.19% after the completion of second capital call from TriReme on 7 September 2022.

Following shareholders' approval for the purported dilution of QTV's shareholdings interest in TriReme from 50% plus one share to approximately 20.19% at an extraordinary general meeting convened on 8 February 2024, the Board of the Directors has on 28 February 2024, after due and careful deliberations, decided and resolved that it would be in the interests of the Group to accept the purported dilution, particularly as any further uncertainty on the actual level of QTV's shareholding interest in TriReme would have an impact on the preparation of the unaudited and audited financial statements of the Company and Group for the financial year ended 31 December 2023.

Due to the dilution of interest, TriReme has become an associate of the Group since 5 January 2022.

	<u>Carrying amount</u> S\$'000
Cash consideration Cash and cash equivalents of TriReme	130
Net cash outflow on disposal of TriReme	130
Loss on disposal: Consideration received Net liabilities derecognised Non-controlling interest Cumulative exchange differences relating to TriReme reclassified from equity to profit or loss	(760) 43 1,504
Loss from deemed disposal of a subsidiary	787

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

13. Investments in subsidiaries (Continued)

Incorporation of subsidiaries and acquisition of business or assets (Continued)

h) Acquisition of subsidiary – EDS Group

In February 2022, the Group incorporated a wholly owned subsidiary, Eastern Dental Centre Pte. Ltd. ("EDC"), in Singapore, through its 60% owned subsidiary, ADG. Subsequently, in March 2022, the Group, via EDC, completed the acquisition of the business of three dental clinics ("Eastern Dental Surgery Group" or "EDS Group") for a total cash consideration of approximately \$\$1,257,000.

As it was an acquisition of a business, the consideration of S\$1,257,000 was wholly allocated as goodwill arising on acquisition of EDS Group on consolidation.

	<u>2022</u> S\$'000
Aggregate cash flow arising from acquisition of business Consideration paid for the acquisition of EDS Group Les: Cash and cash equivalents of EDS Group acquired	1,257
Net cash outflow arising from acquisition	1,257

i) Incorporation of subsidiary – Kairogenix Pte. Ltd. ("Kairogenix")

In May 2022, QTV incorporated a subsidiary, Kairogenix Pte. Ltd. ("Kairogenix"), in Singapore where QTV subscribed and was allotted 70 ordinary shares for a total consideration of S\$70 fully paid in cash. Consequent to the completion of the corporate restructuring as disclosed in Note 2(a), the Company effected the transfer of the 70% equity interest in Kairogenix held by QTV to the Company at cost with effect from September 2022.

j) Incorporation of subsidiary – The Dental Hub Pte. Ltd. ("TDH")

In August 2022, the Group, incorporated a wholly owned subsidiary, The Dental Hub Pte. Ltd., in Singapore, through its 60% owned subsidiary, ADG, where ADG subscribed and was alloted 1,000 ordinary shares for a total consideration of S\$1,000 fully paid in cash.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

14. Investments in associate

	-	<u>2023</u> S\$'000	S\$'	022 000 tated)
Investment in associates, at cost	-			_
The details of the associate is as fo	ollows:	Country of incorporation and principal	Effective e	quity held
Name of associate	Principal activities	place of business	<u>by the</u> 2023 %	
TriReme Medical, LLC ("TriReme")	Development, manufacturing and distribution of medical devices	United States of American	20.19	20.19

The Group has not recognised losses relating to the associate where its share of losses exceeds the Group's carrying amount of its investment in the associate. The Group's cumulative share of unrecognised losses was S\$444,000 (2022: \$524,000) of which there is no share of the current year's losses. The Group has no obligation in respect of those losses.

15. Other Investment

	<u>Group</u>		
	<u>2023</u>	<u>2022</u>	
	S\$'000	S\$'000	
Non-current investment			
Equity Investment – Mandatorily at FVTPL	-	-	

At the end of the current and previous financial year, management had recognised a full fair value loss for the unquoted equity investment of approximately US\$255,000 (approximately S\$344,000) in profit or loss of the Group in view of the negative financial position of the investee company.

16. Other non-current assets

17.

	Group		
	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)	
Security deposits	27	3	
Inventories			
	<u>Group</u>		
	<u>2023</u>	<u>2022</u>	
	S\$′000	S\$'000	
Dental supplies, at cost	37	32	

The cost of inventories sold recognised as an expense and included under "cost of sales" of the Group amounted to S\$102,000 (2022: S\$34,000) for the financial year.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

18. Trade and other receivables

	Group		<u>Company</u>	
	<u>2023</u> S\$′000	<u>2022</u> S\$'000 (Restated)	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Trade receivables				
- Third parties	1,342	845	-	-
- Related parties	531	392	-	-
Less: loss allowance (Note 32)	(27)			
	1,846	1,237	-	-
Other receivables				
- Third parties	34	37	-	-
- Related parties	676	189	-	-
Deposits	322	181	10	-
Prepayments	61	37	3	7
Amount due from subsidiaries	-	-	71	-
Less: loss allowance (Note 32)	-	-	(71)	
=	2,939	1,681	13	7

The movement in the loss allowance during the financial year is as follows:

	<u>Group</u>		Comp	<u>any</u>
	<u>2023</u> S\$'000	<u>2022</u> S\$'000	<u>2023</u> S\$'000	<u>2022</u> S\$'000
At beginning of financial year Loss allowance	27	-	71	-
	27		71	-

Trade receivables (including related parties) are non-interest bearing and are generally on 60 to 90 days (2022: 60 to 90 days) credit terms. Trade receivables are denominated in Singapore Dollars.

Amount due from related parties and subsidiaries are generally non-interest bearing, unsecured and repayable on demand.

Other receivables are denominated in Singapore Dollars.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

19. Cash and cash equivalents

	Group		<u>Company</u>	
	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Cast at bank Cash in hand	678 66	5,064 1	21	1,062
Cash and bank balances	744	5,065	21	1,062

Cash at banks earns interest at floating rates based on daily bank deposit rates.

20. Share capital

	<u>2023</u> Number of s	<u>2022</u> hares ('000)	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Group				
Issued and fully paid				
Ordinary shares At beginning of financial year	6,893,073	2,559,739	234,230	235,188
Effect of change in functional	0,0,0,0,0	2,007,707	2011/200	200,100
currency	-	-	-	(9,647)
Shares issued pursuant to share	574 400		0.000	7 000
placement (i) Shares issued pursuant to	571,428	4,055,556	2,000	7,300
acquisition (ii)	-	277,778	-	1,389
Share issuance expenses	-	-	(67)	
At end of financial year	7,464,501	6,893,073	236,163	234,230
<u>Company</u>				
Issued and fully paid				
Ordinary shares				
At beginning of financial year/date of incorporation*	6,893,073	Λ	234,230	#
Shares issued pursuant to share	010701070		2011/200	
placement	571,428	6,893,073	2,000	234,230
Share issuance expenses	-		(67)	-
At end of financial year	7,464,501	6,893,073	236,163	234,230

* The Company was incorporated on 30 May 2022.

[^] The number of share issued at the date of incorporation was 1.

[#] Less than S\$1,000.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

20. Share capital (Continued)

(i) During the financial year, the Company completed a share placement, where 571,428,600 new ordinary shares were issued in the capital of the Company at an issue price of \$\$0.0035 per share.

In the prior financial year, QTV completed a share placement prior to the corporate restructuring as disclosed in Note 2.1(a), where 4,055,555,556 new ordinary shares were issued in the capital of QTV at an issue price of S\$0.0018 per share.

(ii) In the prior financial year, QTV issued pursuant to the acquisition of ADG Group for the Consideration Shares, where 277,777,777 new ordinary shares were issued in the capital of QTV at an issue price of \$\$0.005 per share.

Fully paid ordinary shares, which have no par value, carry one vote per share and a right to dividends as and when declared by the Company.

21. Reserves

	<u>Gro</u>	Group		<u>bany</u>
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
	S\$′000	S\$′000	S\$′000	S\$′000
		(Restated)		
Merger reserve	(1,866)	(1,866)	-	-
Reserve for own shares	(98)	(98)	-	-
Translation reserve	(4)	-	-	-
Share-based payment reserve	11,606	11,678	48	48
Capital reserve	-	-	(228,762)	(228,762)
	9,638	9,714	(228,714)	(228,714)

Merger reserve

Merger reserve represents the combined amount of issued capital of respective subsidiaries under common control that were previously combined to form QTV Group in 2013.

Reserve for own shares

The reserve for own shares comprises the cost of QTV's shares held by the Group. As at 31 December 2023, the Group held 16,000 (2022: 16,000) of QTV's shares.

Translation reserve

The foreign currency translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Share-based payment reserve

The share-based payment reserve of the Group comprises the cumulative value of employee services received for previous issuance of share options to employees under QTV Group prior to the corporate restructuring.

The share-based payment reserve of the Company comprises the cumulative value of QTV's share options assumed by the Company (Note 28) pursuant to the corporate restructuring.

Capital reserve

This represents the difference between the share capital of the Company which was issued in exchange for the ordinary shares of QTV pursuant to the corporate restructuring and the carrying amount of total equity of QTV at the date of the corporate restructuring.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

22. Deferred tax liabilities

	Gro	oup
	<u>2023</u> S\$'000	<u>2022</u> S\$'000
At beginning of the financial year	61	-
Acquisition of business (Note 13) Charged to profit or loss	57 10	- 61
At end of financial year	128	61

Deferred tax liabilities principally arise as a result of difference between carrying amount and tax written down value of plant and equipment.

23. Trade and other payables

	Group		<u>Company</u>	
	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Trade payables				
- Third parties	958	1,144	-	-
Other payables				
- Third parties	382	500	146	167
- Related parties	-	17	-	-
Accrued payroll and other related				
costs	1,498	827	118	160
Accrued operating expenses	3,311	1,566	95	112
Amount due to subsidiaries	-	-	5,439	5,602
GST payables	220	123	-	
	6,369	4,177	5,798	6,041
Current	6,338	4,177	5,798	6,041
Non-current	31	-		
	6,369	4,177	5,798	6,041

Trade payables are non-interest bearing and are settled on average 30 to 60 days (2022: 30 to 60 days) terms.

The amount due to subsidiaries are non-trade related, unsecured, interest-free and repayable on demand and in cash.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

23. Trade and other payables (Continued)

Accrued operating expenses mainly consist of accrual of legal fee, interest expenses for final milestone and administrative fees payable to American Arbitration Association pertaining to the legal proceedings as disclosed in Note 35.

Other than those disclosed above, other payables (current) are non-trade in nature, unsecured, interest-free and repayable on demand.

The Group's and Company's trade and other payables that are not denominated in the functional currencies of the respective entities are as follows:

	Gro	<u>oup</u>	<u>Compa</u>	any
	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)	<u>2023</u> S\$'000	<u>2022</u> S\$'000
United States dollar	3,020	777	-	-
Euro	713	713		-

24. Lease liabilities

The Group leased certain premises and copier under leases. The lease term is two to four years. Interest rates are fixed at inception of the lease contract dates at 5.25% (2022: 5.25%) per annum. All leases are on fixed repayment basis with no contingent rental payments.

Recognition exemptions

The Group has certain lease contracts with lease terms of 12 months or less. For such leases, the Group has elected not to recognise right-of-use assets and lease liabilities.

(a) Right-of-use assets

Right of dat dates	Clinic <u>premises</u> S\$'000	<u>Copier</u> S\$′000	<u>Total</u> S\$′000
Group			
<u>Cost</u>			
At 1 January 2022	-	-	-
Additions due to acquisition (Note 13)	2,085	-	2,085
Addition	709	6	715
Depreciation	(769)	(2)	(771)
At 31 December 2022 (Restated)	2,025	4	2,029
Additions due to acquisition (Note 13)	206	-	206
Addition	597	-	597
Depreciation	(862)	(2)	(864)
At 31 December 2023	1,966	2	1,968

The total cash outflow for leases during the financial year ended 31 December 2023 is \$951,000 (2022: \$921,000).

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

24. Lease liabilities (Continued)

Recognition exemptions (Continued)

(b) Lease liabilities

	<u>Grou</u>	<u>Group</u>		
	<u>2023</u> S\$′000	<u>2022</u> S\$'000		
		(Restated)		
Lease liabilities – current	1,027	756		
Lease liabilities – non-current	919	1,251		
At end of financial year	1,946	2,007		

The maturity analysis of lease liabilities is disclosed in Note 32.

(c) Amounts recognised in profit or loss

	<u>Gro</u>	<u>Group</u>		
	<u>2023</u> S\$'000	<u>2022</u> S\$'000 (Restated)		
Depreciation of right-of-use assets	864	771		
Interest expense on lease liabilities Expense relating to short-term leases	86 342	111 78		

25. Loans and borrowings

	<u>Grou</u>	D
	<u>2023</u>	<u>2022</u>
	S\$'000	S\$'000
Secured:		
Term Ioan I	812	991
Term Ioan II	153	187
Term Ioan III	456	567
Term Ioan IV	437	549
Term Ioan V	427	569
Term Ioan VI	810	991
Loans from a related party	1,467	1,693
	4,562	5,547
Less: Amount due for settlement within 12 months (shown under		
current liabilities)	(1,804)	(1,309)
Amount due for settlement after 12 months	2,758	4,238

Period of

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

25. Loans and borrowings (Continued)

Bank loans

	Fixed interest rate	Period of Ioan disbursement	commencement of loan repayment	Number of months of <u>repayment</u>
Bank loans	<u></u>		<u></u>	<u></u>
Term Ioan I	5.50%	October 2022	December 2022	60
Term loan II	6.50%	December 2022	December 2022	60
Term loan III	4.75%	July 2022	September 2022	60
Term Ioan IV	4.75%	May 2022	July 2022	60
Term Ioan V	5.50%	August 2022	October 2022	48
Term Ioan VI	4.75%	October 2022	December 2022	60

The bank loans are secured as follows:

- (a) Term Ioan I Principal amount of S\$1,000,000
 - The Company's pledge of its entire 60% shareholding in ADG; and
 - Pledge by a director of ADG, of his entire 40% shareholding in ADG.
- (b) Term Ioan II Principal amount of S\$190,000
 - Personal guarantees from a director of the Company and another director of ADG.
- (c) Term Ioan III Principal amount of \$\$600,000 Term Ioan IV – Principal amount of \$\$600,000 Term Ioan V – Principal amount of \$\$600,000
 - Personal guarantees from a director of ADG.

(d) Term Ioan VI – Principal amount of S\$1,000,000

- The Company's pledge of its entire 60% shareholding in ADG;
- Pledge by a director of ADG, of his entire 40% shareholding in ADG; and
- All funds currently held or deposited into any designated account with the bank

Loan from a related party

The loan from a related party is secured by the Company's pledge of its entire 60% shareholding in ADG and bears a fixed interest rate of 5.50% (2022: 5.50%) per annum. The disbursed loan amount was \$\$2,000,000 and is repayable in 42 monthly instalments commencing in April 2022.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

26. Amount due to a non-controlling interest

	<u>Group</u>		Comp	<u>any</u>
-	<u>2023</u> S\$′000	<u>2022</u> S\$'000	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Within first year (deferred payment) Within second year (deferred	-	1,383	-	1,383
payment)	1,383	1,318	1,383	1,318
Contingent consideration	1,314	1,245	1,314	1,245
_	2,697	3,946	2,697	3,946
Presented as:				
- Current	1,383	1,383	1,383	1,383
- Non-current	1,314	2,563	1,314	2,563
_	2,697	3,946	2,697	3,946

The amount due to a non-controlling interest (or the "Vendor") relates to the Earn-Out Amount which is part of the consideration for the acquisition of ADG Group as disclosed in Note 13.

The Contingent Consideration is payable to the Vendor if the ADG Group achieves the Aggregate EBITDA Threshold. At the reporting date, management has assessed there is no change on the basis of Contingent Consideration which is based on the estimation of post-acquisition performance of the acquired subsidiary. The fair value of the Contingent Consideration is S\$1.314million (2022: S\$1.245 million).

27. Provisions

	Group	
	<u>2023</u> S\$′000	<u>2022</u> S\$'000
Provision for reinstatement costs Provision for unutilised leaves	222 41	155
	263	155

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

27. Provisions (Continued)

a) <u>Provision for reinstatement costs</u>

	Group		
	<u>2023</u> <u>2022</u>		
	S\$'000	S\$'000	
At 1 January	155	-	
Additions	67	155	
At 31 December	222	155	

Provision for reinstatement costs relates to reinstating the leased dental clinic to its original state at the end of the lease term. The provision is based on current reinstatement cost information available and to the best knowledge and experience of the management.

b) <u>Provision for unutilised leaves</u>

		<u>2022</u>	
	2023 2022 S\$'000 S\$'000		
At 1 January Additions	-	-	
At 31 December	41 41		

Provision for unutilised leave relates to the estimated liability for annual leave as a result of services rendered by employees up to the end of the financial year. The provision is based on the unutilised leave as at end of the financial year and the staffs' salary.

28. Share-based payment arrangements

The Group has the following share-based payment arrangements:

a) <u>Share option programme (equity-settled)</u>

In September 2005 ("2005 Stock Plan"), November 2010 ("2010 Stock Plan") and September 2013 ("2013 Stock Plan"), QTV had established share option plans that entitle certain employees, directors and consultants to purchase ordinary shares in QTV. Further, in April 2014, QTV adopted the 2014 QTV Employee Share Option Scheme ("2014 Stock Plan") which had become effective upon the listing of QTV on the Catalist of the SGX-ST in April 2014.

As part of the corporate restructuring, all liabilities and obligations in connection with the outstanding share options ("Options") granted under QTV's 2005, 2010, 2013 and 2014 Stock Plans (collectively, the "Option Schemes") are assumed by the Company ("Options Variation"). The Options Variation do not involve any changes made to the terms of the share options granted or the rules of the Option Schemes except the outstanding Options will be exercisable into shares of the Company.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

28. Share-based payment arrangements (Continued)

The Group has the following share-based payment arrangements (Continued):

a) <u>Share option programme (equity-settled) (Continued)</u>

At the reporting date, the Option Schemes have 11 Option holders with 4,219,000 outstanding Options. Details of the outstanding Options are set out below.

oer of
ion
lers
1

The Company does not intent to issue additional Options under the Option Schemes.

Reconciliation of outstanding Options

	Group <u>No. of options</u>		
	<u>2023</u> ′000	<u>2022</u> ′000	
Outstanding at 1 January Expired during the year	12,186 (7,967)	22,504 (10,318)	
Outstanding at 31 December	4,219	12,186	
Exercisable at 31 December	4,219	12,186	

b) <u>Restricted share awards (equity-settled)</u>

The QT Vascular Restricted Share Plan 2015 ("Award Scheme") was adopted to allow QTV to grant share awards ("Awards") to employees and directors of the Company or its subsidiaries, including controlling shareholders and their associates.

As part of the corporate restructuring, all liabilities and obligations in connection with the outstanding Awards granted under the Award Scheme are assumed by the Company ("Awards Variation"). The Awards Variation do not involve any changes made to the terms of the Awards granted or the rules of the Award Scheme except the outstanding Awards shall be reference to shares of the Company.

At the reporting date, the Award Scheme has 5 share awards holders with an aggregate of 1,091,544 outstanding Awards. The Company does not intend to grant additional Awards under the Award Scheme.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

28. Share-based payment arrangements (Continued)

b) <u>Restricted share awards (equity-settled) (Continued)</u>

Reconciliation of outstanding restricted share awards

	Group		
	No. of Awards		
	<u>2023</u>	<u>2022</u>	
	'000	'000	
Outstanding at 1 January	1,242	1,242	
Forfeited during the year	(150)		
Outstanding at 31 December	1,092	1,242	
	Group)	

	Group		
<u>2023</u>	<u>2022</u>		
S\$'000	S\$′000		
Share-based compensation (forfeiture) recognised			
in profit or loss (72)	-		

Measurement of fair value of Option Schemes

The fair value of Option Schemes assumed by the Company has been measured using Black-Scholes option-pricing model as at 29 July 2022 which is the date of the completion of the corporate structuring. Estimates of volatility has been based on an evaluation of the historical volatility of the Company's share price. The expected term of the share options has been based on estimated option holder behaviour.

The inputs used in the measurement of the fair values of the Options under the Option Schemes are as follows:

	Company <u>2022</u>
Fair value at 29 July 2022 (weighted average)	S\$0.0037 - 0.0044
Share price at 29 July 2022	S\$0.005
Exercise price	S\$0.006 - 0.095
Expected volatility (weighted average)	233.8% - 242.3%
Expected life (weighted average)	2.05 years
Expected dividends	_
Risk-free interest rate (weighted average based on government	
bonds)	2.5 – 2.9%
Share-based compensation expense	S\$48,000

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

29. Significant related party transactions

A related party is defined as follows:

- (a) A person or a close member of that person's family is related to the Group and the Company if that person:
 - (i) Has control or joint control over the Company;
 - (ii) Has significant influence over the Company; or
 - (iii) Is a member of the key management personnel of the Group or Company or of a parent of the Company.
- (b) An entity is related to the Group and the Company if any of the following conditions applies:
 - (i) The entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others);
 - (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member);
 - (iii) Both entities are joint ventures of the same third party;
 - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity;
 - (v) The entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company. If the Company is itself such a plan, the sponsoring employees are also related to the Company;
 - (vi) The entity is controlled or jointly controlled by a person identified in (a);
 - (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and
 - (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity.

The effect of the Group's and Company's transactions and arrangements with related parties is reflected in these financial statements. The balances are unsecured, interest-free and repayable on demand unless otherwise stated.

In addition to the related party information disclosed elsewhere in the financial statements, the Company had the following significant transactions with related parties on terms agreed between the parties as follows:

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Loan from a related party	-	2,000
Interest expense incurred on loan from a related party ⁽¹⁾	90	72
Dental consultancy services rendered to related parties	594	738
Short-term lease expense paid to a related party	78	78

⁽¹⁾ Related parties refer to a company beneficially owned by a director of ADG.

⁽²⁾ A related party refers to a company beneficially owned by a director of the Company.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

29. Significant related party transactions (Continued)

Director transactions

In 2014, Eitan Konstantino, the former executive director and chief executive officer of QT Vascular Ltd. had entered into an amended and restated intellectual property assignment agreement with QT Vascular and its wholly owned subsidiary, Quattro Vascular Pte. Ltd. ("Quattro"), under which he assigned QT Vascular and Quattro all intellectual property rights for a medical device to be utilised in the treatment of blood vessels, i.e., 'chocolate' balloon catheter. Based on the revised agreement, Eitan Konstantino is entitled to 2.85% of the net sales of the product upon commercialisation and the amount is payable quarterly on a date within five business days of the earlier of (i) filing with the applicable regulatory body of the required quarterly and annual financial reports and (ii) 45 days following the end of a fiscal quarter and 60 days following the end of a fiscal year. No royalty expense was recognised in profit and loss of the Group paid/ payable to Eitan Konstantino for the financial year ended 31 December 2023 and 2022.

Compensation of directors and key management personnel

The remuneration of directors and other members of key management during the financial year was as follows:

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Directors' fee	145	160
Short-term benefits	768	856
Post-employment benefits	50	51
	963	1,067
Comprised:		
- Directors of the Company	458	463
- Key management of the Group	505	604
	963	1,067

The remuneration of directors and key management is determined by the board of directors and shareholders having regard to the performance of individuals.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

30. Segment information

For management purposes and resource allocation, the Group is organised into business operating units based on reports reviewed by management team that are used to make strategic decisions. This forms the basis of identifying the segments of the Group under *SFRS(I)* 8 Operating segments as follows:

i) Vascular business

Provision of a range of services including laser and resurfacing therapies, radiofrequency, light and ultrasound-based treatments botulinum toxin and filler injections, chemical peels and various facial and body wellness treatments.

ii) <u>Healthcare business</u>

The healthcare business segment is in the business of rendering of dental services.

iii) Corporate

Corporate segment consists of investment holding company which does not meet any of the quantitative threshold for determining a reportable operating segment.

The Group's operations are mainly domiciled in Singapore.

The accounting policies of the reportable segments are the same as the Group's accounting policies described in Note 2.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segments:

Information about reportable segments

Group	Vascular <u>business</u> S\$'000	Healthcare <u>business</u> S\$'000	<u>Corporate</u> S\$'000	<u>Total</u> S\$'000
<u>2023</u> <u>Revenue</u> External revenue/total revenue	_	13,081	-	13,081
<u>Results</u> (Loss)/Profit before income tax Income tax	(2,322) -	717 (100)	(1,676)	(3,281) (100)
(Loss)/Profit for the year	(2,322)	617	(1,676)	(3,381)
<u>Assets and liabilities</u> Segment assets Segment liabilities	- (3,785)	9,467 (7,028)	3,564 (5,246)	13,031 (16,059)

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

Segment information (Continued) 30.

Information about reportable segments (Continued)

	Vascular <u>business</u>	Healthcare business	<u>Corporate</u>	Total
Group	S\$′000	S\$′000	S\$′000	S\$′000
<u>2023</u>				
Other segment information				
Expenditure for plant and	-	(401)	(13)	(414)
equipment				
Interest expenses	-	267	223	490
Other non-cash items:				
Depreciation of property, plant				
and equipment	-	(152)	(39)	(191)
Depreciation of right-of-use	-	(864)	-	(864)
assets				
Amortisation of intangible assets	-	(58)	(229)	(287)

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

30. Segment information (Continued)

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segments:

Group	Vascular <u>business</u> S\$'000	Healthcare <u>business</u> S\$'000	<u>Corporate</u> S\$'000	<u>Total</u> S\$′000
Group <u>2022</u>				
<u>Revenue</u> External revenue/total revenue	-	9,368	-	9,368
Results				(0.770)
(Loss)/Profit before income tax Income tax	(2,036)	567 (117)	(7,310) -	(8,779) (117)
(Loss)/Profit for the year	(2,036)	450	(7,310)	(8,896)
Assets and liabilities	,	0.010	F 100	
Segment assets Segment liabilities	6 (1,529)	9,310 (7,473)	5,129 (6,947)	14,445 (15,949)
Other segment information Expenditure for plant and equipment	-	(764)	(164)	(928)
Other non-cash items: Depreciation of plant and equipment	-	(69)	(32)	(101)
Depreciation of right-of-use assets	-	(771)	-	(771)
Amortisation of intangible assets Impairment of goodwill	-	- (4,625)	(229) -	(229) (4,625)

Geographical information

The Group operates principally in Singapore after considering the deconsolidation of TriReme LLC which is an entity operating in United States of America.

Information about major customers

There were no customers with revenue of over 10% of the Group's revenue for the financial year ended 31 December 2023 and 2022.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

31. Contingent liabilities

As at 31 December 2023, the Company have given corporate guarantee to a bank for certain bank loans in respect to the banking facilities granted to subsidiaries and corporate guarantee to a related party for a loan from a related party (Note 25).

Such guarantee is in the form of a financial guarantee as they require the Company to reimburse the bank if the subsidiary to which the guarantee was extended fail to make principal or interest repayments when due in accordance with the terms of the borrowings. There has been no default or non-repayment since the utilisation of the banking facility.

The Company has evaluated the fair value of the corporate guarantee. Consequently, the Company is of the view that the fair value of the guarantee to the bank with regard to the subsidiary is not significant. The Company has not recognised any liability in respect of the guarantee given to the bank for banking facility granted to the subsidiary as the Company's directors have assessed that the likelihood of the subsidiary defaulting on repayment is remote.

32. Financial instruments and financial risks

The Group's activities expose it to credit risk, market risks (including foreign currency risk and interest rate risk) and liquidity risk. The Group's overall risk management strategy seeks to minimise adverse effects from the volatility of financial markets on the Group's financial performance.

The Board of Directors is responsible for setting the objectives and underlying principles of financial risk management for the Group. The management then establishes the detailed policies such as authority levels, oversight responsibilities, risk identification and measurement, exposure limits and hedging strategies, in accordance with the objectives and underlying principles approved by the Board of Directors.

There have been no changes to the Group's exposure to these financial risks or the manner in which it manages and measures the risk.

The Group does not hold or issue derivative financial instruments for trading purposes or to hedge against fluctuations, if any, in interest rates and foreign exchange rates.

Credit risk

Credit risk refers to the risk that the counterparty will default on its contractual obligations resulting in a loss to the Group. The Group has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults.

The Group's credit risk arises mainly from bank balances and trade and other receivables carried at amortised cost. Bank balances are mainly deposits with banks with high credit-ratings assigned by international credit rating agencies and the Group does not expect the impairment loss from bank balances to be material, if any.

To assess and manage its credit risk, the Group categorises the aforementioned financial assets and according to their risk of default. The Group defines default to have taken place when internal or/and external information indicates that the financial asset is unlikely to be received, which could include a breach of debt covenant, and/or where contractual payments are 90 days past due as per SFRS(I) 9's presumption.

In their assessment, the management considers, amongst other factors, the latest relevant credit ratings from reputable external rating agencies where available and deemed appropriate, historical credit experiences, latest available financial information and latest applicable credit reputation of the debtor.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Credit risk (Continued)

The Group's interna	l credit risk	aradina	categories a	re as follows.
The Oroup sinterna	I CIEUIL HSK	graung	categories a	

Category	Description	Basis of recognising ECL
1	Low credit risk Note 1	12-months ECL
2	Non-significant increase in credit risk since initial recognition and financial asset is \leq 30 days past due	12-months ECL
3	Significant increase in credit risk since initial recognition Note 2 or financial asset is > 30 days past due	Lifetime ECL
4	Evidence indicates that financial asset is credit-impaired Note 3	Difference between financial asset's gross carrying amount and present value of estimated future cash flows discounted at the financial asset's original effective interest rate
5	Evidence indicates that the management has no reasonable expectations of recovering the write off amount Note 4	Written off

Note 1. Low credit risk

The financial asset is determined to have low credit risk if the financial assets have a low risk of default, the counterparty has a strong capacity to meet its contractual cash flow obligations in the near term and adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the counterparty to fulfil its contractual cash flow obligations. Generally, this is the case when the Group assesses and determines that the debtor has been, is in and is highly likely to be, in the foreseeable future and during the (contractual) term of the financial asset, in a financial position that will allow the debtor to settle the financial asset as and when it falls due.

Note 2. Significant increase in credit risk

In assessing whether the credit risk of the financial asset has increased significantly since initial recognition, the Group compares the risk of default occurring on the financial asset as of reporting date with the risk of default occurring on the financial asset as of date of initial recognition, and considered reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition.

In assessing the significance of the change in the risk of default, the Group considers both past due (i.e. whether it is more than 30 days past due) and forward looking quantitative and qualitative information.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Credit risk (Continued)

Note 2. Significant increase in credit risk (Continued)

Forward looking information includes the assessment of the latest performance and financial position of the debtor, adjusted for the Group's future outlook of the industry in which the debtor operates based on the most recent news or market talks about the debtor, as applicable. In its assessment, the Group will generally, for example, assess whether the deterioration of the financial performance and/or financial position, adverse change in the economic environment (country and industry in which the debtor operates), deterioration of credit risk of the debtor, etc. is in line with its expectation as of the date of initial recognition of the financial asset. Irrespective of the outcome of the above assessment, the Group presumes that the credit risk on a financial asset has increased significantly since initial recognition when contract payments are >30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise.

Note 3. Credit impaired

In determining whether financial assets are credit-impaired, the Group assesses whether one or more events that have a detrimental impact on the estimated future cashflows of the financial asset have occurred. Evidence that a financial asset is credit impaired includes the following observable data:

- Significant financial difficulty of the debtor;
- Breach of contract, such as a default or being more than 90 days past due;
- It is becoming probable that the debtor will enter bankruptcy or other financial reorganisation; or
- The disappearance of an active market for the financial asset because of financial difficulties.

Note 4. Write off

Generally, the Group writes off, partially or fully, the financial asset when it assesses that there is no realistic prospect of recovery of the amount as evidenced by, for example, the debtor's lack of assets or income sources that could generate sufficient cashflows to repay the amounts subjected to the write-off.

The Group performs ongoing credit evaluation of its counterparties' financial condition and generally does not require collateral.

The Group does not have any significant credit exposure to any single counterparty or any groups of counterparties having similar characteristics.

With reference to Note 31, the Company provide financial guarantee to a bank in respect of bank facilities granted to subsidiaries. The date when the Company become a committed party to the guarantee are considered to be the date of initial recognition for the purpose of assessing the financial asset for impairment. In determining whether there has been a significant risk of a default occurring on the drawn-down facilities, the Company considered the change in the risk that the specified debtor (i.e. the applicable subsidiaries) will default on the contract. The Company assessed that the credit risk relating to the financial guarantee is insignificant to the Company.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Credit risk (Continued)

Note 4. Write off (Continued)

As at the end of the financial year, there was no significant concentration of credit risk. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statements of financial position.

Trade receivables (Note 18)

The Group uses the practical expedient under SFRS(I) 9 in the form of allowance matrix to measure the ECL for trade receivables, where the loss allowance is equal to lifetime ECL.

The ECL for trade receivables are estimated using an allowance matrix by reference to the historical credit loss experience of the customers for the last 3 years prior to the respective reporting dates for various customer groups that are assessed by geographical locations, product types and internal ratings, adjusted for forward looking factors specific to the debtors and the economic environment which could affect the ability of the debtors to settle the financial assets. In considering the impact of the economic environment on the ECL rates, the Group assesses, for example, the gross domestic production growth rates of the countries (e.g. Singapore) and the growth rates of the major industries which its customers operate in.

In their assessment, the management considers, amongst other factors, the latest relevant credit ratings from reputable external rating agencies where available and deemed appropriate, historical credit experiences, latest available financial information and latest applicable credit reputation of the debtor.

Trade receivables are written off when there is evidence to indicate that the customer is in severe financial difficulty such as being under liquidation or bankruptcy and there is no reasonable expectations for recovering the outstanding balances.

The loss allowance for trade receivables are determined as follows:

<u>Group</u>	<u>Current</u>	Past due more than 1 to 30 <u>days</u>	Past due more than 31 to 60 <u>days</u>	Past due more than 61 <u>days</u>	<u>Total</u>
<u>31 December 2023</u> Expected credit loss rates Trade receivables (gross) (S\$'000) Loss allowance (S\$'000)	- 1,123 -	- 294 -	- 91 -	2% 365 (27)	1,873 (27)
31 December 2022 Expected credit loss rates Trade receivables (gross) (S\$'000) Loss allowance (S\$'000)	- 880 -	- 134 -	- 61 -	- 162	1,237

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Credit risk (Continued)

Other receivables (Note 18)

As of 31 December 2023, the Group recorded other receivables of S\$1,032,000 (2022: S\$407,000). As of 31 December 2023, the Company recorded other receivables of S\$81,000 (2022: S\$Nil). The Group and the Company assessed the latest performance and financial position of the respective debtors and related party, adjusted for the future outlook of the industry which the debtors operate in, by referring to expert publications on the industry, and for any market talks on the debtors' credit reputation and concluded that there has been no significant increase in the credit risk since the initial recognition of the financial asset. Accordingly, the Group and the Company measured the impairment loss allowance using 12-months ECL and determined that the ECL is insignificant.

The movement in the loss allowance during the financial year and the Group's and Company's exposure to credit risk in respect of the trade receivables is as follows:

Group Internal credit risk grading	Note (i) \$′000	Trade receivables Category 4 \$'000	Total \$′000
Loss allowance Balance at 1 January 2022 and 31 December 2022 Assets recognised/originated	-	- 27	- 27
Balance at 31 December 2023	-	27	27

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Credit risk (Continued)

Other receivables (Note 18) (Continued)

Group Internal credit risk grading	Note (i) \$′000	Trade recelvables Category 4 \$'000	Total \$′000
Gross carrying amount At 31 December 2022	1,237	-	1,237
At 31 December 2023	1,846	27	1,873
Net carrying amount At 31 December 2022 At 31 December 2023	1,237 1,846	-	1,237 1,846
Company Internal credit risk grading	(i) \$′000	Other receivables Category 4 \$'000	Total \$′000
Loss allowance Balance at 1 January 2022 and 31 December 2022 Assets recognised/originated	-	- 71	71
Balance at 31 December 2023	-	71	71
Gross carrying amount At 31 December 2022 At 31 December 2023	- 10	- 71	- 81
Net carrying amount At 31 December 2022 At 31 December 2023	- 10	-	- 10

Note (i) For trade receivables and other receivables, the Group uses the practical expedient under SFRS(I) 9 in the form of an allowance matrix to measure the ECL, where the loss allowance is equal to lifetime ECL.

Market risks

The Group's activities expose it primarily to the financial risk of changes in foreign currency exchange rates and interest rates. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk.

Foreign currency risk

The Group is exposed to foreign currency risk on certain income, expenses, monetary assets, mainly cash and cash equivalents, and liabilities that are denominated in currencies other than the functional currencies of the respective entities in the Group. As at the reporting date, the Group does not have significant foreign currency risk exposure except for the financial liabilities denominated in United States dollar and Euro.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Market risks (Continued)

Foreign currency risk (Continued)

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities as at the end of the financial year are as follows:

	<u>Group</u>			
	Ass	<u>ets</u>	Liabilities	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
	S\$′000	S\$′000	S\$′000	S\$'000
United States dollar	-	-	3,020	777
Euro	-	-	713	713

The following table details the sensitivity to a 3% (2022: 3%) increase or decrease in the relevant foreign currencies against the functional currency of each Group entity. 3% (2022: 3%) is the sensitivity rate representing management's assessment of the possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 3% (2022: 3%) change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Group where they give rise to an impact on the Group's profit or loss.

If the relevant foreign currency strengthens by 3% (2022: 3%) against the functional currency of each Group entity, profit or loss will increase or (decrease) by:

	United States				
	dollar impact Euro impact				
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>	
	S\$′000	S\$′000	S\$′000	S\$′000	
Group					
Profit or loss	91	23	21	21	

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Group's exposure to interest rates risk arises primarily from their loans and borrowings and cash at banks. The Group's policy is to manage interest cost by maintaining an appropriate mix of fixed and floating rate borrowings.

The applicable effective interest rates of the Group's loans and borrowings are disclosed in Note 25. No sensitivity analysis is disclosed in the financial statements as management considers there is no impact on the Group as its loans and borrowings are at fixed interest rates and therefore are not exposed to changes in market interest rates.

The Company does not have any significant interest-bearing borrowings or interest-earning assets that may expose the Company to interest rate risk.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Liquidity risk

Liquidity risk refers to the risk in which the Group encounters difficulties in meeting its short-term obligations. Liquidity risk is managed by matching the payment and receipt cycle.

The Group maintains a level of cash and cash equivalents and bank facilities deemed adequate by the management to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they fall due.

The Group monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by management to finance the Group's operations and to mitigate the effects of fluctuations in cash flows.

The following table details the Group's remaining contractual maturity for its non-derivative financial instruments. The table has been drawn up based on contractual undiscounted cash flows of financial instruments based on the earlier of the contractual date or when the Group is expected to receive or (pay). The table includes both interest and principal cash flows.

Group	Effective Interest rate %	Less than <u>1 year</u> S\$'000	2 to 5 <u>years</u> S\$′000	<u>Total</u> S\$′000
Undiscounted financial assets				
Trade and other receivables (excluding				
prepayments)	-	2,878 744	-	2,878 744
Cash and cash equivalents	-	/44	-	744
As at 31 December 2023	-	3,622	-	3,622
Trade and other receivables (excluding				
prepayments)	-	1,644	-	1,644
Cash and cash equivalents		5,065	-	5,065
As at 31 December 2022	<u>-</u>	6,709	-	6,709
Undiscounted financial liabilities				
Lease liabilities	5.25%	1,098	958	2,056
Loans and borrowings	4.75% - 6.5%	2,040	2,888	4,928
Amount due to a non-controlling interest	5.25%	1,383	1,384	2,767
Trade and other payables (excluding GST	5 30/	(110	05	(10)
payables) Maximum amount of financial guarantee	5.7%	6,149 3,089	35	6,184 3,089
		5,007	-	5,007
As at 31 December 2023	-	13,759	5,265	19,024
Lease liabilities	5.25%	838	1,314	2,152
Loans and borrowings	4.75% - 6.5%	1,568	4,742	6,310
Amount due to a non-controlling interest	5.25%	1,383	2,767	4,150
Trade and other payables (excluding GST		4.05.4		4.05.4
payables) Maximum amount of financial guarantee	-	4,054 3,675	-	4,054 3,675
Maximum amount of infancial guarantee		3,073		3,075
As at 31 December 2022	-	11,518	8,823	20,341
<u>Total undiscounted net financial</u> liabilities				
- At 31 December 2023	=	(10,137)	(5,265)	(15,402)
- At 31 December 2022	=	(4,809)	(8,823)	(13,632)

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Liquidity risk (Continued)

Company	Effective Interest <u>rate</u> %	Less than <u>1 year</u> S\$'000	2 to 5 <u>years</u> S\$'000	<u>Total</u> S\$′000
Undiscounted financial assets				
Other receivables (excluding prepayments) Cash and cash equivalents	-	10 21	-	10 21
As at 31 December 2023	_	31	-	31
Cash and cash equivalents		1,062	-	1,062
As at 31 December 2022	_	1,062	-	1,062
Undiscounted financial liabilities				
Amount due to a non-controlling interest Other payables	5.25%	1,383 5,798	1,384	2,767 5,798
As at 31 December 2023	_	7,181	1,384	8,565
Amount due to a non-controlling interest Other payables	5.25%	1,383 6,041	2,767	4,150 6,041
				·
As at 31 December 2022	-	7,424	2,767	10,191
<u>Total undiscounted net financial liabilities)</u> - At 31 December 2023	_	(7,150)	(1,384)	(8,534)
- At 31 December 2022	-	(6,362)	(2,767)	(9,129)

Financial instruments by category

The carrying amount of the different categories of financial instruments is as disclosed on the face of the statements of financial position and as follows:

·	<u>2023</u> S\$'000	<u>2022</u> S\$'000
Group		
Financial assets at amortised cost		
Trade and other receivables (excluding prepayments)	2,878	1,644
Cash and cash equivalents	744	5,065
	3,622	6,709
Financial liabilities at amortised cost		
Lease liabilities	1,946	2,007
Loans and borrowings	4,562	5,547
Amount due to a non-controlling interest	2,697	3,946
Trade and other payables (excluding GST payables)	6,369	4,177
	15,574	15,677

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

32. Financial instruments and financial risks (Continued)

Financial instruments by category (Continued)

The carrying amount of the different categories of financial instruments is as disclosed on the face of the statements of financial position and as follows (Continued):

	<u>2023</u> S\$'000	<u>2022</u> S\$'000
<u>Company</u>		
Financial assets at amortised cost		
Other receivables (excluding prepayments)	10	-
Cash and cash equivalents	21	1,062
	31	1,062
Financial liabilities at amortised cost		
Amount due to a non-controlling interest	2,697	3,946
Other payables	5,798	6,041
	8,495	9,987

The Group maintains sufficient cash and cash equivalents and internally generated funds to finance its activities.

33. Fair value of assets and liabilities

The Group categories fair value measurement using a fair value hierarchy that is dependent on the valuation inputs used as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date;
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: Unobservable inputs for the asset or liability.

A number of the Group's accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods:

- (a) Management has determined that the carrying amounts of cash at bank, including deposits pledged, trade and receivables, inventories, other financial assets, trade and other payables and loans and borrowings on their notional amounts reasonably approximate their fair values because of their shortterm nature.
- (b) The fair value of the employee share options and restricted share awards are measured using the Black-Scholes options-pricing model. Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on an evaluation of the historic volatility of the Company's share price, particularly over the historical period commensurate with the expected term), expected term of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions are not taken into account in determining fair value.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

33. Fair value of assets and liabilities (Continued)

(c) Other non-derivative financial liabilities are measured at fair value at initial recognition and for disclosure purposes, at each reporting date. Fair value is calculated based on the present value of future principal and interest cash flows, discounted at the market rate of interest at the measurement date.

Except as detailed in the following table (Fair value hierarchy), management considers that the carrying amounts of financial assets and financial liabilities recognised in the financial statements approximate their fair values.

	<u>Level 1</u> S\$′000	<u>Level 2</u> S\$'000	<u>Level 3</u> S\$'000	<u>Total</u> S\$'000
Group				
<u>2023</u>				
Financial liabilities				
Amount due to a non-controlling interest				
- Contingent consideration	-	-	(1,314)	(1,314)
2022 Financial liabilities Amount due to a non-controlling interest - Contingent consideration		_	(1,245)	(1,245)
	_	-	(1,243)	(1,243)

The Group recognised the fair value of Contingent Consideration for acquisition of ADG, as of the acquisition dates as part of the consideration transferred in exchange for acquisition of subsidiary. This fair value measurement requires estimation of post-acquisition performance of the acquired subsidiary and judgement on time value of money. The discount rate used is based on the prevailing incremental cost of borrowings of the Group of 5.25%. If the prevailing incremental cost of borrowings increase/decrease, it will result in a decrease/increase in the fair value of Contingent Consideration.

34. Capital management policies and objectives

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to stakeholders through the optimisation of the debt and equity balance except where decisions are made to exit businesses or close companies.

The capital structure of the Group consists of debts, which includes the borrowings and lease liabilities as disclosed in Note 24 and 25 and equity attributable to owners of the Company, comprising issued capital and reserves as disclosed in Note 20 and 21.

The Group's management reviews the capital structure on a regularly basis. As part of this review, management considers the cost of capital and the risks associated with each class of capital. Upon review, the Group will balance its overall capital structure through the payment of dividends, new share issues as well as the issue of new debt or the redemption of existing debt. The Group's overall strategy remains unchanged from 2022.

Management monitors capital based on a gearing ratio and the gearing ratio is calculated as net debt divided by total equity. Net debt is calculated as borrowings plus lease liabilities less cash and cash equivalents.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

35. Legal proceedings

In August 2021, InnoRa GmbH ("InnoRa"), a licensor to TriReme Medical LLC ("TriReme"), was a subsidiary of the Group and has become an associate of the Group at the beginning of the financial year ended 31 December 2022, was seeking to claim for an amount of (i) US\$1,200,000 in royalties, being 30% of the initial payment made to TriReme and QT Vascular ("QTV") (collectively, the "Sellers"), under the asset purchase agreement between the Sellers and G Vascular Private Limited ("Purchaser") and Genesis MedTech International Private Limited ("Genesis MedTech") in relation to the disposal of Chocolate Touch[®] ("Product") by TriReme to the Purchaser in August 2020, as well as (ii) 30% of all future payments received by Sellers in connection with the aforesaid disposal ("InnoRa Dispute").

In October 2021, TriReme Singapore Pte Ltd ("TriReme SG") and Quattro Vascular Pte Ltd ("Quattro"), subsidiaries of the Group, filed for a demand for arbitration against InnoRa with the American Arbitration Association seeking declaratory judgements and certain damages from InnoRa. InnoRa had responded to claims made by TriReme SG and Quattro in November 2021. Subsequently, in March 2022, TriReme SG and Quattro responded to the statement of counterclaims made by InnoRa.

On 26 August 2022, InnoRa had filed a complaint with a state court in California involving allegations similar to those made in the InnoRa Dispute ("Complaint"). The Complaint made by InnoRa now includes QTV, TriReme, the Purchaser and the Genesis Group as parties to the Complaint.

On 13 January 2023, a case management conference was held by the State Court to discuss the status of the Complaint. Considering that Claimants has an arbitration hearing for the InnoRa Dispute scheduled in March 2023, of which the outcome of the arbitration will have the same effect for this Complaint, the State Court agreed for the case management conference to be deferred to 16 May 2023.

On 26 July 2023, Claimants have received the Award of the arbitration proceedings for the InnoRa Dispute. The key terms of the Award are summarized below:

- The Arbitrator appointed by American Arbitration Association International Centre for Dispute Resolution ("Arbitrator") denied all claims made by either party, except for the payment of the Final Milestone Payment of EUR500,000 originally contracted to be paid by Claimants, which was due within 6 weeks of receipt of FDA approval for the Product. The Arbitrator also requires Claimants to accrue for a simple interest of 10% per annum from the due date of 16 December 2022 until the date the payment is made.
- The Arbitrator also ruled that InnoRa does not have any valid claims for royalties for any sales of the Product in the United States by Claimants or the Purchaser.
- Further, Claimants were not required to assign the Development and Licensing Agreement to Purchaser in conjunction with the entry of the APA.
- As InnoRa is the only party which obtained monetary relief for final milestone payment, Arbitrator ordered Claimants to reimburse InnoRa with the sum of US\$119,875, covering the administrative fees paid to American Arbitration Association ("AAA"), within 30 days of the receipt of the Award.
- Other than the reimbursement and final milestone payment, each party shall bear their respective legal fees and any other relevant costs incurred during the Arbitration.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

35. Legal proceedings (Continued)

Based on the InnoRa Dispute award, the Group has made a provision of S\$762,000 (EUR 500,000) for the final milestone payment and 10% of interest per annum, S\$158,000 (US\$119,875) of administrative fees payable to AAA and a legal fee of S\$2,860,000 (US\$2,168,879) as at 31 December 2023.

With respect to the Complaint, the State Court granted QTV's motion to compel arbitration on 24 April 2023. However, no demand for arbitration has been filed by InnoRa to date. Based on the Group's US legal counsel's advice, the Board of Directors of the Company are of the opinion that should InnoRa proceed with any demand for arbitration, the Respondents may object to the demand for arbitration on the ground that the arbitration is an attempt by InnoRa to reopen the InnoRa Dispute, despite the finality of the Award for the InnoRa Dispute. Hence, no provision need to be provided.

36. Events subsequent to the reporting date

(a) Proposed share placement and settlement shares

On 27 January 2024, the Company announced a Proposed Share Placement of up to 400,000,000 new ordinary shares ("Placement Shares") and a Proposed Settlement Shares of up to 150,000,000 new ordinary shares ("Settlement Shares") of the Company at S\$0.002 per share, which the Company will seek for shareholders' approval at the extraordinary general meeting ("EGM") to be convened in February 2024. Following the receipt of the Company's shareholders approval at an EGM held on 8 February 2024 for the Proposed Share Placement and Settlement Shares, the share placement and the settlement share has been completed on 15 February 2024 and the Company received a gross share placement proceeds of S\$0.8 million and the settlement shares has settled the Company's second tranche consideration payable for the acquisition of ADG group of S\$300,000.

(b) Deconsolidation of TriReme Medical LLC ("TriReme")

On 6 December 2023, the Company announced a Proposed Ractification of the Purported Dilution of a wholly owned subsidiary, QT Vascular Ltd's shareholding interest in TriReme from 50% plus one share to approximately 20.19%, which the Company will seek for shareholders' approval at the extraordinary general meeting ("EGM") to be convened in February 2024. Following the receipt of the Company's shareholders approval at an EGM held on 8 February 2024 for the Proposed Ractification of Purported Dilution of shareholding interest, the Company has deconsolidated TriReme from the Group's results and restated the audited financial statements for the financial year ended 31 December 2022 as the Purported Dilution had occurred in the beginning of financial year ended 31 December 2022.

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

36. Events subsequent to the reporting date (Continued)

(c) Disposal of 11% shares in Asia Dental Group Pte. Ltd. ("the Disposal")

On 14 March 2024, the Company announced that it had completed the disposal of 11% shares in Asia Dental Group Pte. Ltd. to the same Vendor as disclosed in Note 26 for a consideration of S\$1,383,000. It is agreed that, this consideration shall be fully set off against the contingent consideration arising from the prior year acquisition of ADG Group (notwithstanding that the Contingent Consideration is not yet determined or due as at the date of the Disposal) (Note 13).

Following the Disposal, notwithstanding that the Company will hold 49% of the shares in Asia Dental Group Pte. Ltd., the Company will continue to have control over the board seats and the relevant activities via shareholders agreements. In view of the foregoing, the management are in opinion that the Company shall continue to consolidate the Asia Dental Group Pte. Ltd. as a subsidiary following completion of the Disposal.

(d) Incorporation of subsidiary – The Dental Hub (Sengkang) Pte. Ltd.

On 20 March 2024, the Company incorporated a subsidiary, The Dental Hub (Sengkang) Pte. Ltd., in Singapore, through ADG. ADG subscribed and was allotted 1,000 ordinary shares for a total consideration of \$\$1,000 fully paid in cash.

37. Prior year adjustments

Deconsolidation of TriReme Medical LLC ("TriReme")

As disclosed in Note 13(g), as the Group's interest in TriReme has diluted to 20.19% since the beginning of the financial year ended 31 December 2022, the Group has deconsolidated TriReme from the Group's results and has restated the audited financial statements for the financial year ended 31 December 2022.

As a result of the restatements to the comparative figures due to the abovementioned matter, certain line items have been amended on the consolidated statement of profit or loss and other comprehensive income, consolidated financial statement of financial position, statement of financial position, consolidated statement of changes in equity, consolidated statement of cash flows and related notes to the financial statements.

Summary of the significant accounts for the year ended 31 December 2022 financial statements before and after the restatement are as follows:

Consolidated Statement of Profit or Loss and Other Comprehensive Income For the financial year ended 31 December 2022

	Balance as previously <u>reported</u> S\$'000	<u>Adjustments</u> S\$'000	Balance as <u>restated</u> S\$'000
Administrative expenses Finance costs Loss from deemed disposal of subsidiary	(7,232) (472)	624 22 (787)	(6,608) (450) (787)

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

37. Prior year adjustments (Continued)

Consolidated Statement of Financial Position As at 31 December 2022

Group	As previously <u>reported</u> S\$'000	Adjustments S\$'000	Balance as <u>restated</u> S\$'000
Non-current assets			
Right-of-use assets	2,295	(266)	2,029
Other non-current assets	45	(42)	3
Current assets			
Cash and cash equivalents	5,195	(130)	5,065
Trade and other receivables	1,707	(26)	1,681
Non-current liabilities			
Lease liabilities	(1,294)	43	(1,251)
Current liabilities			
Trade and other payables	(4,477)	300	(4,177)
Lease liabilities	(1,001)	245	(756)
Equity			
Translation reserve	1,024	(1,024)	-
Accumulated losses	244,840	1,205	246,045
Non-controlling interests	(292)	(305)	(597)

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

37. Prior year adjustments (Continued)

Consolidated Statement of Cash Flows For the financial year ended 31 December 2022

Group	As previously <u>reported</u> S\$'000	<u>Adjustments</u> S\$'000	<u>As restated</u> S\$'000
Cash flows from operating activities			
Loss before tax	(8,516)	(263)	(8,779)
Adjustments for:			
Depreciation of right-of-use assets	1,004	(233)	771
Provision for reinstatement cost	-	155	155
Less from deemed disposal of a subsidiary	-	787	787
Interest expenses	472	(24)	448
Unrealised foreign exchange gain	(4)	4	-
Changes in working capital			
Trade and other receivables	(475)	(524)	(999)
Other non-current assets	200	1	201
Trade and other payables	1,208	1	1,209
Net cash used in operating activities			
Income taxes paid	(15)	(1)	(16)
Cash flows from investing activities			
Deemed disposal of subsidiary	-	(130)	(130)
Cash flows from financing activities			
Repayment of lease liabilities	(1,021)	100	(921)
Net change in cash and cash equivalents	4,848	(127)	4,721
Effect of exchange rate changes on cash and cash equivalents	3	(3)	-

STATISTICS OF SHAREHOLDINGS

AS AT 21 MARCH 2024

ISSUED AND FULLY PAID UP CAPITAL : S\$237,329,829 NUMBER OF SHARES IN ISSUE : 8,014,501,108 CLASS OF SHARES VOTING RIGHTS

: ORDINARY SHARES : ONE VOTE PER ORDINARY SHARE

The Company does not have any treasury shares.

DISTRIBUTION OF SHAREHOLDERS BY SIZE OF SHAREHOLDINGS AS AT 21 MARCH 2024

SIZE OF SHAREHOLDERS	NO. OF	%	NO. OF SHARES	%
	SHAREHOLDERS			
1 – 99	12	0.35	391	0.00
100 – 1,000	42	1.22	28,413	0.00
1,001 – 10,000	413	12.01	3,157,084	0.04
10,001 - 1,000,000	2,644	76.86	540,023,008	6.74
1,000,001 AND ABOVE	329	9.56	7,471,292,212	93.22
TOTAL	3,440	100.00	8,014,501,108	100.00

TWENTY LARGEST SHAREHOLDERS

NO.	SHAREHOLDER'S NAME	NUMBER OF SHARES HELD	%
1	CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.	1,558,795,126	19.45
2	CHONG LEONG FAH DERRICK	1,132,480,974	14.13
3	THOMAS TAN GIM CHUA	871,296,804	10.87
4	ANG LAY KOONG (WANG LIJUN)	800,000,000	9.98
5	GIAN SIONG LIN JIMMY (YAN XIANGLIN JIMMY)	567,777,778	7.08
6	CITIBANK NOMINEES SINGAPORE PTE LTD	271,792,983	3.39
7	LAU CHEE HERNG (LIU ZHIHENG)	250,000,000	3.12
8	KENJI CHIN CHOON TSZE (CHEN ZUNZHI)	212,539,200	2.65
9	RAFFLES NOMINEES (PTE) LIMITED	117,579,479	1.47
10	DBS NOMINEES PTE LTD	103,882,722	1.30
11	PHILLIP SECURITIES PTE LTD	58,542,900	0.73
12	TAN KIAN HING	58,000,000	0.72
13	TEO SENG WAH	45,714,300	0.57
14	LIM CHYE HUAT @ BOBBY LIM CHYE HUAT	43,557,100	0.54
15	EITAN KONSTANTINO	43,328,460	0.54
16	TIGER BROKERS (SINGAPORE) PTE. LTD.	39,503,100	0.49
17	OCBC SECURITIES PRIVATE LTD	37,378,243	0.47
18	HO BENG SIANG	34,500,000	0.43
19	UOB KAY HIAN PTE LTD	33,406,218	0.42
20	SOLIGNY BRUNO LUDOVIC	31,900,100	0.40
	TOTAL	6,311,975,487	78.75

STATISTICS OF SHAREHOLDINGS

AS AT 21 MARCH 2024

SUBSTANTIAL SHAREHOLDER AS PER REGISTER OF SUBSTANTIAL SHAREHOLDERS

No	Name	No. of shares held as	%	No. of shares held as	%
		Direct		Deemed	
1	Thomas Tan Gim Chua	871,296,804	10.87	827,424,658(1)(2)	10.32
2	Ang Lay Koong ⁽²⁾	800,000,000	9.98	-	-
3	Quek Chin Thean ⁽³⁾	1,472,353,150	18.37	-	-
4	Chong Leong Fah Derrick	1,132,480,974	14.13	-	-
5	Gian Siong Lin Jimmy ⁽⁴⁾	568,977,778	7.10	-	-

Notes:

- (1) Thomas Tan Gim Chua is deemed to be interested in 27,424,658 held in Emerald Apex Pte. Ltd. and MDIE Pte. Ltd. pursuant to Section 7 of Companies Act 1967, as he entered into a sale and purchase agreement with Emerald Apex Pte. Ltd. and MDIE Pte. Ltd to purchase the shares. The shares have yet to be transferred pending payment and processing of the transfer.
- (2) During the financial year, Thomas Tan Gim Chua transferred 800,000,000 shares to his spouse, Ang Lay Koong.
- (3) 1,472,353,150 shares are held in the name of CGS-CIMB Securities (Singapore) Pte Ltd.
- (4) 1,200,000 shares are held separately in the name of Philip Securities Pte Ltd.

SHAREHOLDING HELD IN THE HANDS OF PUBLIC

Based on the information available to the Company as at 21 March 2024, approximately 39.18% of the issued ordinary shares of the Company was held in the hands of the public and therefore, Rule 723 of the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited, is complied with.

NOTICE IS HEREBY GIVEN that the Annual General Meeting ("**AGM**") of QUANTUM HEALTHCARE LIMITED (the "**Company**" and together with its subsidiaries, the "**Group**") will be held at 02:00 p.m. on Monday, 29 April 2024, at 745 Lorong 5 Toa Payoh, Singapore 319455 for the purposes of considering and, if though fit, passing with or without amendments, the resolutions as set out below ("**Notice**").

AS ORDINARY BUSINESS

1. To receive and adopt the Directors' Statement and the Audited Financial Statements for (Resolution 1) the financial year ended 31 December 2023 together with the Independent Auditor's Report thereon. 2. (Resolution 2) To re-elect Thomas Tan Gim Chua who was appointed on 27 April 2023 and is retiring pursuant to Article 110 of the Company's constitution ("Constitution") as a director of the Company ("Director"). [See Explanatory Notes (i) and (ii)] (Resolution 3) 3. To re-elect Ng Fook Ai Victor who was appointed on 27 April 2023 and is retiring pursuant to Article 110 of the Company's Constitution as a Director of the Company. [See Explanatory Notes (i) and (iii)] 4. To approve the payment of Directors' fees of S\$145,000 for the financial year ending on (Resolution 4) 31 December 2024 to be paid quarterly in arrears. (FY2023: S\$145,000) [See Explanatory Note (iv)] 5. To re-appoint Mazars LLP as the auditors of the Company ("Auditors") and to authorise (Resolution 5) the Directors to fix their remuneration. [See Explanatory Note (v)] 6. To transact any other ordinary business that may be properly transacted at an AGM.

AS SPECIAL BUSINESS

To consider and, if thought fit, to pass the following resolutions as Ordinary Resolutions, with or without any modifications:

7. Authority to Allot and Issue Shares Pursuant to the Share Issue Mandate (Resolution 6)

That pursuant to Section 161 of the Companies Act 1967 of Singapore ("**Companies Act**") and Rule 806 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited ("**Catalist Rules**"), authority be and is hereby given to the Directors (the "**Share Issue Mandate**") to:

- (a) allot and issue shares in the capital of the Company ("**Shares**") whether by way of rights, bonus or otherwise; and/or
- (b) make or grant offers, agreements or options (collectively, "Instruments") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other Instruments convertible into Shares;

At any time and upon such terms and conditions and for such purposes and to such persons as the Directors may, in their absolute discretion deem fit and, notwithstanding the authority conferred by this Resolution may have ceased to be in force, issue Shares in pursuance of any Instrument made or granted by the Directors while this Resolution was in force, provided that:

- (a) the aggregate number of shares (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) to be issued pursuant to this Resolution shall not exceed one hundred percent (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below), of which the aggregate number of Shares to be issued other than on a pro-rata basis to existing shareholders of the Company shall not exceed fifty percent (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below) or such other limit as may be prescribed by the Catalist Rules as at the date this Resolution is passed;
- (b) subject to such calculation as may be prescribed by the Singapore Exchange Securities Trading Limited ("SGX-ST"), for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (a) above, the total number of issued Shares (excluding treasury shares and subsidiary holdings) shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) at the time of the passing of this Resolution, after adjusting for:
 - (i.) new Shares arising from the conversion or exercise of any convertible securities;
 - (ii.) new Shares arising from exercising of share options or vesting of share awards which are outstanding or subsisting at the time of passing of this Resolution, provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - (iii.) any subsequent bonus issue, consolidation or subdivision of Shares;

any adjustments in accordance with (i) and (ii) are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution.

- (c) In exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance is waived by the SGX-ST) and the Constitution of the Company; and
- (d) Unless revoked or varied by the Company in a general meeting, such authority shall continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier.

[See Explanatory Note (vi)]

8. Authority to allot and issue shares under 2014 QTV Employee Share Option Scheme (Resolution 7) (the "Option Scheme").

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors to allot and issue from time to time such number of fully paidup Shares as may be required to be issued pursuant to the exercise of options granted under the Option Scheme ("**Options**"), such authority (unless revoked or varied by the company in a general meeting) to continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (vii)]

9. Authority to allot and issue shares under the QT Vascular Restricted Share Plan 2015 (Resolution 8) (the "Share Plan")

THAT the directors of the Company be and are hereby authorised to:

- Grant awards of Shares ("Awards") in accordance with the provisions of the Share Plan as from time to time amended, modified or supplemented and approved by shareholders in a general meeting;
- (b) Pursuant to Section 161 of the Companies Act, allot and issue from time to time such number of fully paid-up Shares as may be required to be allotted and issued pursuant to the exercise of the Awards; and
- (c) (notwithstanding the authority conferred by this Resolution may have ceased to be in force), pursuant to Section 161 of the Companies Act, allot and issue fully paid-up Shares pursuant to the exercise of any Awards granted by the Directors in accordance with the Share Plan while this Resolution was in force,

such authority to continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held whichever is the earlier.

[See Explanatory Note (viii)]

10. **Proposed Renewal of the Share Buy-Back Mandate**

(Resolution 9)

THAT:

- (a) for the purposes of the Companies Act, the exercise by the Directors of all the powers of the Company to purchase or otherwise acquire issued Shares not exceeding in aggregate the Maximum Limit (as hereafter defined), at such price or prices as may be determined by the Directors from time to time up to but not exceeding the Maximum Price (as hereafter defined), whether by way of
 - (i.) market purchase(s) ("Market Purchase(s)") on the SGX-ST transacted through the SGX-ST trading system and/or any other securities exchange on which the Shares may for the time being be listed and quoted (the "Other Exchange"); and/or
 - (ii.) off-market purchase(s) ("Off-Market Purchase(s)") (if effected otherwise than on the SGX-ST or, as the case may be, the Other

Exchange) in accordance with any equal access scheme(s) as may be determined or formulated by the Directors as they consider fit, which scheme(s) shall satisfy all the conditions prescribed by the Companies Act,

and otherwise in accordance with all other laws and regulations and the Catalist Rules or, as the case may be, the Other Exchange, as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the "**Share Buyback Mandate**");

- (b) unless revoked or varied by the Company in general meeting, the authority conferred on the Directors pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earliest of:
 - the date on which the authority conferred by the Share Buyback Mandate is revoked or varied by the Company at general meeting (if so varied or revoked prior to the next AGM); and
 - (ii.) the date on which the purchases or acquisitions of Shares by the Company pursuant to the Share Buyback Mandate are carried out to the full extent mandated;
- (c) in this Resolution:

"Maximum Limit" means that number of Shares representing ten percent (10%) of the total issued Shares of the Company (excluding any treasury shares and subsidiary holdings) as at the date of the passing of this Resolution, unless the Company has effected a reduction of the share capital of the Company in accordance with the applicable provisions of the Companies Act, at any time during the Relevant Period (as hereafter defined), in which event the total number of Shares of the Company shall be taken to be the total number of Shares of the Company as altered after such capital reduction (excluding any treasury shares and subsidiary holdings that may be held by the Company from time to time);

"Relevant Period" means the period commencing from the date on which the last AGM of the Company was held and expiring on the date of the next AGM of the Company is held or is required to be held, or the date on which the purchases of the Shares are carried out to the full extent mandated, whichever is earlier, unless prior to that, it is varied or revoked by resolution of the shareholders of the Company in general meeting;

"**Maximum Price**" in relation to a Share to be purchased, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) not exceeding:

- (i.) in the case of a Market Purchase, one hundred and five percent (105%) of the Average Closing Price; and
- (ii.) in the case of an Off-Market Purchase, one hundred and twenty percent (120%) of the Average Closing Price, where:

"Average Closing Price" means the average of the closing market prices of a Share over the last five (5) Market Days on which the Shares are transacted on the SGX-ST or, as the case may be, such securities exchange on which the Shares are listed or quoted, immediately preceding the date of the Market Purchase by the Company or, as the case may be, the date of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted, in accordance with the Catalist Rules, for any corporate action that occurs after the relevant five (5) Market Day period and the day on which the purchases are made;

"date of the making of the offer" means the date on which the Company announces its intention to make an offer for the purchase or acquisition of Shares from holders of Shares, stating therein the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase;

"Market Day" means a day on which the SGX-ST is open for trading in securities;

(d) the Directors and/or any of them be and are hereby authorised and empowered to complete and do all such acts and things (including executing such documents as may be required) as they and/or he may consider expedient or necessary to give effect to the transactions contemplated and/or authorised by this Resolution.

[See Explanatory Note (ix)]

By Order of the Board

Lee Pih Peng Company Secretary 12 April 2024

Explanatory Notes:

- (i) Pursuant to Article 110 of the Constitution, at least one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third), selected in accordance with Article 111, are to retire from office by rotation at each AGM of the Company. Pursuant to Article 111, Directors who wish to retire and not to offer himself for re-election and Directors who have been longest in office since their last re-election or appointment or have been in office for the three (3) years since their last election shall be selected to retire. Between Directors who were re-elected on the same day, those to retire shall (unless they otherwise agree among themselves) be determined by lot. A retiring Director shall be eligible for re-election. As all of the Directors were re-appointed during the last AGM held on 27 April 2023, Thomas Tan Gim Chua and Ng Fook Ai Victor have elected to retire and offer themselves for re-election pursuant to Article 110.
- (ii) Resolution 2, if passed, will re-appoint Thomas Tan Gim Chua, as a Director of the Company. Thomas Tan Gim Chua, who was re-appointed during the last AGM held on 27 April 2023, will retire and seek re-appointment pursuant to Article 110 of the Company's Constitution at the upcoming AGM. Thomas Tan Gim Chua is the Executive Director and Chief Executive Officer of the Company. Thomas Tan Gim Chua will upon the re-election, remain as a member of the Nominating Committee. Further information on Thomas Tan Gim Chua is set out under the sections entitled "Board of Directors" and "Report on Corporate Governance" of the Company's annual report for FY2023 ("Annual Report").

- (iii) Resolution 3, if passed, will re-appoint Ng Fook Ai Victor, as a Director of the Company. Ng Fook Ai Victor who was re-appointed during the last AGM held on 27 April 2023, will retire and seek re-appointment pursuant to Article 110 of the Company's Constitution at the upcoming AGM. Ng Fook Ai Victor is an Independent Non-Executive Director. Ng Fook Ai Victor will upon the re-election, remain as Independent Non-Executive Chairman of the Board and the Remuneration Committee, and a member of the Audit and Nominating Committees. The Board considers Ng Fook Ai Victor to be independent for the purpose of Rule 704(7) of the Catalist Rules. Further information on Ng Fook Ai Victor is set out under the sections entitled "Board of Directors" and "Report on Corporate Governance" of the Annual Report.
- (iv) Resolution 4, if passed, will allow for payment of Directors' fees in respect of the financial year ending 31 December 2024, payable quarterly in arrears which will be computed based on a basic fee and the number of chairmanships and memberships held on Board and the Board committees of the Company and assuming that all non-executive Directors will hold office for the full year. The Directors' fees payable to the non-executive Director shall be pro-rated accordingly should any Director cease to hold office prior to the end of the financial year ending 31 December 2024.
- (v) Mazars LLP was appointed as the Company's Auditors on 8 February 2024 following the completion of the extraordinary general meeting held on the same date, whereupon shareholders had granted their approval to appoint Mazars LLP as the Company's Auditors to hold office until the conclusion of the upcoming AGM, to be held on 29 April 2024, further details of which can be found in this Notice. Resolution 5, if passed, will re-appoint Mazars LLP as the Company's Auditors until the conclusion of the next AGM of the Company for the financial year ending on 31 December 2024 and authorise the Directors to fix the remuneration of the Auditors.
- (vi) Resolution 6, if passed, will authorise the Directors, from the date of the AGM until (a) the conclusion of the next AGM, or (b) the date by which the next AGM is required to be held pursuant to the Constitution of the Company or any applicable laws of Singapore, or (c) it is carried out to the full extent mandated, or (d) the date on which such authority is varied or revoked by ordinary resolution of the shareholders in a general meeting, whichever is the earliest, to issue Shares, make or grant Instruments convertible into Shares and to issue Shares pursuant to such Instruments, up to an amount not exceeding, in total, one hundred percent (100%) of the issued share capital of the Company (excluding treasury shares and subsidiary holdings), of which up to fifty percent (50%) may be issued other than on a pro-rata basis to existing shareholders of the Company. As at the date of this Notice, the total number of issued Shares in the Company is 8,014,501,108 Shares.
- (vii) Pursuant to the scheme of arrangement under Section 210 of the Companies Act, which was carried out on the terms of the scheme document dated 1 June 2022 ("Scheme"), the Company had assumed all liabilities and obligations of QT Vascular Ltd, its wholly-owned subsidiary, in connection with the outstanding Options granted by QT Vascular Ltd to the Options holders under the Option Scheme. Resolution 7, if passed, will authorise the Directors, from the date of the AGM until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held or such authority is varied and revoked by the Company in a general meeting, whichever is the earlier, to allot and issue Shares to holders of outstanding Options which were awarded under the Option Scheme pursuant to the exercise of such outstanding Options.
- (viii) Pursuant to the Scheme, the Company had assumed all liabilities and obligations of QT Vascular Ltd, its wholly-owned subsidiary in connection with the outstanding Awards granted by QT Vascular Ltd to the Awards holders under the Share Plan. Resolution 8, if passed, will authorise the Directors, from the date of the AGM until the conclusion of the next AGM of the Company, or the date by which the next AGM of the Company is required by law to be held or such authority is varied and revoked by the Company in a general meeting, whichever is the earlier, to (i) grant awards under the terms of the Share Plan and (ii) allot and issue Shares pursuant to the vesting of the Awards to be granted under the Share Plan.

(ix) Resolution 9, if passed, will renew the Share Buyback Mandate which authorises the Company to purchase or otherwise acquire issued Shares by way of Market Purchases or Off-Market Purchases, in accordance with the terms and conditions set out in the Resolution 9 and the Appendix to the Annual Report dated 12 April 2024 ("Appendix"). Please refer to the Appendix for additional information in relation to the proposed renewal of the Share Buyback Mandate

Notes:

- 1. The AGM will be held at 02:00 p.m. on Monday, 29 April 2024, at 745 Lorong 5 Toa Payoh, Singapore 319455. There will be no option for shareholders to participate virtually. Printed copies of this Notice, the Proxy Form and the request form for members to request for physical copies of the Annual Report ("Request Form") will be sent to the members at their addresses registered with the Company's Share Registrar, Tricor Barbinder Share Registration Services. The Company will <u>NOT</u> be sending printed copies of the Annual Report 2023 to members. This Notice, the Proxy Form, the Request Form and the Annual Report and the Appendix will be made available to members on the website of the SGX-ST at its URL <u>https://www.sgx.com/securities/company-announcements</u> and may be accessed at the Company's website at its URL <u>https://www.quantumhealthcare.com.sq/.</u>
- 2. A member who is not a relevant intermediary is entitled to appoint not more than two (2) proxies. Where such member's Proxy Form appointing a proxy(ies) appoints more than one (1) proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the Proxy Form.
- 3. A member who is a relevant intermediary is entitled to appoint more than two (2) proxies, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where a relevant intermediary appoints more than 2 proxies, separate Proxy Form should be used.
- 4. "Relevant intermediary" has the meaning ascribed to it in section 181(6) of the Companies Act.
- 5. Members (whether individuals or corporates) exercising their voting rights at the AGM may do so by attending and voting at the AGM themselves personally or through their duly appointed proxy(ies) or may appoint the Chairman of the AGM as their proxy to attend, speak and vote on their behalf at the AGM. In appointing the Chairman of the AGM as proxy, members (whether individuals or corporates) must give specific instructions as to voting, or abstentions from voting, in the Proxy Form, failing which the appointment will be treated as invalid.
- 6. For investors who have used their Supplementary Retirement Scheme ("SRS") monies to buy Shares in the Company ("SRS Investors"), who wish to vote should approach their respective SRS operators to submit their votes by 5:00 p.m. on 18 April 2024, in order to allow sufficient time for their respective SRS operators to in turn submit a Proxy Form to vote on their behalf by the cut-off date as stated below.
- 7. A proxy, including the Chairman of the AGM, need not be a member of the Company.
- 8. The duly executed Proxy Form must:
 - (a) if sent personally or by post, be received by the Company's Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, #26-01, Republic Plaza Tower I, Singapore 048619; or
 - (b) if submitted by email, be received by the Company's Share Registrar, Tricor Barbinder Share Registration Services by email at <u>sg.is.proxy@sg.tricorglobal.com</u>,

in either case no later than 02:00 p.m. on 26 April 2024, and in default the Proxy Form shall not be treated as valid. A member who wishes to submit a Proxy Form must first download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

- 9. The Proxy Form must be signed by the appointor or his attorney duly authorised in writing. Where the Proxy Form is executed by a corporation, it must be executed either under its common seal or signed on its behalf by a duly authorised officer or attorney. A copy of the power of attorney or such other authority must be submitted together with the Proxy Form, failing which the Proxy Form may be treated as invalid.
- 10. In the case of shares entered in the Depository Register, the Company may reject a Proxy Form if the member, being the appointor, is not shown to have Shares entered against his name in the Depository Register as at 72 hours before the time appointed for holding the AGM, as certified by The Central Depository (Pte) Limited to the Company.
- 11. Shareholders may submit questions which are substantial and relevant to the proposed resolutions tabled for approval at the AGM as set out in this Notice, by writing to the Company in advance of the AGM. Alternatively, shareholders may also pose such questions during the AGM. Substantial and relevant questions related to the agenda of the AGM must be submitted in the following manner:
 - (a) via email to <u>ir.sg@quantumhealthcare.com.sg</u>; or
 - (b) via post to the business office of the Company at 745 Lorong 5 Toa Payoh #01-00, Singapore 319455

in either case, by 21 April 2024 for the purposes of the AGM.

- 12. For verification purposes, when submitting any questions via email, members MUST provide the Company with their particulars (comprising full name (for individuals)/company name (for corporates), email address, contact number, NRIC/passport number/company registration number, shareholding type and number of shares held), failing which the submission will be treated as invalid.
- 13. The Company will endeavour to address the substantial and relevant questions (as determined by the Company in its sole discretion) pertinent to the resolutions to be tabled for approval at the AGM as received from shareholders by 02:00 p.m. on 24 April 2024 (that is, at least 48 hours prior to the closing date and time for the lodgement of the Proxy Form) The Company will, within one month after the date of the AGM, publish the minutes of the AGM on SGXNet and the Company's website.
- 14. The Company shall be entitled to reject the Proxy Form if it is incomplete, improperly completed, illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the Proxy Form (such as in the case where the appointor submits more than one Proxy Form).
- 15. Any reference to a time of day is made by reference to Singapore time.

PERSONAL DATA PRIVACY:

By submitting a Proxy Form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the AGM and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"), (ii) warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

Mr Thomas Tan Gim Chua and Mr Ng Fook Ai Victor are the Directors seeking re-election at the forthcoming Annual General Meeting of the Company to be convened at 2:00 p.m. on Monday, 29 April 2024 ("AGM") (the "Retiring Directors").

Pursuant to Rule 720(5) of the Catalist Rules of the SGX-ST, the information relating to the Retiring Directors as set out in Appendix 7F of the Catalist Rules of the SGX-ST are disclosed below:

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
Date of initial Appointment	30 May 2022	30 May 2022
Date of last re-appointment	27 April 2023	27 April 2023
Age	51	76
Country of principal	Singapore	Singapore
residence		3.1.1.1
The Board's comments on this appointment (including	The re-election of Mr Thomas Tan Gim Chua as the Chief Executive	The re-election of Mr Ng Fook Ai as the Independent Chairman of the Company
rationale, selection criteria,	Officer and Executive Director of the	was recommended by the NC and the
and the search and	Company was recommended by the	Board has accepted the recommendation,
nomination process)	NC and the Board has accepted the	after taking into consideration his
	recommendation, after taking into	qualifications, expertise, past experiences
	consideration his qualifications,	and overall contribution since he was
	expertise, past experiences and	appointed as a Director of the Company.
	overall contribution since he was	Mr Ng Fook Ai Victor is considered
	appointed as a Director of the	independent for the purposes of Catalist
	Company.	Rule 704(7).
Whether appointment is	Executive. Primarily responsible for	Non-Executive
executive, and if so, the area	the business development and	
of responsibility	overall management of the Group.	
Job Title (e.g. Lead ID, AC	Chief Executive Officer and	Independent Chairman, Chairman of the
Chairman, AC member etc.)	Executive Director, and Member of	Remuneration Committee and member of
	the Nominating Committee	the Audit Committee and Nominating
		Committee
Professional qualifications	Bachelor of Engineering from	Bachelor of Science (Honours) in
	Nanyang Technological University	Economics from University of London
		Master of Science in Economics from
		Birkbeck College, University of London
Working experience and occupation(s) during the past 10 years	 Ridgeline Technology Pte Ltd, Managing Director from 2000 to present 	1. DConstruct Systems Pte Ltd, Director in 2018
		2. Millet World Trading Post Private
	2. Awesome Food Holdings Pte Ltd, Director from 2004 to 2021	Limited, Director from 2018 to 2020
		3. Millet Capital Private Limited,
	3. Ridgeline Engineering Pte Ltd,	Director from 2018 to 2020
	Director from 2004 to 2021	
		4. Ocision Pte Ltd, Director from 2017
	4. White Water Capital Pte Ltd,	to 2021
	Executive Director from 2004 to	
	present	5. LI TV Asia Pte Ltd, Director from 2017
		to 2019
	5. Intex Fabric Sdn Bhd, Non-	
	Executive Director from 2009 to	6. Star Publications (Singapore) Pte Ltd,
	present	Director from 2017 to 2021

Mr	Thomas Tan Gim Chua	Mr	Ng Fook Ai Victor
			<u> </u>
6.	Lifeline Corporation Pty Ltd, Non-Executive Director from 2016 to present	7.	Sun Resources Holdings Pte Ltd, Director from 2017 to 2020
7.	Perpetual Insurance Agency Pte Ltd, Chief Executive Officer from	8.	Director of Laviani Pte Ltd from 2017 to 2019
	2017 to present	9.	SG Makers Association Ltd, Director from 2017 to 2018
8.	Folomi (S) Pte Ltd, Non- Executive Director from 2018 to present	10.	Cityneon Holdings Limited (NKA Cityneon Holdings Pte Ltd), Lead Independent Director from 2016 to
9.	Lifeline Corporation Pte Ltd, Chief Executive Officer from		2017
10.	2019 to -present Lifeline Wellness Pte Ltd, Non-	11.	SB REIT Management Pte Ltd, Independent Director from 2015 to 2021
	Executive Director from 2018 to present	12.	Global Arena Asia Pte Ltd, Director from 2015 to present
11.	Lifeline Holdings Pte Ltd, Non- Executive Director from 2018 to present	13.	SHC Capital Asia Limited (NKA Memories Group Limited), Lead Independent Director from 2014 to
12.	Ezwills Pte Ltd, Non-Executive Director from 2018 to present		2017
13.	Lifeline Innovator Sdn Bhd, Non- Executive Director from 2018 to	14.	1Rockstead GIP Fund II Pte Ltd, Non- Executive Director from 2013 to 2018
14.	present Lifelab Pte Ltd, Non-Executive	15.	Nee Soon Social Enterprise Limited, Non-Executive Chairman and Director from 2013 to 2020
	Director from 2020 to present	16.	Jiahui New Climate Holdings Pte Ltd,
15.	Arona Industrial Products Pte Ltd, Non-Executive Director from 2020 to present	17.	Director from 2013 to 2015 New Climate Pte Ltd, Non-Executive
16.	Lifeline Healthcare Pte Ltd, Non-		Director from 2013 to 2015
	Executive Director from 2020 to present	18.	JH Global Resources Pte Ltd, Director from 2013 to 2015
17.	Asia Dental Group Pte Ltd, Director from 2022 to present	19.	Grand Canal Property Pte Ltd, Director from 2013 to 2014
18.	Kairogenix Pte Ltd, Director from 2022 to present	20.	1Rockstead GIP Fund Ltd, Non- Executive Director, Non-Executive Chairman from 2010 to 2018
19.	QT Vascular Ltd, Executive Director and Chief Executive Officer from 2022 to present	21.	MY E G Services Bhd, Independent Director from 2008 to 2017

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
	20. Quantum Healthcare Holding	22. Devotion Energy Group Limited,
	Sdn Bhd Director from Feb 2023 to present	Independent Chairman from 2002 to 2014
	21. Quantum Specialist Sdn Bhd Director from Feb 2023 to present	23. Mercur Business Control Asia Pte Ltd, Director from 1999 to 2017
	prosont	24. London Asia Capital Co Ltd, Director from 2003 to 2017
		25. Asia Power Corporation Limited, Independent Director from 1999 to 2014
		26. QT Vascular Ltd, Independent Non- Executive Chairman from 2022 to present
Shareholding interest in the	Direct interest: 871,296,804 shares	Direct interest: 2,000,000 shares
listed issuer and its subsidiaries	representing approximately 10.87%	representing approximately 0.02%
	Deemed interest: 827,424,658 shares representing approximately 10.32%	
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issue and/or substantial shareholder of the listed issue or of any of its principal subsidiaries	No	No
Conflict of Interest (including any competing business)	No	No
Undertaking (in the format set out in Appendix 7H) under Rule 720(1) has been submitted to the listed issuer	Yes	Yes
Other Principal Commitments including Directorships - Past (for the last 5 years)	 Awesome Food Holdings Pte Ltd Ridgeline Engineering Pte Ltd 	 DConstruct Systems Pte Ltd Millet World Trading Post Private Limited Millet Capital Private Limited Ocision Pte Ltd LI TV Asia Pte Ltd Star Publications (Singapore) Pte Ltd Sun Resources Holdings Pte Ltd Laviani Pte Ltd SG Makers Association Ltd Cityneon Holdings Limited (NKA Cityneon Holdings Pte Ltd) SB REIT Management Pte Ltd (Soilbuild Business Space REIT)

	Mr Thomas Tan Gim Chua	Mr Ng Fook Al Victor
		 SHC Capital Asia Limited (NKA Memories Group Limited) 13. 1Rockstead GIP Fund II Pte Ltd 14. Nee Soon Social Enterprise Limited 15. 1Rockstead GIP Fund Ltd 16. MY E G Services Bhd 17. Mercur Business Control Asia Pte Ltd 18. London Asia Capital Co Ltd 19. Wosh.World Holdings Pte Ltd
Other Principal Commitments including Directorships - Present	 White Water Capital Pte Ltd Intex Fabric Sdn Bhd Lifeline Corporation Pty Ltd Perpetual Insurance Agency Pte Ltd Ridgeline Technology Pte Ltd Folomi (S) Pte Ltd Lifeline Corporation Pte Ltd Lifeline Wellness Pte Ltd Lifeline Holdings Pte Ltd Ezwills Pte Ltd Lifeline Innovator Sdn Bhd Lifeline Healthcare Pte Ltd Arona Industrial Products Pte Ltd Kairogenix Pte Ltd Kairogenix Pte Ltd Quantum Healthcare Holdings Sdn Bhd Quantum Specialist Sdn Bhd 	 Blue Monsoon Pte Ltd The Mediciwatermark Pte Ltd Healthbank Holdings Limited Millet World Private Limited The Place Holdings Limited Millet Holdings Private Limited Caregiver Group Pte Ltd Futsalarena @ Yishun Limited Sunshine 100 China Holdings Ltd SHC Investments Ltd Soilbuild Construction Group Ltd QT Vascular Ltd
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?	No	No
 (b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a 	No	No

		Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
L	partnership) of which		5
	he was a director or		
	an equivalent person		
	or a key executive, at		
	the time when he was		
	a director or an		
	equivalent person or a		
	key executive of that		
	entity or at any time		
	within 2 years from the		
	date he ceased to be a		
	director or an		
	equivalent person or a		
	key executive of that		
	entity, for the winding		
	up or dissolution of		
	that entity or, where		
	that entity is the		
	trustee of a business		
	trust, that business		
	trust, on the ground of		
	insolvency?		
(C)	Whether there is any	No	No
(0)	unsatisfied judgment		
	against him?		
(d)	Whether he has ever	No	No
(0)	been convicted of any		
	offence, in Singapore		
	or elsewhere, involving		
	fraud or dishonesty		
	which is punishable		
	with imprisonment, or		
	has been the subject		
	of any criminal		
	proceedings (including		
	any pending criminal		
	proceedings of which		
	he is aware) for such		
	purpose?		
(e)	Whether he has ever	No	No
	been convicted of any		
	offence, in Singapore		
	or elsewhere, involving		
	a breach of any law or		
	regulatory requirement		
	that relates to the		
	securities or futures		
	industry in Singapore		
	or elsewhere, or has		
	been the subject of		
	any criminal		
	proceedings (including		
	any pending criminal		
	proceedings of which		

		Mr Thomas Tan Gim Chua	Mr Ng Fook Al Victor
	he is aware) for such		
	breach?		
(f)	breach? Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or	No	No
(g)	dishonesty on his part? Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business	No	No
(h)	trust? Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?	No	No
(i)	Whether he has ever been the subject of any order, judgment or ruling of any court,	No	No

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
tribunal or governmental body, permanently or temporarily enjoining		
him from engaging in any type of business practice or activity?		
 (j) Whether he has ever, to his knowledge, been concerned with the management or 		
conduct, in Singapore or elsewhere, of the affairs of: i. any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or	No	Yes 1. Special Audit of Asia Power Corporation Limited ("Asia Power") Mr Ng was the Chairman of the Audit Committee at the time of the matter in 2013. Notwithstanding, Mr Ng confirmed that there were no known material weaknesses of internal controls prior to the incident. The forgery and wrongful withdrawal of funds was carried out by Asia Power's then financial controller, who admitted to the wrongdoing and was terminated with immediate effect. Furthermore, Mr Ng represented that he initiated the special audit once this matter had surfaced, and the special audit concluded with additional controls to be implemented.
		 Public reprimand of MY E.G. Services Berhad ("MYEG") by Bursa Malaysia Securities Berhad ("Bursa Malaysia")
		Mr Ng represented that he was not present at the CIMB conference held on 6 January 2015 and he was not aware of the material information which was disclosed to fund managers at the conference by the MYEG's managing director. A public reprimand for breaching paragraph 9.08(2) of the Main Market Listing Requirements of the Bursa Malaysia (" Main LR ") was made against MYEG for failing to ensure that disclosure

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
		of material information made on an
		individual or selective basis to analysts,
		shareholders, journalists or other persons
		has previously been fully disclosed and
		disseminated to the public. In the event
		of such disclosure, it must be publicly
		disseminated as promptly as possible.
		MYEG's then managing director was also
		publicly reprimanded and fined. In
		addition to the public reprimand, MYEG
		was required to undertake or arrange for
		the necessary training programme(s) in
		relation to compliance with the disclosure
		obligations under the Main LR and to
		ensure its directors and relevant
		personnel of MYEG attend the same.
		Mr Ng represented that no actions were
		taken against him, being the independent
		director of MYEG.
		3. Penalties imposed against MYEG and
		MyEG Commerce Sdn Bhd (" MyEG
		Commerce") by Malaysia
		Competition Commission(" MyCC ")
		As Mr Ng was an Independent Director at
		the time of the matter, he was not
		involved in the day-to-day business of the
		company. The matter concluded with,
		inter alia, penalties imposed on both
		MYEG and its wholly owned subsidiary,
		MyEG Commerce for the breach of
		Section 10(2)(d)(iii) of the Competition Act
ii. any entity (not	No	by abusing its dominant position in
being a		harming competition in the downstream
corporation) which		market in which MyEG Commerce
has been		participated as an insurance agent for the
investigated for a		online foreign workers permit renewal
breach of any law		applications.
or regulatory requirement		
governing such		Mr Ng represented that no actions were
entities in		taken against him, being the independent
Singapore or		director of MYEG.
elsewhere; or		

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
 iii. any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or iv. any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period 	No	For the appointment of Mr Ng as Independent Director of the Company on 30 May 2022, the Nominating Committee noted that Mr Ng was not a subject of the investigations above and Mr Ng continues to be a director of several SGX listed companies after the occurrence of the events set out above. The Nominating Committee also noted that there were no adverse actions taken against Mr Ng in relation to the above matters. No
 when he was so concerned with the entity or business trust? (k) Whether he has been the subject of any current or past 	No	No
investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?		
Any prior experience as a director of an issuer listed on the Exchange? If yes, please provide details of prior experience.	Not applicable. This is a re-election of a director.	Not applicable. This is a re-election of a director.

	Mr Thomas Tan Gim Chua	Mr Ng Fook Ai Victor
If no, please state if the		
director has attended or will		
be attending training on the		
roles and responsibilities of		
a director of a listed issuer		
as prescribed by the		
Exchange.		
Please provide details of	Not applicable. This is a re-election	Not applicable. This is a re-election of a
relevant experience and the	of a director.	director.
nominating committee's		
reasons for not requiring the		
director to undergo training		
as prescribed by the		
Exchange (if applicable).		



QUANTUM HEALTHCARE LIMITED

(Company Registration No. 202218645W) (Incorporated in the Republic of Singapore)

PROXY FORM Annual General Meeting

This Proxy Form has been made available on SGXNet and the Company's website and may be accessed at the URLs <u>https://www.sgx.com/securities/company-announcements</u> and <u>https://www.quantumhealthcare.com.sg/</u>. A printed copy of this Proxy Form will be sent to members.

IMPORTANT

- 1. Pursuant to section 181(1C) of the Companies Act 1967 of Singapore (the "Companies Act"), relevant intermediaries (as defined in the Companies Act) may appoint more than 2 proxies to attend, speak and vote at the AGM.
- 2. For investors who have used their Supplementary Retirement Scheme monies to buy Shares in the Company (the "SRS Investors"), this Proxy Form is not valid for use and shall be ineffective for all intents and purposes if used or purported to be used by them.
- 3. SRS Investors may direct their SRS operators to appoint the Chairman of the AGM (and not third-party proxy(ies) as proxy to vote on their behalf at the AGM in which case they should approach their SRS operators to submit their votes at least seven (7) working days before the AGM, by 5:00 p.m. on 18 April 2024, to allow sufficient time for their respective relevant intermediaries to, in turn, submit a Proxy Form to appoint the Chairman of the AGM to vote on their behalf.

(Name including NRIC/Passport No./Company Registration (Address) being a shareholder / shareholders of

I/We*, _____ Number)* of

QUANTUM HEALTHCARE LIMITED (the "**Company**"), hereby appoint:

(a) the Chairman of the Annual General Meeting ("**AGM**"); or

(b) the individual(s) named below:

Name	NRIC/Passport Number	Proportion of Shareholdings	
		Number of Shares	%
Address			

Name	NRIC/Passport Number	Proportion of Shareholdings	
		Number of Shares	%
Address			

as my/our** proxy/proxies** to attend, speak and vote for me/us** on my/our** behalf at the AGM of the Company to be held at 02:00 p.m. on Monday, 29 April 2024, at 745 Lor. 5 Toa Payoh, Singapore 319455 and at any adjournment thereof.

Please note that where the Chairman of the AGM is appointed as proxy, the proxy appointing the Chairman of the AGM must be directed, i.e., the member must indicate for each resolution whether the Chairman of the AGM is directed to vote "For" or "Against" or "Abstain" from voting. If no specific direction as to voting is given, the appointment of the Chairman of the AGM as proxy for the resolution will be treated as invalid at the AGM and at any adjournment thereof. In addition, if no specific direction as to voting is given for the individual(s) named above, the proxy/proxies* will vote or abstain from voting at his/her/their* discretion, as he/she/they* will on any other matter arising at the AGM and at any adjournment thereof.

The Ordinary Resolution put to the vote at the AGM shall be decided by way of poll.

PROXY FORM

No	Resolutions	Number of votes FOR	Number of votes AGAINST	Number of votes ABSTAIN
Ordir	hary Business			
1.	Adoption of the Directors' Statement, Audited Financial Statements and Independent Auditor's Report for the financial year ended 31 December 2023			
2.	Re-election of Thomas Tan Gim Chua as a Director of the Company pursuant to Article 110 of the Company's Constitution			
3.	Re-election of Ng Fook Ai Victor as a Director of the Company pursuant to Article 110 of the Company's Constitution			
4.	Approval of Directors' fees amounting to S\$145,000 for the financial year ending 31 December 2024 to be paid quarterly in arrears (FY2023: S\$145,000)			
5.	Re-appointment of Mazars LLP as auditors of the Company and to authorise Directors to fix their remuneration			
Spec	al Business			
6.	Authority to allot and issue shares pursuant to the Share Issue Mandate			
7.	Authority to allot and issue shares under the 2014 QTV Employee Share Option Scheme			
8.	Authority to allot and issue shares under the QT Vascular Restricted Share Plan 2015			
9.	Proposed renewal of the Share Buyback Mandate			

Notes: If you wish to exercise all your votes "For", "Against" or "Abstain", please tick within the box provided. Alternatively, please indicate the number of shares the Chairman of the AGM, as your proxy, is directed to vote "For", "Against" or "Abstain".

Dated this _____day of 2024

Total number of Shares in:	No. of Shares
(a) CDP Register	
(b) Register of Members	

Signature(s) of Shareholder(s)/Common Seal

*Delete where inapplicable

NOTES FOR PROXY FORM:

- Printed copies of the Notice of AGM, Request Form and this Proxy Form will be sent to members at their addresses registered with the Company's Share Registrar, Tricor Barbinder Share Registration Services. The Notice of AGM, Request Form and this Proxy Form will be made available to members on the website of the SGX-ST at its URL https://www.sgx.com/securities/company-announcements and may be accessed at the Company's website at its URL https://www.guantumhealthcare.com.sg/.
- 2. If the member has Shares entered against his name in the Depository Register (maintained by The Central Depository (Pte) Limited), he should insert that number of Shares. If the member has Shares registered in his name in the Register of Members (maintained by or on behalf of the Company), he should insert that number of Shares. If the member has Shares entered against his name in the Depository Register and shares registered in his name in the Register of Members, he should insert the aggregate number of Shares. If no number is inserted, this Proxy Form will be deemed to relate to all the Shares held by the member.
- 3. A member who is not a relevant intermediary is entitled to appoint not more than two (2) proxies. Where such member's Proxy Form appoints more than one (1) proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the Proxy Form.
- 4. A member who is a relevant intermediary is entitled to appoint more than two (2) proxies, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member's Proxy Form appoints more than two (2) proxies, the number and class of shares in relation to which each proxy has been appointed shall be specified in the Proxy Form. Where a relevant intermediary appoints more than 2 proxies, separate Proxy Form should be used.
- 5. "Relevant intermediary" has the meaning ascribed to it in section 181(6) of the Companies Act.
- 6. SRS Investors who wish to vote should approach their respective SRS operators to submit their votes by 5:00 p.m. on 18 April 2024, in order to allow sufficient time for their respective relevant intermediaries to in turn submit a Proxy Form to vote on their behalf by the cut-off date as stated below.
- 7. A proxy, including the Chairman of the AGM, need not be a member of the Company.
- 8. The Proxy Form must:
 - (a) if sent personally or by post, be received by the Company's Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, #26-01, Republic Plaza Tower I, Singapore 048619; or
 - (b) if submitted by email, be received by the Company's Share Registrar, Tricor Barbinder Share Registration Services, by email at <u>sg.is.proxy@sg.tricorglobal.com</u>,

in either case no later than 02:00 p.m. on 26 April 2024, and in default the Proxy Form shall not be treated as valid. A member who wishes to submit a Proxy Form must first download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

- 9. The Proxy Form must be signed by the appointor or his attorney duly authorised in writing. Where the Proxy Form is executed by a corporation, it must be either executed under its common seal or signed on its behalf by a duly authorised officer or attorney. A copy of the power of attorney or such other authority must be submitted together with the Proxy Form, failing which the Proxy Form may be treated as invalid.
- 10. The Company shall be entitled to reject the Proxy Form if it is incomplete, improperly completed, illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the Proxy Form (such as in the case where the appointor submits more than one Proxy Form).
- 11. In the case of shares entered in the Depository Register, the Company may reject a Proxy Form if the member, being the appointor, is not shown to have Shares entered against his name in the Depository Register as at 72 hours before the time appointed for holding the AGM, as certified by The Central Depository (Pte) Limited to the Company.
- 12. By submitting this Proxy Form, a member accepts and agrees to the personal data privacy terms set out in the Notice of AGM dated 12 April 2024.

This page is intentionally left blank.

This page is intentionally left blank.



8 Temasek Boulevard, Level 42, Suntec Tower Three, Singapore 038988